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Abstract 
The role of coagulation proteins (CPs) in systems other than haemostasis is now 
recognised. Many of these cellular effects are through protease activated receptors 
(PARs). This project investigates how CPs influence the adaptive immune response, 
firstly through the expression of tissue factor (TF) on DCs; secondly through the 
action of PARs on dendritic cells (DCs) and T cells; and thirdly by examining the 
direct effect of anti-thrombin (AT) on DCs.  
 
This work identified for the first time a subset of mouse DCs that expresses TF. The 
form of TF changed from cryptic to pro-coagulant as DCs matured. In addition it was 
found that blocking TF on immature but not mature DCs enhanced their stimulatory 
capacity, possibly through PAR-2 signalling. In vivo studies supported this finding 
and suggest that inhibiting TF breaks T cell tolerance. 
 
Thrombin enhanced the T cell response through an effect on DCs but not T cells.  
Both primary and secondary responses increased but there was no change when 
stimulated T cells were rechallenged with thrombin-incubated DCs.  This mechanism 
was not through changes in MHCII, co-stimulatory molecules or cytokine production.  
Although DCs expressed PAR, individual PAR-1 or PAR-4 activation did not affect 
DC stimulatory capacity. 
 
Anti-thrombin was found to reduce T cell activation in vivo.  When DCs were treated 
with AT alone there was no change in T cell response, whereas treatment with AT 
before LPS led to an increase in IL-4 and IL-10 from T cells suggesting induction of 
tolerance. Anergy and T cell suppressor assays, however, failed to demonstrate a 
tolerant phenotype. 
 
Overall the findings demonstrate that DCs have the ability to generate and respond to 
CPs and thus influence the T cell response. This work identifies potential new targets 
in the innate system which may be used to influence the adaptive immune response. 
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Overview 
A vigorous or misdirected T cell response lies at the heart of pathological processes 
such as allograft rejection and autoimmunity. Treatments exist but 
immunosuppressive drugs have many unwanted effects which may be reduced by a 
more targeted approach to the immune response. It is now realised that both 
exogenous and endogenous factors influence adaptive immunity and further insight 
into the specific mechanisms involved may lead to new avenues for therapeutic 
manipulation.  
  
When this project started there was some evidence that coagulation proteins affected 
the adaptive immune response. This included the successful use of anti-coagulants to 
prolong graft survival in animal models of transplantation. It was considered that 
exploration of this process may provide insight into the interaction of coagulation and 
immunity and also reveal new targets to regulate the immune system. The aim of the 
project was to systematically examine the effect of coagulation proteins and anti-
coagulant on the cells involved in the adaptive immune response and hence 
understand the mechanisms at play. 
  
The introduction reviews important elements related to the project. The dendritic cell 
is a key player in controlling the adaptive T cell response. For this reason, along with 
T cells, it is the main cell type studied in this project. The first chapter reviews 
characteristics of dendritic cells and the way in which these are affected and so 
influence the type of T cell response, which is also described. The second chapter 
reviews the coagulation cascade and evidence for the role of coagulation proteins in 
biological systems other than haemostasis. The third chapter focuses on the key 
hypotheses behind the work and leads onto the experimental aims.
Introduction: Chapter 1 
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Chapter 1: The dendritic cell 
The dendritic cell (DC) was first described by Ralph Steinman in 1973 (1), who 
recently won the Lasker prize highlighting the importance of this cell type.  At the 
time Steinman noted the cell’s potent stimulatory capacity for naive T cells, which is 
why it is known as the professional antigen presenting cell.  The unique properties of 
the DC allow for its ability to sample and respond to the environment, acting as the 
immunological sentinel, and subsequently to initiate and shape the T cell response in 
magnitude and quality.  DCs are central in the control of adaptive immunity and this 
chapter aims to review some of their key features and so understand potential ways in 
which they are influenced and thus affect the T cell response.  Overall this project 
aims to gain further insight into the role of coagulation proteins in the adaptive 
immune system, which in part may be through the influence of DC characteristics. 
 
In the steady state DCs reside in peripheral tissue, secondary lymphoid organs and 
blood.  Most often DCs encounter changes in the environment such as microbial 
invasion within the periphery whilst interaction with T cells occurs mainly within the 
secondary lymphoid tissue. To elicit an anti-microbial immune response the DCs 
undergo a process of maturation from mainly antigen processing to antigen 
presentation. 
 
There are morphological and cytoskeletal changes to allow for migration of DCs with 
acquisition of high cellular motility (2), loss of endocytic and phagocytic receptors as 
further antigen processing is minimised, translocation of major histocompatibility 
complex class II (MHCII) molecules to the cell surface.  These changes allow antigen 
presentation and upregulation of co-stimulatory molecules for an effective T cell 
response (3).  Furthermore there is secretion of chemokines in co-ordinated waves 
which, depending on the timing, attracts different cells of the immune system.  There 
is also cytokine secretion from DCs, which differentiate and polarise effector cells.   
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This process of maturation is activated by a variety of stimuli, which are recognised 
by the DC including components of microbes and dying cells as well as interaction 
with other cells and products of the innate and adaptive immune systems.  This 
system will be discussed in greater detail.   
Dendritic cell subsets 
All DCs are derived from haemopoetic stem cell (HSC) precursors and share a 
common ability to process and present antigen.  However they are heterogenous and 
multiple subtypes have been identified with specialised immune functions (4, 5).  
Over the years research into the development of DCs has been difficult for a variety of 
reasons, one of which is the existence of multiple DC subtypes as well as the constant 
flux within the system.  Another factor is the rarity of the DC with according 
difficulty in isolating this cell and its precursor.  This has led to the use of in vitro 
model systems for DC generation in the mouse and human as well as different in vivo 
systems in the mouse (6-8), from which different patterns may surface depending on 
what manipulations are used and which DC subtypes are in play. 
 
The subsets of DCs can be divided in a number of similar ways in both human and 
mouse.  Initially the DC can be defined as conventional (cDC) or precursor (preDC).  
The latter applies to cells which, unlike the former, do not have DC form but with 
little or no cell division can develop into DCs following stimulation.  An example of 
this is the plasmacytoid DC (pDC), which develops cDC properties in the presence of 
stimuli such as unmethylated C- and G- rich DNA sequences (CpGs) leading to the 
production of high levels of type 1 interferon.   
 
The cDCs can be further sub-categorised as lymphoid and non-lymphoid depending 
on where they reside in the steady state.  The non-lymphoid or migratory cDCs are the 
classically defined DC as they are resident in tissue, where they sample the 
environment by processing antigen.  When they are activated by microbial stimuli or 
tissue damage they then migrate via lymph to the secondary lymphoid organs, where 
they mature and interact with T cells.  The non-lymphoid DCs can be further defined 
depending on the tissue of origin, for example Langerhans DC (LDC) of the 
epidermis, which uniquely express high levels of langerin (9).  LDCs are also present 
Introduction: Chapter 1 
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in the epidermal layers of the intestine, respiratory and reproductive tracts.  Other 
non-lymphoid DCs include dermal and interstitial DCs.   
 
Unlike non-lymphoid migratory DCs, the lymphoid DCs are present in their immature 
state in the lymphoid tissue.  They can be further categorised depending on their 
surface phenotype and function.  In mice, lymphoid DCs can be separated into CD8α+ 
and CD8α-, which secrete distinct patterns of cytokines (10) and differ in MHCI 
presentation of antigen (11, 12).  The CD8α- DCs can be further divided into CD8α-
4α+ or CD8α-4α- (13).  In humans the CD4α but not the CD8α homodimer is 
expressed on DCs. 
 
A third category of DC is the inflammatory DC, which is not present in the steady 
state but develops transiently with inflammation, such as the monocyte-derived DC 
dependent on granulocyte macrophage colony stimulating factor (GM-CSF) 
production, the tumour necrosis factor (TNF)- producing DC and the inducible nitric 
oxide synthetase (iNOS)-producing DC. 
 
Human blood contains two preDC, monocytes and pDC, which can be cultured ex-
vivo to develop into cDCs.  Immature interstitial DCs also circulate in the blood, 
where they are considered to be migrating from bone marrow to secondary lymphoid 
organs or peripheral tissues. They are thought to be related to in vitro generated 
monocyte derived or CD34+ derived DCs, are CD11c+ and express CD45Ro and 
myeloid markers such as CD33 and CD13.  This allows for a clear distinction from 
pDC, which lack CD11c but express blood dendritic cell antigen 2 (BDCA2) and 
migrate through blood via high endothelial venules (HEVs), rather than lymphatics, to 
the lymphoid tissue (14). 
 
Mouse blood also contains two populations of pre-DCs.  Those that resemble pDCs 
and express the surface phenotype of CD11clowCD11b-CD45RA+ and those that 
express CD11c+CD11b+CD45RA- and closely resemble the immature CD11c+ DC. 
Table 1.1 outlines the categories of DCs and their main characteristics. 
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Category Main characteristics Examples
Pre DC cells without 
immediate DC function
but develop into DC 
with little or no cell 
division
interferon  producing  
plasmacytoid DC
monocytes
Conventional DC have DC form and 
function
different categories
lymphoid DC function and  life 
history restricted to one 
lymphoid organ
thymic DC
splenic DC
non-lymphoid DC    
(migratory)
classical DC,
acts as sentinel in 
peripheral tissue then
migrates to lymph 
nodes
Langerhans DC
dermal DC
interstitial DC
Inflammatory DC not normally present in 
the steady state but 
appears as a 
consequence of 
inflammation or 
microbial stimuli
TNF producing DC
iNOS producing  DC
Table 1.1 Categories of DC
 
All blood cells are derived from HSCs, which give rise to downstream precursor cells 
committed to myeloid or lymphoid lineages.  Initially it was thought that DCs would 
be myeloid lineage due to their close resemblance to macrophages, generation from 
monocytes and association with granulocytes and macrophages from bone marrow 
cells cultured with GM-CSF.  However it is now clear that all DC subtypes can be 
derived from common lymphoid and myeloid precursors, which highlights the 
developmental flexibility of DCs compared to other haemopoetic cells (15).  It is also 
clear that expression of the transcription factor FMS-like tyrosine kinase 3 (FLT3) 
preferentially favours DC development and this is required for DC development in the 
steady state.  FLT3 gene knock-out (KO) mice are severely deficient in DCs (16) and 
delivery of FLT3 in vivo (6, 17) and in vitro (18, 19) boosts DC numbers in mice and 
humans.  It was initially surprising that this was not the case with GM-CSF, as GM-
CSF KO mice still had DCs and giving GM-CSF did not greatly boost DC numbers in 
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lymphoid tissues (20).  However this fits more with the idea that GM-CSF is not 
essential in the steady state but present in inflammatory conditions leading to transient 
increases in DCs (21). 
Culture models of dendritic cells 
Several culture systems have been developed to study both human (22-29) and mouse 
DCs (2, 30-39).  They are derived from different source populations of cells and 
involve distinct cytokines for generation into distinct DC subtypes.  Table 1.2 
summarises some of the DC culture models.  Each DC subset has unique properties 
which confer specialised function on the DCs.  However maturation and 
immunological properties of all the DCs are affected by the microenvironment and 
interaction with other cells and their products.    
 
Since DCs are so well equipped to initiate an adaptive immune response they are 
considered prime targets to modulate the immune response in diseases such as cancer 
and autoimmunity as well as in transplantation.  Much of our understanding about DC 
biology and hence how to influence the T cell response has come from work using 
DCs from these culture models.   
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Table 1.2 DC culture models
Adapted from Nature Reviews Immunology 2007 7 19. 
Precursor cells Culture conditions Generated DC type
Mouse bone marrow GM-CSF 
(±TNF, ±SCF)
interstitial DC, LC, 
inflammatory DC 
(through monocytes)
Mouse bone marrow FLT3L pDC, CD8+ cDC,
CD8- cDC
Mouse spleen  cells GM-CSF inflammatory DC
medium alone CD11c- MHCII- cells 
(DC equivalence
uncertain)
Human monocytes GM-CSF 
(+IL-4)
inflammatory DC 
(monocyte derived)
transendothelial
migration
interstitial  DC, 
migratory DC
Human CD34+ 
precursors
GM-CSF 
(±TNF, ±IL-3, 
±TGF-β, ±SCF)
interstitial DC, LC, 
inflammatory DC 
(through monocytes)
 
Antigen capture 
Immature DCs classically reside in the peripheral tissues, but are also known to exist 
in the lymphoid tissues as previously discussed.  They sample the environment and so 
are well equipped for efficient antigen capture. They do this through three main 
pathways (40).  The first, macropinocytosis, is a constitutive process and accounts for 
the uptake of large quantities of extracellular fluid and soluble antigen (41-43).  The 
second, endocytosis, is receptor mediated uptake and internalisation of proteins. The 
proteins eventually reach the endosomal and lysosomal compartments where they can 
be processed by proteases and loaded onto MHC (44, 45).  There are a large number 
of endocytic receptors expressed on immature DCs and these include Fcγ receptors 
and C-type lectins, which will be discussed later on.  The third, phagocytosis, 
mediates the internalisation of large particles and cells (46, 47).  Generally the same 
receptors that mediate endocytosis are also involved in this process.  Receptor 
engagement leads to particle engulfment.  The former can also signal changes in the 
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cytoskeleton, including actin polymerisation with pseudopod extension, which leads 
to DC mobilisation (48).  
Dendritic cell activation and maturation 
To elicit an immune response DCs have to undergo a process of activation or 
maturation in response to changes within the environment such as following microbial 
invasion.  These changes are a continuous process involving a switch from antigen 
processing to antigen presentation.  The DC loses its capacity to sample the 
environment with down regulation of macropinocytosis, pinocytosis and 
phagocytosis.  Morphological changes in the DC occur with more branch like 
extensions, from which its name is derived, to increase the likelihood of T cell 
interaction.  MHC molecules are synthesised by the DC but these are mainly stored 
intracellularly in the immature form.  Upon activation there are cytoplasmic changes 
which shift these intracellular stores to the cell surface for presentation of antigen in 
the MHC-peptide complex to permit T cell recognition (49, 50).  There is concurrent 
upregulation of co-stimulatory molecules, which enables T cell interaction (51). 
 
The DCs also secrete a number of chemokines, which attract other cells and allow for 
migration of the DCs to lymphoid tissue where interaction with the T cell occurs (52).   
Dendritic cell chemokine secretion 
Chemokines have been defined as small chemo attractive proteins which are secreted 
and act across a gradient to recruit cells and signal through transmembrane receptors.  
They are named after the number and spacing of cysteine residues in the amino 
terminal region as C, CC, CXC or CX3C (53) and can be divided into those that are 
constitutively expressed and those that are induced or upregulated, although there is 
considerable overlap.   
 
DCs secrete a number of chemokines which attract other cells.  They also 
differentially express chemokine receptors to guide their migration (54).  Secretion 
appears to occur in three different waves following DC activation, dictating the sort of 
cells that are recruited (55).  The initial wave appears to be two to four hours after 
activation with secretion of CXCL1, 2, 3 and 8, attracting peripheral blood 
mononuclear cells (PBMCs).  The intermediate wave, at four to eight hours following 
Introduction: Chapter 1 
10 
 
activation, includes inflammatory chemokines CXCL3, 4 and 5 as well as CXCL9, 10 
and 11, which are described as interferon regulated chemokines.  They all attract 
activated memory T cells and the former are also ligands for CCR5, which is 
expressed on monocytes and DCs.  The late phase of chemokine secretion occurs over 
twelve hours after activation and includes CCL19, 22 and CXCL13, all of which 
attract lymphocytes. CCL19 also recruits CCR7 expressing cells, namely naive and 
central memory T cells as well as mature DCs; CCL22 attracts T helper 2 (Th2) 
effector T cells and CXCL13 is the main attractant for B cells.  
 
In this way there appears to be a co-ordinated release of multiple chemokines at 
varying times to recruit different cell populations.  The first wave of chemokines 
attracts mainly innate effector cells and cytotoxic cells.  The second wave attracts 
memory T cells and monocytes possibly to replenish the pool of antigen presenting 
cells.  The late wave occurs in the secondary lymphoid organ, following migration of 
DCs, and seems to attract naive T cells, B cells and mature DCs for cell priming and 
an effective immune response.  Although there are some qualitative and quantitative 
differences in the chemokine production between different DC subsets, the sequential 
release of chemokines over time seems remarkably similar between them.   
 
Differential chemokine secretion between DC subsets described in some studies 
includes the production of homeostatic chemokines like CCL17 and 22 by cDCs 
whilst pDCs preferentially produce pro-inflammatory chemokines such as CCL3 (56).  
This preferential secretion of chemokines suggests the capacity to recruit a different 
combination of cell types by distinct DC subsets. 
Dendritic cell migration 
There are similar, although not identical, patterns of chemokine receptors on different 
subsets of DCs.  Immature DCs express receptors such as CCR3, CCR5 and CCR12 
that interact with ligands of inflammatory cytokines and attract DCs to sites of 
inflammation.  Variations in expression have been described, for example in vitro 
human monocyte derived DCs are found to express CCR1, 4, 5 and CXCR4, whilst 
the circulating immature DCs derived from CD34+ precursor cells additionally 
express CCR6, which is the receptor for macrophage inflammatory protein-3α (MIP-
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3α) constitutively produced by keratinocytes (57).  Triggering of some receptors such 
as CCR1 and 5 additionally directs reorganisation of the actin cytoskeleton, which 
permits DC mobilisation as well as guides migration (58). 
 
In the immature state, although pDCs have been found to express a very similar 
pattern of receptors to cDCs, most of them on the pDCs are non-functional.  In fact, 
pDCs only seem to respond to CXCL12 through expression of CCR4, which probably 
accounts for their migration from the circulation to secondary lymphoid organs.  They 
appear to have minimal capacity to respond to inflammatory stimuli and therefore fail 
to home to sites of inflammation (54, 56).  In contrast, cDCs express functionally 
responsive receptors to a variety of pro-inflammatory chemokines  which enable them 
to home to sites of inflammation (57). 
 
Upon maturation of the DC there is rapid downregulation of the receptors responsive 
to inflammatory chemokines, which in part is due to a process of auto desensitisation 
in which binding of the receptor to its own ligand leads to internalisation of the 
receptor (59).  Loss of expression of these receptors permits exit of DCs from the 
inflammatory site accompanied by upregulation of CCR7. This allows homing of 
mature DCs to secondary lymphoid organs due to attraction by CCR7’s ligands, MIP-
3β and secondary lymphoid tissue chemokine (SLC) (53).  The former is produced 
mainly by interdigiting DCs; the latter by stromal cells of the secondary lymphoid 
organ. CCR7 expression is already high on immature pDC but it is not coupled with 
ligand response.  Maturation therefore leads to functional coupling as well as to 
further upregulation (57).   
Recognition of danger 
DCs possess pattern recognition receptors (PRRs), which recognise conserved motifs 
on microbes and enable the DC to respond upon stimulation with initiation of the 
maturation process (60, 61).  These microbial patterns are known as pathogen 
associated molecular patterns (PAMPs) and are highly conserved over time and across 
species but importantly are not expressed on human cells.  This ability of the DC to 
distinguish non-self, in the form of microbial invasion from self, was first proposed 
by Janeway (62) and later became known as the stranger hypothesis.  
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However the stranger hypothesis does not explain the immune response generated in 
transplantation, tumour biology and autoimmunity, none of which involve microbes 
with PAMP but nevertheless incite a T cell response.  This led to Matzinger proposing 
the danger hypothesis (63), in which DCs recognise and respond to endogenous 
signals, induced by injured cells following damage by pathogen or toxin, rather than 
non-self signals, which are exogenous.  These molecules derived from self are also 
known as danger associated molecular patterns (DAMPs).  Both exogenous and 
endogenous activators will be discussed next. 
Exogenous activators 
Exogenous activators are molecules made by bacteria but not by eukaryotic cells and 
as such can be viewed as microbial signature molecules, which signal the presence of 
infection through PRRs, of which toll like receptors (TLRs) are archetypal.  Examples 
of PAMPs include lipopolysaccaride (LPS), which is a membrane component of most 
Gram’s negative bacteria and is recognised by TLR4; lipoproteins, which are found 
on most Gram’s positive bacteria and are recognised by TLR2 and CpGs found in 
most prokaryotic genomes, which are recognised by TLR9 (64).  
 
As shown in table 1.3 multiple PAMPs can exist on one microbe and are recognised 
by different PRRs.  The stimulation of these receptors overall leads to DC activation 
but stimulation by different combinations of PAMPs may lead to changes in the 
polarising signals initiated. 
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Table 1.3 Examples of multiple pathogen associated molecular patterns (PAMPs)
on microbes and their receptors (PRRs)
Pathogen PAMP PRR
Mycobacterium 
tuberculosis
lipoarabinomannan TLR2
phosphatidylinositol
mannosides
TLR4
DNA TLR9
Salmonella 
typhimurium
bacterial lipoprotein TLR2
lipopolysaccharide TLR4
flagellin TLR5
Candida  albicans phospholipomannan TLR2
mannan TLR4
DNA TLR9
Herpes simplex virus viral protein TLR2
double stranded RNA TLR3
DNA TLR9
 
Endogenous activators 
CD40L, TNF-α and IL1-β were the first endogenous signals to be described (51, 65).  
They are produced by activated cells of the immune system and further enhance the 
immune response; however they can also act as primary danger signals, when 
produced by non-immune cell types.  The expression of CD40L on T cells requires 
stimulation by previously activated DCs. However CD40L is also expressed by 
activated platelets (66).  Under normal conditions platelets and DCs do not come into 
contact with each other but in injured or bleeding tissue, the expression of platelet 
CD40L can act as a maturation signal for DCs.  Likewise TNF-α and IL-1β are 
produced by activated T cells and DCs but can also act as primary danger signals 
when produced by injured myocardium (67) or by keratinocytes at a site of 
inflammation (68) respectively.  IFN-α is another example of a dual purpose signal 
that enhances the immune response, when produced by a subset of activated DCs (69), 
but can also act as a primary activator of resting DCs (70).  
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Interaction of DCs with innate cells has also been found to activate DCs and shape the 
immune response (71, 72).  For example neutrophils and macrophages secrete pro- 
inflammatory cytokines such as IL-6, TNF-α and IL-1, which activate immature DCs.  
Furthermore neutrophils can induce DC maturation through interaction between DC-
specific intercellular adhesion moleule-3-grabbing non-integrin (DC-SIGN) and Mac-
1 and secretion of beta defensins (73, 74); epithelial cells can secrete GM-CSF and 
IL-15 both of which have effects on DC activation and polarisation (75); 
keratinocytes secrete large amounts of thymic stromal lymphopoetin (TSLP) in 
inflammatory skin lesions, which induces a DC capable of initiating a Th2 response 
(76) and many cells produce prostaglandins which have been shown to modulate DC 
function (77). 
 
Reciprocal interactions occur between DCs and innate cells, in which DCs initially 
affect innate cells to produce factors, which then polarise DCs.  In certain 
circumstances NK cells are dependent on DCs for activation, which leads to enhanced 
IFN-γ production (71, 78).  This in turn polarises DCs to induce a Th1 response (79).  
Mature DCs can also activate NKT and γδT cells, with upregulation of CD40L 
expression on the former, which itself is a strong activator of DCs (72).   
 
The observation that dying cells induce maturation of immature DCs in vitro indicated 
that components of dying cells could be endogenous DC activators (70, 80).  Dead 
cells mixed with antigen and injected into animals were found to increase antigen 
specific CD4+ and CD8+ T cell responses (70, 81) offering further proof that dead 
cells contain endogenous activators that promote T cell immunity. A number of 
components have subsequently been identified. 
 
The components identified so far, called DAMPs, can be broadly divided into two 
categories.  In both categories the molecules are normally hidden within the cell and 
are only revealed following cell necrosis, when membrane integrity is lost.  In contrast 
apoptotic cells generally do not appear to stimulate an immune response (82).  The 
key feature appears to be maintenance of an intact membrane since apoptotic cells that 
are not rapidly cleared then undergo secondary necrosis whereby they become 
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permeable and lose their membrane integrity.  This process permits release of DAMPs 
which then induce an immune response.  
 
In the first category of DAMPs, termed intracellular, the released molecules have a 
direct effect as endogenous activators.  In the second category, termed extracellular, 
the molecules released from dead cells work indirectly through extracellular 
molecules to thereby generate endogenous activators.  Both of these categories are 
discussed in turn. 
Intracellular  
Heat shock proteins 
Heat shock proteins (HSP) were first discovered in studies attempting to identify 
tumour antigens (83).  They are a family of highly conserved molecules found in 
specialised compartments of cells (cytosol, nucleus, mitochondria) and are normally 
involved in protein folding, protection and transportation.  They are soluble proteins 
without a transmembrane domain, which can be translocated to the membrane upon 
cellular stress (84).  HSPs such as HSP70, HSP90 and grp96 are released from 
necrotic but not apoptotic cells (85) and several groups have shown that under these 
circumstances they activate DCs and macrophages (85-87) and stimulate their 
migration to lymphoid organs (88).   
 
Further studies have suggested that HSP60 and 70 signal through the LPS receptor, 
TLR4 (89), with tight controls in these studies attempting to exclude the possibility of 
microbial contamination accounting for this effect.  Other studies have suggested that 
HSPs bind to different families of receptors with data showing that Gp96 binds to low 
density lipoprotein (LDL) receptors (90) and may also bind to CD36, a scavenger 
receptor (86).  Controversy remains surrounding the immunostimulatory activity of 
purified HSPs in view of the possibility that it could be due to contamination by 
microbial products such as LPS (91).   
Uric acid 
Uric acid has been found to have adjuvant properties through activation of DCs.   It is 
the end product of purine degradation and a normal constituent of the cell cytosol, 
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which is released from dying cells when membrane integrity is lost.  Only very high 
supersaturating concentrations, which favour crystallisation in the presence of 
extracellular sodium into monosodium urate (MSU), and not soluble uric acid, have 
been shown in vitro and in vivo to have adjuvant properties in a TLR4 independent 
manner (92, 93). The receptor through which these effects occur is thought to be 
NACHT domain, leucine-rich-repeat- and PYD-containing protein 3 (NALP3), a 
NOD-like receptor (NLR), and leads to IL-1β production from the activated DC (94).  
High mobility group box 1  
High mobility group box 1 (HMGB-1) is an intracellular DNA-binding protein that 
stabilises nucleosomes and regulates transcription.  It is released following 
stimulation of certain viable leucocytes such as DCs when it then functions as a 
cytokine (95).  It is also released from necrotic cells where it has been found to have 
pro-inflammatory properties and act as an adjuvant (96).  Furthermore necrotic 
supernatant from HMGB-1-/- cells, or use of a neutralising antibody (Ab) specific for 
HMGB-1, was found to decrease adjuvant activity by 50%.  This  strengthens 
evidence for its role as an endogenous activator of DCs but also suggests that it is not 
the only one to be released by necrotic cells (96).  HMGB-1 has also been found to 
stimulate maturation of DCs, which is consistent with its adjuvant role (97). 
Intracellular nucleotides 
Intracellular nucleotides, which are involved in energy metabolism, are found in the 
cytosol of cells and released under conditions of inflammation, hypoxia and stress 
(98).  Some of these molecules such as adenosine triphosphate (ATP) and uridine 
triphosphate (UTP) have been found to activate DCs by themselves or in conjunction 
with TNF-α (99, 100).  The effects are thought to be mediated through apurinergic 
receptors, P2xz/P2x7, which are found on resting DCs (101). 
Extracellular 
Molecules are exposed or released from necrotic dying cells which have been found to 
act on extracellular components to generate endogenous activators.  The released 
molecules remain unidentified but are thought to be various hydrolases and proteases 
which are not themselves pro-inflammatory but through their actions generate pro-
inflammatory mediators.  The released molecules activate the complement cascade 
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(102) or cleave extracellular matrix molecules such as collagen (103), hyaluronic acid 
(104), fibrillar proteins and heparan sulphate (105) into pro-inflammatory fragments.  
They also trigger the activation of clotting, fibrinolytic and kinin cascades (106).  
Many have been found to stimulate DC maturation in vitro and in vivo and induce 
cytokine release. 
Complement 
The function of complement in innate immunity is well established and achieved by 
complement effector molecules interacting with Abs and phagocytes and through the 
formation of the membrane attack complex. Although the liver is the primary site of 
C3 synthesis (107), myeloid derived and parenchymal cells have the capacity to 
produce complement both constitutively and in response to cytokine or microbial 
stimulation.  This includes the ability of DCs to synthesise C3, which is enhanced 
following LPS stimulation (108).   
 
Zhou and colleagues have shown that DCs from C3-/- mice have reduced expression 
of MHCII, CD80 and 86, produce less IL-12 and induce more of a Th2 response upon 
stimulation of allogeneic T cells (108).  These findings suggest that C3 is an 
endogenous factor that shapes the immune response through its action on DCs.  The 
mechanism through which this occurs has been recently investigated.  It appears that 
DCs possess a functional set of complement components as well as complement 
receptors, and that they are also capable of producing complement with subsequent 
downstream generation of C3a leading to C3aR signalling on the DC.  This mediates 
DC activation by upregulating MHC and co-stimulatory molecules and contributes to 
more aggressive rejection in a mouse model of transplantation.  When complement is 
inhibited DCs are less activated, and there is less subsequent T cell proliferation and 
more IL-10 production.  This leads to increased survival of skin allografts (109). 
 
The evidence described suggests that many endogenous activators or DAMPs exist 
but leaves many questions unanswered such as how many there are, if expression 
between different cells varies and if so, whether they all elicit the same biological 
response or have specialised functions. 
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Pattern recognition receptors  
PRRs, which are the receptors through which PAMPs are recognised, are expressed 
by innate immune cells and most non-immune innate cells such as fibroblasts, 
epithelial and endothelial cells.  There are a number of different types of receptors, 
which can be classified into three main families based on their functions.  
Signalling receptors  
This family are involved in cell activation in response to a range of microbial 
moieties. Here, three different groups will be discussed. 
Toll like receptors 
The best understood of all the PRRs are Toll like receptors (TLRs). Mammals have at 
least twelve different types of TLR.  They are transmembrane receptors that trigger 
responses through define NFκB and interferon regulatory factor (IRF) dependent 
pathways (110).  All TLRs, except for TLR3, and their bound ligands associate with 
myeloid differentiation primary response gene (88) (MyD88) Toll/inlerleukin-1 
receptor (TIR) adaptor molecules, which then stimulate a kinase cascade that 
ultimately activates NFκB.  TLR3 associates with another TIR adaptor protein, TIR 
domain containing adaptor molecule 1, which then signals to activate type 1 
interferons (111).  The transcription pathways stimulate expression of key molecules 
including co-stimulation and vascular adhesion molecules, and cytokines (112).    
 
As previously mentioned TLRs have been shown to recognise and bind highly 
conserved carbohydrates, peptide and nucleic acid structures uniquely expressed on 
microbes and not on host cells.  Cells simultaneously express multiple TLRs which 
are overlapping but not identical and this variation in expression profile is evident in 
different DC subsets (113).  
 
Co-operation between TLRs leads to synergistic responses e.g. multiple TLR 
activation on DCs causes a several fold increase in TNF-α, IL-6 and IL-12 compared 
with single TLR agonist activation (114).  Conversely negative regulation may also 
occur through simultaneous stimulation of multiple TLRs e.g. IL-10 production by 
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TLR2 activation on human DCs blocks IL-12 production through stimulation of 
TLR3 or 4 ligands (115).   
NOD-like receptors and RIG-I-like receptors 
It is not just TLRs that are important in the recognition of and response to microbes.  
The two main other types of receptor are intracellular and divided into RIG-I-like 
receptors (RLRs) and NOD-like receptors (NLRs), which make up the largest family 
of the signalling receptors and in humans consist of 23 members (110).  RLRs include 
the cytosolic helicases, retinoic-acid-inducible gene-I (RIG-I) and melanoma-
differentiation-associated gene 5 (MDA5), which recognise viruses (116).  Most 
members of the NLRs remain ill defined but some are better characterised and include 
nucleotide-binding oligomerisation domain 2 (NOD2) and NALP3.  NOD2 recognises 
bacterial wall products and activates NFκB transcription pathway (116) whilst 
NALP3 forms a caspase-1 activating molecular complex termed the inflammasome 
(117) and recognises pathogens as well as some of the endogenous danger signals 
such as uric acid.  Inflammation through this pathway appears to be mediated mainly 
through IL-1β production (118).  
Endocytic receptors 
Endocytic receptors are expressed on the cell surface and mediate the recognition and 
internalisation of microbes and microbial moieties.  
C- type lectin receptors 
C-type lectins (CLR) include the mannose receptor (MR), langerin and DC-SIGN 
(119).  They recognise specific glycans on antigens and function as antigen binding 
and uptake receptors that facilitate MHC loading (120).  Several CLRs are involved in 
the recognition of similar pathogens e.g. Candida albicans binds to MR, DC-SIGN 
and dectin-1, however restricted expression is seen between subsets of DCs and this 
may select for preferential pathogen recognition (121).   
 
It has also become clear that several CLRs additionally induce signalling and thus 
modify the immune response through pathways initiated by TLR (122).  For example 
binding of fungal β glycan to dectin-1 can directly signal or synergistically act with 
TLR2 to stimulate cytokine secretion of IL-10, TNF-α and IL-12 leading to DC 
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activation (123).  Conversely TLRs have been shown to influence antigen processing 
and presentation (124) including those regulated by CLRs (125). 
Scavenger receptors 
Most scavenger receptors are cell surface glycoproteins that bind modified LDL, 
which are oxidised or acetylated, but not native LDL (126).  Recognition of their 
ligand is followed by rapid internalisation and either accumulation or destruction 
(127).   
Bridging molecules 
Soluble bridging molecules are also known as opsonins and facilitate recognition and 
clearance of their ligands by phagocytes such as collectins and ficollins.  Some are 
also involved in the activation of the complement pathway.   
Receptors for DAMPs 
Much more is known about receptors that recognise and bind to microbial 
components than those involved in the recognition of endogenous signals.  One 
hypothesis is that similar mechanisms are involved in both pathways.  There is 
certainly evidence to suggest a role for TLRs in the recognition of DAMPs.  In a 
model of liver ischaemia-reperfusion injury the inflammatory effects of HMBG-1 
were found to be stimulated through TLR2 and 4 (128). A number of other 
endogenous activators have also been reported to mediate their effects through the 
same TLRs including fibrin (129), heparan sulphate (130), HSPs (131) and hyaluronic 
acid (132).  The fact that contamination with microbial components may account for 
these results has not been completely excluded and may be the reason why other 
studies have not found a role for TLR2 and 4 in the stimulatory activity of MSU (94) 
and HSPs (91). 
 
The involvement of TLRs in the actions of DAMPs is only part of the picture since 
mice lacking the ability to signal through TLRs still generate acute monocytic 
inflammation to dead cells (133).  It is likely that major receptors involved in the 
recognition of endogenous signals have yet to be identified.  Others implicated 
include one of the intracellular NLRs, NALP3, as the receptor involved in the 
inflammatory response to MSU (94),  and receptor for advanced glycation end-
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products (RAGE), which has been found to bind to HMBG-1 and mediate its pro-
inflammatory effects (134); CD14 (135) and scavenger receptors have also been 
implicated in the effects of HSPs and other endogenous activators. 
 
It is now apparent that complement’s effect as a DC activator is mediated through its 
own receptor.   Furthermore DCs not only express complement receptors but also 
possess the ability to generate complement and so have the potential to both produce 
danger signals and to respond to them. 
Interaction of dendritic cells with adaptive cells 
The fate of the naive T cell is dictated by three signals from the activated DC, 
illustrated in figure 1.  Signal 1 results from T cell receptor (TCR) ligation by antigen 
derived peptide presented in the context of MHCII and determines antigen specificity.  
Signal 2 involves interaction of co-stimulatory molecules to initiate an immune 
response.  Lack of signal 2 leads to T cell anergy and may lead to tolerance (136).  
The formation of the immunological synapse with TCR and co-stimulation leads to an 
effective immune response where the naive T cells develop into effector T cells with 
expression of a selective pattern of cytokines.  The type of immune response and 
balance of cytokines is dependent on the conditions under which DCs are primed for 
the expression of polarising signal 3 (137).   
 
The next section will discuss molecules which make up signal 2. 
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Co-stimulatory molecules 
This family of molecules is ever expanding but CD80 and 86 are the commonly used 
markers of DC maturation.  CD80 and 86 both bind stimulatory CD28 and inhibitory 
cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) although affinity to the latter 
is at least ten times higher than to the former.  CD28 is expressed on naive T cells and 
interaction is necessary for initiation of most T cell responses with blockade resulting 
in ineffective T cell activation.  CTLA-4 is not found on naive T cells but is 
transcriptionally induced following T cell activation (138).  The critical role of 
CTLA-4 is as a negative regulator of T cell activation as evidenced by overwhelming 
lymphocytic infiltration with tissue destruction of CTLA-4 deficient mice leading to 
an early death (139, 140).    Engagement of CTLA-4 leads to a negative signal which 
antagonises CD28 and limits the duration and magnitude of T cell activation (141, 
142). 
 
Up-regulation of CD80 and 86 on DCs does not always indicate the ability to induce 
an immune response.  For example, RSV infected DCs have high expression of CD80, 
86 and 83 are rendered incapable of inducing proliferation of allogeneic naive T cells; 
furthermore their relative differential expression may affect the type of immune 
response. 
 
Different DC subsets have differential expression of CD80 and 86, which may lead to 
variation in immune effector responses.  Using transfectants, it has been shown that 
CD86 causes higher CTLA-4 expression on activated CD4 T cells than does CD80.  
Furthermore CD86 seems to have a negative effect on proliferation of memory T 
cells, but not naive T cells, and this may be through the higher expression of CTLA-4 
leading to an inhibitory effect (143).  Other studies have shown that CD80 is the main 
functional ligand for CTLA-4 and that the interaction of CD28 with CD86 promotes 
Th2 differentiation (144, 145).  These data do not all correlate but certainly indicate 
that CD80 and 86 have differential effects on the immune response. 
Programmed death ligands (B7 family –co-inhibitory molecules) 
Programmed death 1 (PD1) was originally identified on a T cell hybridoma (146) and 
subsequently found to be detected on activated but not resting T and B cells (147).  
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Evidence supports its role as a co-inhibitor by delivering a negative signal (through 
deactivating downstream signal transducers) to T and B cells upon ligation (148).   
 
Programmed death ligand 1 (PDL1) and PDL2 have both been described as ligands 
for PD1.  Both are found on DCs and expression can be induced by inflammatory 
cytokines.  IFN-γ appears to have a greater role in inducing the former whilst IL-4 
appears to stimulate the latter suggesting distinct functions in regulating Th1 or Th2 
responses (149).   PDL1 is also found on various other cells including T, B and 
endothelial cells, both at rest and following activation, as well as non-lymphoid 
organs such as the heart, lung and placenta.  In contrast, the expression pattern of 
PDL2 is similar to CD80 and 86, which is limited to DCs and macrophages (150, 
151).  As PDL1 and 2 were both found to be ligands for PD1, their main role was 
thought to be as co-inhibitory molecules since in vitro studies showed that their 
ligation inhibited T cell proliferation and cytokine production (152).  However other 
studies have shown co-stimulatory activity independent of PD1, thus suggesting that 
PDL1 and 2 bind to at least one other receptor and have dual co-stimulatory and 
inhibitory functions depending on the environment (153).  
Inducible co-stimulator ligand 
Inducible co stimulator (ICOS) is a homologue of CD28 and expressed on activated, 
but not naive, T cells (154).  ICOSL is found on DCs and other antigen presenting 
cells including B cells and macrophages (155) and also on non-haemopoetic cells 
such as endothelial cells (ECs) and fibroblasts.  Regulation of ICOSL is different from 
CD80 and 86 expression as it is not dependent on NFκB signalling and therefore is 
not upregulated by CD40 stimulation (156).  Data suggest that it is found at low levels 
on resting cells and is regulated by inflammatory stimuli such as IFN-γ, TNF-α and 
LPS in a variety of locations (154, 157). 
 
Engagement of ICOSL with ICOS was initially shown to produce high levels of IL-10 
and IL-4.  In the mouse bronchial tree ICOSL was shown to be expressed on DCs 
involved in the induction of IL-10 producing regulatory T cells (Tregs) (158).  
Furthermore activation of human pDCs by virus was found to lead to IL-10 
production by these DCs which in turn induced IL-10 producing Tregs (159).   
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However in vivo studies in several disease models have shown that ICOS stimulation 
not only induces a regulatory phenotype but can also affect both Th1 and Th2 
cytokines in effector T cell responses (160).  ICOS KO mice exhibit resistance to 
Listeria infection with decreases in both Th1 and Th2 cytokines resulting in less 
severe disease compared to wild type (161).  Indeed, ICOSL has also been found to 
regulate the balance of cytokine responses but without enhancing IL-2 production 
from T cells (162).  This suggests that, unlike signalling through CD28, it is not 
involved in initiation (or maintenance) of the T cell response but in shaping and 
enhancing the T cell effector response.  This appears to be mainly through 
enhancement of a regulatory phenotype but also through effects on Th1 and Th2 
polarisation. 
B7-H3 
The receptor for this molecule has not yet been identified but is thought to differ from 
known CD28 family members (163).  Binding of activated but not naive T cells 
suggests the receptor is on the former (164). 
B7-H4 
This is the newest member identified with co-inhibitory function and its receptor is 
thought to be distinct from other known CD28 members and the receptor for B7-H3 
(165). 
 
It is worth mentioning another two groups of molecules, which are involved with DC-
T cell interaction, in the next section. 
TNF family 
Molecules of the TNF family include CD40, CD70, OX40L and 4-1BBL (166).  
CD40 ligation by CD40L has been shown to activate DCs by upregulating CD80 and 
86 with production of IL-12.  Activation through CD40 also promotes upregulation of 
other TNF molecules.  OX40L expression can be induced by TSLP, which is secreted 
by keratinocytes, and has been shown to promote Th2 T cell proliferation (167) and 
inhibit IL-10 production from Tregs (168).  Many studies have shown ligation of 
OX40 to play a preferential role in Th2 differentiation but some data also supports its 
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involvement in a Th1 response (169, 170).  It appears to contribute to an ongoing 
effector response rather than to initially determine the type of response.   
Adhesion molecules 
Inter-cellular adhesion molecule-1 (ICAM-1) is upregulated on the surface of mature 
antigen presenting cells, which, as its name suggests, serves as an intercellular 
adhesive with its ligand lymphocyte function associated  antigen 1 (LFA-1), 
expressed on activated T cells (171).  The binding of ICAM-1 and LFA-1 forms a 
molecular seal around the TCR-MHC-peptide complex and co-receptors to form the 
immunological synapse.  Clustering of the receptors around this site causes 
polarisation of the T cell and allows for reorganisation of the cytoskeleton, which 
focuses the secretion of effector molecules at the site of contact (172).  
 
Interactions between DCs and exogenous and endogenous activators, other cells and 
their products, lead to the development of distinct DC phenotypes.  The subsequent 
expression of polarising molecules from DCs then shapes the differentiation of naive 
T cells into effector ones.  In this way DCs are able to react to the environment and 
control the T cell response.  Here, T cell differentiation will be discussed before 
expanding on DC polarising signals, which make up signal 3. 
T cell differentiation 
The various effector T cells have different phenotypic and functional characteristics 
but are derived from the same precursor naive T cells.  Different, but overlapping, sets 
of cytokines released from the effector T cells then define their distinct functions as 
initially demonstrated by Mosmann and Coffman (173) in the mouse and Romagnani 
(174) in humans.  Th1 cells produce IFN-γ and TNF-β, whereas Th2 cells secrete IL-
4, IL-5, IL-13 and IL-10.  Th0 effector cells can also be induced, which are activated 
T cells and have effector functions characteristic of both Th1 and Th2.  They have the 
potential to differentiate into either of the two types.  More recently a Th17 class of 
effector T cell has been described (175, 176), which appears to have a key role in 
tissue damage in many diseases including infection and autoimmunity.  
 
Besides these effector classes, T cells are also involved in a regulatory capacity by 
inducing and maintaining tolerance and preventing autoimmunity.  Naturally 
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occurring regulatory T cells (nTregs) develop from thymic precursors (177) and 
express the transcription factor forkhead box p3 (foxp3) (178, 179). There is also 
growing evidence for the induction of Tregs from naive T cells, the so-called induced 
or adaptive Tregs (iTregs) (180, 181).  The variety of iTregs identified is increasing 
but currently they cannot reliably be distinguished from nTregs based on surface 
expression of specific markers.  Their expression of foxp3 is variable as is their 
mechanism of action.  The suppressive property of some iTregs results from the 
secretion of immunosuppressive cytokines such as IL-10 and TGF-β rather than cell 
contact dependent mechanisms as shown in nTregs.  Examples of conditions leading 
to these type of Tregs include in vitro chronic stimulation of conventional CD4+ T 
cells with IL-10 and in vivo induction following oral tolerance induction leading to 
IL-10 and TGF-β secreting Tregs respectively (182, 183). 
Dendritic cell polarising signals 
Categorisation and definition of the inflammatory networks which influence DC 
polarising signals is complex.  Unique properties of microbes initiate these different 
inflammatory networks, which polarise DCs and thereby initiate distinct effector T 
cell responses.  Broadly speaking a first network is associated with the development 
of Th1 cells and can be initiated by intracellular bacteria or viruses; a second network 
leads to the development of Th2 cells and can follow infection by extracellular 
organisms such as nematodes; whereas a third network involves induction of 
tolerance and down regulation of the immune response.  This third network can be 
initiated by certain elements such as the hyphae of Candidia albicans, which induce 
IL-10 producing DCs thereby leading to selective expansion of Tregs, and can also 
occur in immune-privileged areas such as the eye. 
 
The inflammatory networks that contribute to polarisation of the DC consist of a 
number of factors.  Individual factors may prime the DC towards either Th1 inducing, 
such as through type 1 or 2 IFNs or CCL18 (184, 185); Th2 inducing, for example 
through PGE2, CCL2 or interaction of OX40 with OX40L (186); or Treg inducing 
such as through IL-10 or TGF-β (187, 188).  Other examples include TSLP-DCs, 
which induce Th2 polarisation with T cells also producing TNF-α (76), and the more 
recently described Th17 polarising factors, which include IL-6 in the presence of 
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TGF-β and IL-23 (189, 190).  Table 1.4 shows examples of known DC polarising 
factors. 
Th1 inducing Th2 inducing Treg inducing
Cytokines IFN-γ, IFN-α/β, 
IL-12, TNF-β, 
IL-18
IL-4, IL-5, IL-9, 
IL-13, IL-25, 
TSLP
IL-10, TGF-β, 
TSP1
Chemokines CXCL9, 
CXCL10, 
CCL21
CCL2, CCL7, 
CCL8, CCL17 
CCL17
Co-stimulatory OX40L CTLA-4, GITRL
Eicosanoids PGE2
Other histamine
Table 1.4 Polarising factors for DCs
GITRL-glucocorticoid-induced TNF receptor ligand , TSP1-thrombospondin 1.
Adapted from Nature Reviews Immunology 2003 3 984.
 
In summary the conditions of activation and degree of maturation of the DC govern 
the three signals delivered to the T cell.  DCs are a heterogenous population of cells 
and the subtype of DC also influences the effector immune response.  Originally it 
was thought that the T cell polarising molecules were fixed and pre-programmed 
depending on the DC subtype.  However this is clearly not the case as much data 
show the ability of a particular DC subset to induce Th1, Th2 or regulatory T cell 
phenotypes depending on the priming activators.  
 
Exogenous signals from microbial invasion are involved in activating the immune 
response but it has also become clear that endogenous signals from injured tissue as 
well as the host’s innate systems play a key role in activating and shaping the adaptive 
immune response.  The full extent of endogenous activators of the immune system has 
not been explored and many questions remain unanswered for further investigation. 
 
The coagulation network is one of the innate systems and will be discussed in greater 
detail in the next chapter.  
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Chapter 2: The coagulation network 
Initiation and propagation of the coagulation cascade in haemostasis and thrombosis 
is well characterised (191) and results in the formation of a fibrin clot.  In contrast, its 
importance in other biological systems has been appreciated only relatively recently 
(192).  Many of these other effects are mediated in a fibrin-independent manner by 
activation of a family of cellular receptors called protease activated receptors (PAR).   
 
This project aims to gain further insight into the role of coagulation proteins in the 
adaptive immune system.  
The coagulation network  
The blood coagulation network is activated when cells expressing active tissue factor 
(TF) come into contact with blood leading to a series of feedback amplification loops 
(193) as shown in figure 2.1. TF is a cellular receptor and co-factor for factor VII 
(FVII), present in blood, leading to rapid activation to FVIIa.  The TF-FVIIa complex 
catalyses activation of both FIX and FX to FIXa and FXa respectively.  The initial 
FXa produced activates small amounts of prothrombin (factor II) to thrombin (factor 
IIa).  This initial thrombin is essential for acceleration of the process by serving as an 
activator for other coagulation products leading to a propagation phase which 
generates more thrombin.  The coagulation factors involved in this back activation by 
thrombin are FVa and FVIIIa.  Small amounts of thrombin are produced in the 
initiation phase amounting to 5 to 10 nM concentration; subsequently the major bolus 
of over 95% of thrombin is produced by the propagation phase.  Thrombin is the main 
effector protease of the coagulation cascade and production is essential for 
haemostasis by cleaving fibrinogen to fibrin (194) which polymerises to form the 
fibrous matrix of a clot.   
Regulation of the coagulation network 
The coagulation process is tightly regulated by several inhibitors, which under normal 
circumstances are present in excess of the pro-coagulant factors.  The three principal 
endogenous inhibitors are anti-thrombin (AT), tissue factor pathway inhibitor (TFPI) 
and activated protein C (aPC) (194) as shown in figure 2.1. 
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Figure 2.1  The coagulation cascade
TFPI   inhibits TF/VII/Xa, Xa
AT      inhibits thrombin, IXa, Xa, XIa
aPC    inhibits Va, VIIIa
Regulators of coagulation
prothrombin thrombin
VII
XI
XaX
TF/VIIa
TF
VIIa
VVa
VIIIVIIIa
IXa
IX
XIa
 
AT is a single chain glycoprotein with a molecular mass of 58kDa. It is a serine 
protease inhibitor (serpin) and shares 30% homology in amino acid sequence with 
other serpins. AT binds directly to coagulation factors to form an equimolar complex 
and effectively neutralises their action irreversibly.  Its principal targets are the 
uncomplexed, activated serine proteases in the coagulation cascade, the main one of 
which is thrombin (195) but also includes FIXa, FXa, FXIa, FXIIa and FVIIa (in the 
presence of heparin).  It is normally present in plasma at over twice the concentration 
of any potential target coagulation factor.  Binding to AT, in the absence of heparin, is 
low affinity and therefore inhibition is relatively slow but very effective.  Thus AT 
can be seen as a modulator of physiological reactions allowing, for example, time for 
wound closure but preventing systemic activation of coagulation (196).   
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TFPI directly inhibits FXa as well as inhibiting TF/VIIa/Xa complex and so prevents 
further generation of FXa.  It has a high binding affinity but is normally present at 
much lower concentrations than AT in the plasma.  The major site of TFPI production 
is the EC (197), on which it is constitutively expressed and appears to exist in 
different cellular pools either attached to the cell surface via proteoglycans (198) or 
within caveolae linked to the surface via glycosylphosphatidylinositol (199, 200).  
TFPI is secreted by ECs and released by both these cellular stores into the plasma, 
where it circulates.  It is also expressed under normal conditions on vascular smooth 
muscle cells (201), fibroblasts, platelets and monocytes (202) and has been detected 
on macrophages and T cells within atherosclerotic plaques (203).  Whether these cell 
types have the same cellular pools of TFPI as ECs is uncertain.  Many of the factors 
which induce TF expression have been found to upregulate TFPI expression in vitro 
such as endotoxin, TNF-α and IL-1 (204).   
 
The protein C system is dynamic.  Generated thrombin binds to constitutively 
expressed thrombomodulin on vascular ECs.  This changes the substrate specificity of 
thrombin leading to activation of protein C to aPC (205).  aPC then competitively 
binds to FVIIIa and FVa (206) and inhibits their effects involved in the propagation 
phase of thrombin generation. 
 
Many soluble anti-coagulants have been developed as therapeutic inhibitors of 
thrombosis.  Hirudin is a 65 amino acid (aa) protein originally derived from the 
salivary gland of the medicinal leech (207).  It inhibits thrombin directly by binding 
irreversibly to two of its sites, one of which is the active site, thereby preventing 
cleavage of fibrinogen to fibrin.   
 
Heparin is less specific but is more widely used as its action is reversible.  It enhances 
the effect of AT by altering its conformation, mediated through a unique 
pentasaccharide sequence on heparin, and allowing more avid, irreversible binding of 
AT to the relevant coagulation factors thereby accelerating the process 1000 to 4000 
fold (196).   Low molecular weight heparins have the same mechanism of action but 
are smaller molecules than heparin.  Unlike heparin they only affect the binding of AT 
Introduction: Chapter 2 
32 
 
to FXa and not the other coagulation factors, which are thought to require 
simultaneous interaction of heparin with both AT and the relevant coagulation factor.   
Tissue factor 
TF is the initiator of the coagulation cascade and is a 47 kDa transmembrane 
glycoprotein that serves as a receptor and co-factor for FVII/VIIa.  TF comprises a 
219aa extracellular domain, 23aa transmembrane domain and 21aa cytoplasmic tail.  
The extracellular domain is necessary and sufficient for coagulation as recombinant 
variants that lack either the transmembrane or cytoplasmic domain or both retain full 
pro-coagulant function (208).  
  
TF is constitutively expressed on cells at biological boundaries such as skin, organ 
surfaces and vascular adventitia but not on cells within the vasculature, leading to the 
traditional concept of TF forming an haemostatic envelope.  This pattern of 
distribution ensures that following vascular damage.  FVII/VIIa in blood is exposed to 
cells expressing TF leading to the initiation of coagulation.   
 
TF can also be induced upon inflammatory cells within the vasculature and has been 
implicated in the pathogenesis of a variety of diseases involving thrombosis such as 
atherosclerosis (209), disseminated intravascular coagulation (DIC), malignancy (210) 
and hyperacute rejection of xenografts (211).   
 
In these circumstances inflammatory stimuli cause accumulation of TF mRNA by 
both transcriptional and post-transcriptional mechanisms.  Functional studies of the 
TF gene promoter have indentified two regions important in the transcriptional 
regulation (212).  The first termed LRE (LPS-response element) contains two 
activator protein-1 (AP-1) and one NFκB binding sites and mediates the response to 
stimuli such as IL-1β, TNF-α and LPS.  The second region termed SRE (serum 
response element) contains three overlapping Sp1/Egr-1 binding sites and mediates 
the response to serum, shear stress, hypoxia and LPS.   
 
In this way TF is induced on cells which are not normally able to initiate coagulation 
and thus enables thrombosis to occur following a variety of pathological stimuli.  
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Macrophages within an atherosclerotic plaque strongly express TF and so initiate 
intravascular thrombosis following plaque rupture leading to infarction (209).  
Monocytes and ECs are clearly recognised to express TF following a variety of 
stimuli such as by endotoxin and cytokines like TNF-α and IL-1 (213).  In vivo 
monocytes and ECs have been shown to express TF in an experimental model of 
Gram’s negative sepsis in baboons and the lethal effect of sepsis was prevented by 
pre- treatment with anti-TF Abs (214).  TF expression on peritumour inflammatory 
macrophages, vascular ECs and fibroblasts have been described to be associated with 
extravascular tumour fibrin deposition (210).   
 
The role of TF in these diverse settings is not only as an initiator of coagulation but 
also involves pro-inflammatory effects and a role in the regulation of angiogenesis, 
tumour growth and metastasis.  There are a number of mechanisms involving TF 
which would account for its role in these other settings.   
 
Many of the cellular effects of the coagulation proteins are now recognised to occur 
through a family of receptors called protease activated receptors (PARs).  TF leads to 
generation of downstream coagulation proteins, which are known ligands of PARs, 
and TF/VIIa can itself activate PAR-2.  PARs and their role in inflammation will be 
discussed in a separate section.   
 
TF is structurally related to the cytokine receptor family, which is known to signal 
through a cytoplasmic tail, and is most closely related to IL-10 and IFN-α, -β and –γ 
receptors (215).  These 21aa in human and 20aa in mouse are highly conserved in the 
TF cytoplasmic tail.  Stimulation with phorbol ester leads to phosphorylation of the 
three serine residues present in the tail (216), which suggests the potential for 
signalling to occur through its cytoplasmic domain following receptor ligation.  
Further evidence includes a role for its cytoplasmic domain in cell migration (217) 
and in activation of mitogen activated protein (MAP) kinase p38, extracellular signal-
regulated kinases 1/2 (ERK1/2) and Rac pathways leading to these effects (218, 219).   
 
The pro-inflammatory effects as well as the effects on angiogenesis and tumour 
growth have been shown to occur through both mechanisms described above.  Firstly, 
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through activation of PARs by TF-VIIa complex and downstream generated FXa 
(220) and thrombin leading to cell signalling. Secondly, by signalling events through 
the cytoplasmic domain of TF following binding of FVIIa, which does not appear to 
require the catalytic activity of FVIIa.  Figure 2.2 illustrates the different ways TF can 
exert an effect. 
TF/VIIa
FXa
Thrombin
aPC
clot
TF
FVIIa
(1)
(2)
(3)
Figure 2.2 Different mechanisms of the action of TF
TF is able to exert an effect by signalling through its cytoplasmic tail (1), generation of downstream
coagulation proteins, including TF/VIIa, FXa and thrombin which can signal through PAR-2 and PAR-1
respectively (2) as well as the latter leading to clot formation (3).
 
 
It is now clear that TF is involved in more than merely initiation of clot formation as 
indicated by its different mechanisms of action.  Its diverse roles are also reflected in 
the expression of TF on a variety of cell types, which includes those of the immune 
system. This will be discussed next along with blood borne sources of TF. 
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Tissue factor expression on immune cells 
Expression of TF can be induced on a number of cells including monocytes, 
macrophages and ECs by mediators such as LPS, phorbol 12-myristate 13-acetate 
(PMA), CD40L and various cytokines (213, 221).  Increased TF expression on these 
cell types has been described in a number of disease states; high TF expression on 
monocytes, macrophages and foam cells in atherosclerotic vessels, where it plays a 
role in thrombus formation in acute coronary disease; increased TF expression on 
monocytes of cancer patients (222, 223) and in tumour bearing mice (224); and 
enhanced TF expression on ECs and monocytes in endotoxaemia (214).    
 
TF has also been found on neutrophils (225, 226) but their ability to synthesise and 
express TF is controversial and it is now thought that the TF originates from 
monocytes and is transferred to neutrophils (227, 228).   
 
T cell lines have been shown to support pro-coagulant activity but this has been found 
to be related to expression of anionic phospholipid and not TF (229).  Other studies 
have concurred with these results and neither found evidence of TF expression on T 
lymphocytes (230) nor NK cells at baseline and following stimulation with PMA and 
LPS.   In contrast a subpopulation of B lymphocytes has been reported to express TF 
upon activation with PMA (231).  
 
Several different groups have also demonstrated that TF is expressed on human DCs 
of lymphoid follicles (230) and monocyte derived human DCs (232, 233) with 
stimulation leading to release of active TF microparticles in the latter study.  Niessen 
and colleagues have published data whilst this work was ongoing, which also supports 
TF expression on mouse DCs (234). 
 
Together these data suggest expression of TF on a number of innate cells of the 
immune system, where it appears to play a pathophysiological role in a number of 
disease states.  A pro-inflammatory as well as pro-thrombotic function for TF has 
already been implicated.  Of particular note is the expression of TF on a variety of 
antigen presenting cells, which also raises the possibility of a role in the adaptive 
immune response.   
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Blood borne tissue factor 
Recently, apart from constitutive and induced cell surface expression, an additional 
third source of TF has been described, known as blood borne TF.  This TF antigen has 
been measured in low but readily detectable levels (100-150pg/ml) in normal plasma. 
These levels appear to increase dramatically in various disease states such as during 
DIC, in patients with certain leukaemias and atherosclerosis.  The source of the blood 
borne TF, how it is formed and how production is regulated is still under 
investigation.   
 
It is believed that microparticles contribute to the development of thrombi by binding 
of TF and p-selectin glycoprotein ligand-1 (PSGL-1) on their surface to p-selectin on 
activated platelets, which have concentrated on a vessel wall at the site of injury 
(235). Studies have shown the existence of cell derived microparticles of TF from 
different cell types including platelets (236), leukocytes (237) and endothelial cells 
(238).   
 
More recently another form of blood borne TF has been proposed, which is 
alternatively spliced and so generates soluble TF lacking a transmembrane domain 
(239) indicating that two isoforms of TF exist in circulating blood.  Furthermore, what 
is clear is that since blood remains fluid in the absence of vascular injury, blood borne 
TF must normally circulate in an inactive form.   
Encrypted tissue factor and its regulation 
It has been known for some time that TF exists in an inactive or encrypted form, 
which is when post translational suppression of TF pro-coagulant activity on the cell 
surface occurs (240).  The cell surface TF becomes fully pro-coagulant when the cells 
are stimulated in a number of ways, some of which have secondary effects on cell 
structure.  This includes by complement and calcium ionophores, which leave the cell 
membrane intact as opposed to by non-ionic detergent or freeze-thawing when the 
membrane is disrupted (241).  The control of encryption is unknown but there have 
been several proposed mechanisms.  
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Since TF pro-coagulant activity is sensitive to phospholipid composition, the 
regulated exposure of phosphatidylserine on the outer leaflet of the plasma cell 
membrane, rather than remaining on the inner leaflet, has been suggested as a 
potential mechanism.  The mechanism through which increased anionic phospholipid 
converts encrypted TF into its pro-coagulant form is unknown but some evidence 
suggests that phospholipid exposure leads to enhanced TF-VIIa activity by altering 
the structure of TF-VIIa and so increasing the rate of catalysis (241). The association 
of TF with cholesterol and lipid rafts has also been shown to affect pro-coagulant 
activity (242).  
 
More recently data suggests that encryption is regulated by a disulphide exchange 
mechanism although there is much controversy surrounding this novel mechanism.  
Studies suggest that the cryptic form of TF contains unpaired cysteine thiols at cys186 
and cys209 and activation involves formation of the cys186 to cys209 disulphide 
bond (243).  Work from the same group also suggested that protein disulphide 
isomerase (PDI) plays a critical role in isomerisation of the disulphide bond.   
 
PDI is a member of a family of proteins of the same name.  It was the first to be 
characterised and is the most studied of the family.   All members are found in the 
endoplasmic reticulum (ER) of most eukaryotic cells and many exert their action 
exclusively in this location, although at least three of the proteins have been found in 
non-ER locations including the cell surface (244).  They are involved in proper 
folding and formation and reshuffling of disulphide bonds in newly synthesised 
proteins within the ER (245) and so are essential for cell viability.  The mechanism by 
which the enzymes escape to non-ER locations is not understood but PDI has been 
found on the cell surface of a variety of cells and has been implicated as regulating TF 
encryption.   
 
Ahamed and colleagues not only suggest that PDI disables coagulation by acting on 
the critical cys186 cys209 disulphide bond but that it also favours signalling of the 
TF-VIIa complex through PAR-2, demonstrating that alternative conformations of the 
TF-VIIa complex have distinct functions of coagulation or signalling (246).  Other 
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groups raise questions against this proposed mechanism and have published data to 
the contrary (247). 
Tissue factor in inflammation 
Sepsis 
Inhibition of TF in a number of animal models of sepsis has been shown to attenuate 
septic shock and improve survival rates.  Studies in a baboon model of lethal 
endotoxaemia using LPS include the use of anti-TF Ab (214), active site inhibited 
FVIIa (248) and TFPI (249).  The Ab directly inhibits TF, whilst active site inhibited 
FVIIa behaves as a non-functional ligand to TF and TFPI inhibits FXa and 
TF/VIIa/Xa complex all preventing generation of downstream coagulation proteins as 
well any further action of TF.  All of these studies have shown reduced coagulation 
parameters with higher levels of fibrinogen and platelets and reduced fibrinogen 
degradation products, confirming an inhibition of TF-dependent coagulation and 
intravascular fibrin deposition.  
 
Moreover the latter two studies using active-site-inhibited FVIIa and TFPI also 
measured inflammatory parameters and showed a reduction in levels of IL-6, IL-8 but 
not TNF-α at later time points (after four hours) following LPS injection, suggesting 
coagulation was coupled with an inflammatory response.  A further study in the same 
model of sepsis using active-site-blocked FXa did not prevent mortality nor did it lead 
to a reduction in the inflammation but did show reduced coagulation parameters 
(250).  Active-site-blocked FXa inhibits the generation of downstream coagulation 
parameters but does not prevent the action of TF and TF/VIIa complex therefore 
suggesting that TF and TF-VIIa are involved in the interaction of coagulation with 
inflammation. 
 
In a mouse model of abdominal sepsis using a virulent strain of E coli there was no 
benefit in survival or reduction in inflammatory parameters when TF-VIIa pathway 
was inhibited by recombinant nematode anti-coagulant protein c2 (rNAPc2) (251).  
However in another mouse model of sepsis, using a different strain of LPS, low TF- 
expressing mice were found to be protected from death and had reduced levels of IL-6 
and IL-8 (252).  This study, which further investigated the role of PARs as the 
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mechanism of action linking coagulation and inflammation, showed the involvement 
of multiple PAR signalling and will be discussed in detail later. 
 
More evidence for the crosstalk between coagulation and inflammation comes from a 
recent study in which a similar mouse model of intraperitoneal injection of endotoxin 
used mice with the cytoplasmic tail of TF deleted (CT∆).  These mice had improved 
survival and reduced levels of monocyte chemotactic protein-1 (MCP-1), IL-6 and IL-
1β at time points later than eight hours following LPS injection (253).  The 
mechanism for this effect was not elucidated but suggestion was made as to the 
involvement of PAR-2 signalling.   The study also showed an auto-regulatory role for 
the cytoplasmic tail of TF in influencing its own expression through coupling with 
transcription factors, which are activated following stimulation of TLR4 by LPS.  
This led to an increased expression of TF with an increase in coagulation parameters 
in the CT∆ mice but was not the factor that led to protection against death.  Due to the 
loss of regulation of TF expression, macrophages isolated from the transgenic mice 
had higher expression of TF than macrophages from wild type mice in response to 
LPS.   
 
The cytoplasmic tail of TF has also been shown to contribute to leucocyte recruitment 
in a mouse model of endotoxaemia (254).  CT∆ mice, which have normal coagulation, 
were found to have reduced neutrophil recruitment to the lung with reduced leucocyte 
rolling, adhesion and emigration observed by intravital microscopy together with 
reduced levels of IL-6, TNF-α and IL-1β.   This was found to be in conjunction with 
reduced nuclear translocation of NFκB suggesting involvement in signalling through 
the cytoplasmic tail of TF leading to cytokine release.  
 
During endotoxaemia TF expression is upregulated on macrophages.  The 
cytoplasmic tail has been found to be involved in their activation and inflammatory 
effect (255). Addition of FVIIa to macrophages expressing TF led to enhanced 
production of reactive oxygen species (ROS), which are inflammatory effector 
molecules, and upregulation of MHCII and adhesion molecules.  The interaction of 
receptor and ligand induced intracellular Ca2+ flux, and was dependent upon the 
cytoplasmic tail of TF.  Further evidence for signalling through the cytoplasmic tail of 
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TF comes from a study of CT∆ mice with antigen induced arthritis, in which 
peritoneal macrophages were reduced in number with reduced ROS when stimulated 
with LPS (256).  Collectively, these data indicate that TF affects macrophage function 
directly through signalling via its tail, following interaction with its ligand FVIIa.  
This occurs rather than the TF-VIIa interaction going on to associate with another 
receptor on the cell surface, such as PAR-2, or going on to generate other coagulation 
proteins.  
Glomerulonephritis  
TF expression is clearly associated with fibrin deposition leading to exacerbation of 
disease in glomerulonephritis (GN) (257, 258) but studies have also shown TF 
contributes to other mediators of glomerular injury. Use of anti-TF Ab in rabbit 
experimental GN not only ameliorated disease and inhibited fibrin deposition but also 
reduced MHCII expression (258). Moreover anti-TF and ancrod, a selective 
defibrinogenating agent, attenuated disease more than ancrod alone, with the former 
combination additionally inhibiting macrophage and T cell infiltration with less MHC 
II expression (259).  This suggests an effect on inflammation as well as coagulation. 
Ischaemia-reperfusion 
Increased TF expression has been found in rodent models of renal ischaemia-
reperfusion (IR) with a protective effect of inhibiting TF with TFPI (260) and TF anti- 
sense oligonucleotides (261).  The mechanism for this effect appears not to be through 
TF directly but by thrombin-dependent PAR-1 activation.  This evidence comes from 
a study in which anti-TF Ab was found to protect against myocardial IR injury in a 
coronary ligation model in rabbits.  The same occurred with hirudin but not ancrod 
treatment leading to reduced neutrophil infiltration and lower levels of IL-8 and MCP-
1 (262).  Hirudin irreversibly binds to and inhibits thrombin thereby preventing both 
fibrin generation and PAR-1 activation whilst ancrod only prevents the former.  With 
this in mind, the data suggest protection in this model is mediated through inhibition 
of PAR-1 activation.  
 
In support of these findings, low TF mice were found to be protected from renal IR 
with lower mortality compared with wild type (WT) mice.  The low TF mice had 
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reduced levels of chemo attractants including MIP-2 leading to less renal neutrophil 
accumulation and less tissue necrosis  
 
In this model, hirudin treated WT mice and PAR-1 KO mice had equivalent 
phenotypes to low TF mice.  This suggests that deficiency of TF protects against IR 
injury through reduced PAR-1 signalling, from inhibition of generation of 
downstream coagulation proteins, and not through fibrin generation.  PAR-2 KO mice 
were not protected from disease implying there was no contribution of TF signalling 
through PAR-2 or its cytoplasmic tail in this disease model (263).    
 
In contrast PAR-2 activation with a PAR-2 agonist was found to enhance 
haemodynamic recovery and limb salvage following hind limb ischaemia in mice 
(264). 
Arthritis  
Increased expression of TF and thrombin have been found in the synovium of patients 
with rheumatoid arthritis (265) suggesting a role for coagulation proteins in this 
inflammatory condition.  In mice, intra articular injection of TF and TF/VIIa induced 
cellular infiltration of the synovium and cartilage with bone destruction (266).  
Furthermore thrombin inhibition was found to ameliorate collagen induced arthritis 
with reduced fibrin deposition and IL-1β and IL-12 levels in the synovium (267), 
indicating the pro-inflammatory effects of TF and the coagulation proteins may not be 
necessarily distinguished from their pro-coagulant effects.   
 
A more recent study has suggested a role for the cytoplasmic tail of TF in modulating 
the immune response in an antigen induced arthritis model in mice (256).  CT∆ mice 
were used and were found to have less severe arthritis with reduced synovial levels of 
IL-1β, IL-6 and TNF. Moreover the systemic immune response was also modified 
with reduced cytokine production from LPS stimulated peritoneal cells from 
immunised CT∆ mice.  Interestingly the adaptive immune response seemed to be 
modified in the mutant mice with reduced antigen specific T cell proliferation, a shift 
towards a Th2 effector response with more IL-4 production and more serum antigen 
specific IgG1 Ab.  
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Angiogenesis 
Different groups have generated TF KO mice and reported a ~90% rate of lethality of 
the embryo at around day ten (268, 269).  This high rate of death in TF deficient mice 
coupled with no reports of TF deficiency in humans suggests TF’s absolute 
requirement for life, most likely related to haemostasis.  One group proposed that the 
high rate of death in the TF KO mice was not purely related to a haemostatic defect 
but that TF played an additional non haemostatic role in vascular development as 
suggested by the findings of disorganised yolk sac vasculature in the TF gene KO 
embryos.  Subsequent studies involving various transgenic mice reveal a possible role 
for PAR-1 signalling on ECs in stabilising the yolk sac vasculature (270).   
 
The studies outlined indicate that TF plays a role in diverse settings of inflammation 
often through mechanisms separate from its pro-coagulant effects although the latter 
can also contribute.  Factors that influence which of the different mechanisms 
dominate are unresolved but these data review much of the literature about the broad 
range of diseases in which TF has been implicated.   
Coagulation proteins and inflammation  
Initiation of the coagulation cascade results in the formation of clot with cleavage of 
fibrinogen to fibrin by thrombin.  Studies show fibrinogen and fibrin exert 
inflammatory effects but it is now well described that cellular effects of coagulation 
proteins are involved in inflammation.  These effects, expressed through the PAR 
family (271) will be discussed next, followed by the inflammatory effects of 
fibrinogen and fibrin. 
Protease activated receptors  
PAR are a family of four different seven-transmembrane-spanning-domain, G-protein 
coupled receptors known as PAR-1 to -4.  PAR-1, -3 and -4 are activated by thrombin 
whereas PAR-2 is activated by a number of proteases including TF/VIIa (272), FXa 
(220), trypsin, tryptase (273) and neutrophil proteinase 3 (PR3) but not by thrombin.  
aPC bound to endothelial cell protein C receptor (EPCR) has also been shown to 
signal through PAR-1 (274) (See figure 2.3). 
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Figure 2.3 Cellular effects of the coagulation network  
 
The receptor is activated by proteolytic cleavage of its N terminus exodomain to 
reveal a new sequence which acts as its own tethered ligand, folding back and binding 
to the receptor leading to transmembrane signalling and G-protein activation (275, 
276) as shown in figure 2.4A.  Synthetic peptides, which mimic the first six amino 
acids of the newly exposed tethered ligand sequence, can act as PAR agonists without 
the need for proteolytic cleavage of the receptor (277, 278) as shown in figure 2.4B.  
These agonists, along with mis-sense sequences acting as PAR antagonists (279), 
have been used to explore the function of these receptors.   
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There are differences in expression of PARs between man and mouse (see table 2.1).  
PAR-1 (280) was originally identified in the search for a receptor that mediated 
activation of platelets by the coagulation protein thrombin.  Subsequently PAR-1 and 
-4 were found to be expressed on human platelets whilst PAR-3 and-4, but not PAR-
1, were found on mouse platelets.  Furthermore PAR-3 on mouse platelets appears to 
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have no signalling role but acts as a co-factor lowering the thrombin threshold 
required for PAR-4 activation (281).   The effect of thrombin stimulation of the PARs 
on platelets is a change in shape with release of activators, serotonin, thromboxane A2 
and adenosine diphosphate (ADP) and upregulation of p-selectin and CD40L. 
     
Human Mouse
PAR-1 PAR-2 PAR-3 PAR-4 PAR-1 PAR-2 PAR-3 PAR-4
Platelet
Endothelial cell
NK cell
Monocyte ND ND ND ND
T cell ND ND ND ND
Bone marrow 
DC
Splenic DC
Table 2.1 PAR expression on human and mouse cell types
ND not determined
*  peripheral & T cell line
#   T cell line
‡ PAR-1 & -2 on DC progenitors 
‡‡
‡ ‡
* # # #
 
 
PAR expression on different cell types 
PAR expression has also been described on a number of cells of the immune system 
either by direct detection of expression or by induction of a response following 
stimulation with selective PAR agonists.  
Endothelial cells 
Mouse microvascular ECs have been shown to express PAR-1 and -4, through which 
thrombin signalling is mediated, although PAR-1 appears to be more responsive to 
lower concentrations of thrombin (282).  It is not clear whether PAR-4 merely offers 
redundancy or confers alternative or additional capabilities in this system. PAR-2 
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expression has also been found on mouse microvascular ECs with responses detected 
upon activation of the receptors by PAR-2 agonists.   
 
A number of human ECs including human umbilical vein ECs (HUVECs), and lung 
and dermal microvascular ECs have been shown to express PAR-1 and respond to 
thrombin and PAR-1 agonists but with no evidence of PAR-4 expression (282, 283). 
In contrast PAR-4 agonist treatment induced endothelial dependent vasorelaxation of 
human coronary vessels, which had been treated with TNF and IL-1α to stimulate 
PAR-4 expression (284).   
 
A variety of pro-inflammatory events have been described to occur following PAR 
stimulation of ECs by thrombin.  Adhesion molecules are upregulated on the EC 
surface with increased permeability of the endothelium (271) along with release of 
platelet activating factor (PAF), a potent neutrophil  activator (285), and cytokines IL-
6, IL-8 (286, 287) and MCP-1(288). 
 
An inflammatory environment driven by IL-1α, TNF-α and LPS appears to upregulate 
PAR-2 expression on human ECs, whereas PAR-1 expression remains unchanged in 
these conditions (289).  Stimulation of PAR-2, like PAR-1, mediates mitogenic 
responses in human ECs leading them to proliferate when incubated with thrombin, 
PAR-1 or PAR-2 agonists (290).   
 
In addition to thrombin, the anti-coagulant aPC activates PAR-1 on human ECs (274) 
but conversely promotes anti-inflammatory as opposed to pro-inflammatory effects 
(291).  The anti-coagulant function of aPC has been well characterised but the 
mechanisms underlying the cell signalling function remain less well understood.  
Protein C binds to EPCR, which increases the likelihood of activation by thrombin 
bound to thombomodulin on the endothelial surface, thereby forming activated 
protein C.  aPC bound to EPCR is able to cleave and signal through PAR-1 (274).  
EPCR is found on ECs and appears to be more abundant on larger vessels (292); it has 
also been found on other cell types such as monocytes and HSCs.  aPC mediated 
PAR-1 signalling requires the presence of EPCR as it increases the affinity of aPC 
binding to the EC membrane.  It also co-localises aPC and PAR-1 with caveolin-1 in 
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caveolae/glycosphingolipid rich  rafts (293).  It is thought that redistribution of PAR-1 
into distinct cellular pools either by direct binding of thrombin or by binding of aPC 
to EPCR directs its signalling actions to either pro-inflammatory or cytoprotective 
pathways respectively (294).  Further work is required on several aspects of this 
hypothesis. 
Monocytes 
Much work has been done on stimulating human PBMCs and purified monocytes 
with thrombin and PAR-1 agonists.  It has shown that PAR-1 stimulation enhances 
their proliferation and production of IL-1α and -1β (295), MCP-1, TNF-α (296), IL-10 
(297) and IL-6 (298), but reduces levels of IL-12.  The latter appears to be dependent 
on IL-10 since the effect was abolished by the addition of anti-IL-10 Ab suggesting 
thrombin may influence polarisation of the T cell effector response.  However it is not 
clear through which cell this effect occurs (299). 
 
Initial work on a human monocytic cell line provided evidence for PAR-1 expression 
since thrombin and PAR-1 agonist both stimulated intracellular Ca2+ mobilisation and 
actin polymerisation (297).  More recent work on highly purified freshly isolated 
human monocytes has shown expression of PAR-1 and -3 on the cell surface by flow 
cytometry and PAR-1, -2 and -3 at the mRNA level by RT-PCR.  However there was 
no evidence of PAR-4 using either technique.  Additionally, these experiments 
demonstrated that macrophages derived from monocytes cultured in macrophage 
colony stimulating factor (M-CSF) expressed high levels of PAR-1 and lower levels 
of PAR-2 and-3 (300).  
Natural killer cells 
The majority of natural killer (NK) cells in human PBMCs have been shown to 
express PAR-1 (301).  Thrombin has also been shown to enhance NK cell mediated 
cytotoxic activity, which appeared to involve exaggerated production of IL-2 from 
PBMCs as well as enhanced responsiveness of the NK cells to the released IL-2.  
These effects were shown to be PAR-1 mediated as they were duplicated with PAR-1 
agonist but not with inactivated thrombin (302). 
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T cells 
Initially studies showed that thrombin activated human naive T cells and leukaemic T 
cell lines, but not a B cell line, with a measurable increase in intracellular Ca2+ influx 
suggesting the presence of PAR (303).  PAR-1 expression was also detected on 
human naive T cells by northern blot analysis and flow cytometry (301).  Sub-
population analysis of lymphocytes using dual Ab staining with flow cytometry found 
that the majority of NK T cells and a variable proportion of CD4+ and CD8+ T cells 
expressed PAR-1, with an average percentage of 10% and 44% respectively. 
 
More recently PAR-1 expression on human peripheral naive CD3+ T cells has been 
confirmed with concomitant detection of PAR-2 and -3 but not -4 by flow cytometry 
and northern blotting.  Sub-population analysis of CD4+ and CD8+ was not done.   
This study also showed that incubation of T cells with thrombin, trypsin or tryptase 
led to enhanced IL-6 release (304).  Other work has shown that thrombin pre-
treatment of highly purified human CD3+ T cells with PBMCs enhanced proliferative 
responses to a variety of stimuli although thrombin alone was not mitogenic.  There 
was an associated increase in IL-2 and IL-6 production with an increase in the number 
of CD25+ (IL-2 receptor) T cells (298).   Further work has also shown that thrombin 
through PAR-1 promoted a Th2 effector T cell response, which could have been 
through action on either antigen presenting cells or T cells (299). 
Dendritic cells 
Differential expression of PARs has been described on human monocytes and 
monocyte-derived DCs, cultured with GM-CSF and IL-4.  Colognato and colleagues 
detected small amounts of PAR-1 and -3 and trace amounts of PAR-2 at the mRNA 
and protein level by RT-PCR and flow cytometry respectively (300).  This is in 
contrast to much higher levels found on monocytes.  The authors suggested that down 
regulation of PAR expression in vitro was related to culture with IL-4, especially as 
macrophages had high PAR expression, and addition of IL-4 in to the culture led to 
their down regulation. 
 
Correlating with these findings, Csernok and colleagues also demonstrated PAR-2 
expression on human monocyte derived DCs, which were cultured in the same way.  
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Functional assays found that PAR-2 activation led to maturation of the DC with 
upregulation of MHCII, CD80, CD86 and CD83 and concomitant down regulation of 
CD14. This study was investigating Wegener’s granulomatosis, an autoimmune small 
vessel vasculitis.  It found that PR3, an autoantigen, acted through PAR-2 leading to 
DC maturation as described, which enhanced the ability of DCs to stimulate PR3 
specific T cell proliferation leading to increased numbers of IFN-γ secreting T cells 
(305).  Overall this study suggests that PAR-2 activation may play a role in DC 
maturation, and in the setting of Wegener’s granulomatosis, that PR3 may activate 
autoreactive T cells through PAR-2/DC interaction.  
 
More recently Yanagita and colleagues have shown differential expression of PAR in 
distinct subtypes of human DCs.  Plasmacytoid and myeloid DCs, isolated from 
human PBMCs by positive selection with BDCA-4 and BDCA-1 Ab respectively, 
were found to express PAR-1 and release IL-10, IL-12 and MCP-1 in response to 
thrombin, which appeared to be mediated through PAR-1.  Furthermore thrombin 
incubation appeared to induce MHCII and CD86 expression on these blood DCs 
resulting in enhanced proliferation of allogeneic T cells with increased IFN-γ 
production. Unlike the blood DCs, monocyte derived DCs cultured in vitro with GM-
CSF and IL-4 did not express PAR-1, and were unresponsive to thrombin (306).  The 
lack of PAR-1 on monocyte derived DCs contrasts with the study by Colognato but 
monocytes were isolated by CD14 microbead positive selection in the former and by 
adherence in the latter study. The other PARs were not assessed in this study but it is 
feasible, based on their thrombin responsiveness, that the blood DCs may express 
both PAR-3 and -4. 
 
Mouse bone marrow and spleen derived DCs have also been found to express PARs.  
Fields and colleagues found that by semi-quantitive RT-PCR mouse bone marrow 
progenitor cells expressed all four PARs and culture with GM-CSF and IL-4 become 
DCs with reduced expression of both PAR-1 and -2.  Splenic DCs were also found to 
express PAR-3 and -4 but much lower levels of PAR-1 and -2.  It was also noted that 
DCs from PAR-2 KO mice and WT DCs cultured in the presence of soya bean trypsin 
inhibitor, a serine protease inhibitor, failed to develop and had a reduced ability to 
stimulate allogeneic T cells but an enhanced capacity to take up fluorescein 
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isothiocynate (FITC)-dextran.  This was overcome by the addition of TNF-α or CD40 
Ab or PAR-2 agonist, which led to maturation of DCs.  The arrest in DC 
differentiation did not occur with other serine protease inhibitors including hirudin 
(307). 
 
Ruf and colleagues have suggested the presence of PAR-1 on mouse bone marrow 
derived DCs through the use of PAR-1 KO transgenic mice.  They found that PAR-1 
on mouse DCs was essential for disseminating the inflammatory response in sepsis 
(234).  The study is described in more detail in the next section. 
 
Understanding the contribution of PARs in a number of models of disease has been 
possible due to the availability of gene knockout and transgenic mice, agents to 
deplete fibrinogen, and selective PAR agonists and antagonists that promote or inhibit 
PAR activation without fibrinogen cleavage.  Evidence for the involvement of PARs 
in these settings will be discussed in more detail. 
PARs in sepsis 
In the context of sepsis, endotoxin and inflammatory mediators induce TF 
upregulation on a number of cell types, which in turn initiate the coagulation cascade 
leading to generation of downstream coagulation proteases.  Animal studies of 
endotoxaemia have clearly shown that inhibiting TF-induced coagulation prevents 
mortality (214, 248, 249, 252).  Further work in mice has shown potential redundancy 
in PAR signalling.  Isolated PAR-1 or -2 deficiency did not protect against 
inflammation or improve survival; however blocking multiple PARs with hirudin-
treated PAR-2 deficient mice produced both these effects to the same extent as in low 
TF mice. Inhibiting fibrin deposition with ancrod treatment of WT mice led to an 
independent survival benefit (252). 
 
Another study using a mouse model of endotoxaemia corroborated the above findings 
that a single PAR deficiency showed no survival advantage (308).  This study was 
also able to generate double KO mice for PAR-1 and -2 or PAR-2 and -4 but triple 
KO mice were not possible due to embryonic lethality.  However, for the same reason, 
it was not possible to back cross the double KO mice until they had a pure C57BL/6 
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background and so differences in the background genotype may have confounded 
results.  They found that neither the double KO strains nor the fibrinogen KO mice or 
the hirudin treatment of WT mice conferred survival benefit.  The differences in 
findings from the former study may be due to variations of the experimental 
conditions, particularly the higher doses of endotoxin at 60 and 30 mg/kg in the latter 
study as compared to 10mg/kg in the former. 
 
More recently another group, using two different models of endotoxaemia, has found 
a distinct survival advantage in single PAR-1 KO (234).  Ruf and colleagues used 
both an 8mg/kg endotoxin dose injected intraperitoneally and the ceacal ligation 
model.  They measured a large panel of cytokines and found reduced levels at later 
(after 18 hours) but not earlier (6 hours) time points following endotoxin delivery.   
Furthermore a sequence of experiments using different KO mice suggested that the 
main cell type involved was the DC.  Their findings suggest that DCs generate 
thrombin and coagulation proteins, which act in an autocrine fashion on PAR-1 and 
through coupling with sphingosine 1-phosphate (S1P) signalling, to initiate migration 
of the DC through the lymphatics to disseminate coagulation. The PAR-1-S1P is 
coupled to activation of the DC inflammasome, which leads to an inflammatory 
response with the production of cytokines such as IL-1β.  In short they propose DCs 
as the source of coagulation and the inflammatory response.  In PAR-1 KO mice both 
these parameters are attenuated as DCs are sequestered in the lymph node, where 
paradoxically higher levels of coagulation and inflammation are found rather than 
systemically. 
PARs in glomerulonephritis 
A pivotal pro-inflammatory role for thrombin has been described in experimental 
crescentic GN with predominant effects through PAR-1 signalling, although fibrin 
deposition is also implicated (309).  The mouse model involves nephritogenic antigen 
sensitisation by subcutaneous (sc) administration of sheep globulin with adjuvant 
followed 10 days later by intravenous (iv) sheep anti-mouse glomerular basement 
membrane globulin.  This led to induction of GN which would only occur when 
administered to immunised mice.  Hirudin treatment of these mice significantly 
attenuated markers of glomerular inflammation with significantly less crescent 
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formation, T cell and macrophage infiltration, fibrin deposition and lower serum 
creatinine.  PAR-1 deficiency conferred a similarly protected phenotype except that 
the hirudin treated mice gained benefit from a greater reduction in fibrin deposition.  
Conversely when a PAR-1 agonist was delivered regularly to WT mice starting 
shortly after induction of GN, the histological and functional parameters of 
glomerular inflammation were augmented. 
 
The same model has also shown a contribution, although through a different 
mechanism, of PAR-2 in the pathogenesis of GN (310).  PAR-2 KO mice have 
reduced crescent formation, fibrin deposition, proteinuria and serum creatinine; 
however, unlike PAR-1 KO mice, there is no change in T cell and macrophage 
infiltration.  The mechanism by which PAR-2 exerts an effect appears to be through 
decreased levels of plasminogen activator inhibitor-1 (PAI-1).  This is a major 
regulator of fibrinolysis, which inhibits the action of tissue type plasminogen activator 
and urokinase.  The reduced levels of PAI-1 lead to a subsequent increase in matrix 
metallo-proteinase-9 (MMP-9), which can potentially augment fibrinolysis. Overall 
this results in reduced fibrin deposition in GN in PAR-2 KO mice. 
 
The link between PAR-2 and the regulation of fibrinolysis has also been described in 
human cells using an immortalised proximal tubule cell line from normal adult kidney 
(311).  These cells were shown to express PAR-2 and incubation with PAR-2 agonist 
or FXa induced upregulation of PAI-1 gene as well as TGF-β expression.  This has 
been potentially linked to interstitial fibrosis due to the finding that levels of PAR-2 
expression in renal biopsy samples from patients with IgA nephropathy directly 
correlate with the degree of interstitial fibrosis (311). 
PARs in ischaemia-reperfusion injury 
PAR-1 signalling has been found to play a role in renal IR injury affecting neutrophil 
infiltration through chemokine and MIP-2 levels (263).  As described earlier low TF 
mice were protected from IR injury as were PAR-1 KO and hirudin treated mice but 
not PAR-2 KO mice.  In contrast PAR-2 has been shown to modulate IR injury in the 
rat heart with activation of PAR-2 by its agonist conferring a survival benefit (312). 
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PARs in arthritis 
The disease models described so far demonstrate a role for PARs in acute 
inflammation.  However PAR-2 has also been implicated in chronic inflammation.  In 
a mouse model of adjuvant induced arthritis, a classic example of a chronic 
inflammatory condition, disease was almost completely abolished in PAR-2 deficient 
mice.  Substantial upregulation of PAR-2 expression was also detected in chronically 
inflamed tissues suggesting a key role for PAR-2 in orchestrating the chronic 
inflammatory response.  Although the mechanism was not elucidated it was suggested 
that it may be through cytokine release, particularly as other studies have shown that 
PAR-2 induces cytokine release by activation of NFκB (313) and stimulates 
prostanoid as well as cytokine pathways (314).    
 
These studies implicate the role of coagulation proteins as PAR ligands in a range of 
inflammatory conditions.  With better understanding of the mechanisms at play it may 
be possible to target some of these effects, especially with the availability of specific 
PAR agonists and antagonists, without affecting thrombotic and bleeding risks. 
Fibrin 
Work has shown the importance of fibrin and the fibrinolytic system in inflammation 
and some models have shown an independent beneficial anti-inflammatory effect of 
fibrinogen depletion or deficiency (252, 315).  In a mouse model of peritoneal 
inflammation, intraperitoneal thioglycollate elicited a macrophage response, which 
was found to be fibrinogen dependent. In fibrinogen KO mice the recruitment of 
macrophages was not impaired but there was minimal activation.  Furthermore 
fibrinogen KO mice had reduced levels of IL-6 and MCP-1 compared to WT 
suggesting a role for fibrinogen in both macrophage adhesion and cytokine release 
(316).  A mouse model of crescentic GN supports the role of fibrinogen in 
macrophage adhesion.  Fibrinogen KO mice had notably less macrophage recruitment 
into Bowman’s capsule and glomerular tufts in this model with formation of fewer 
crescents and a lower serum creatinine (317).   The relative importance of fibrinogen, 
insoluble fibrin and fibrinogen degradation products (FDPs) were not dissected and 
each of these has been shown to have pro-inflammatory effects, which are not 
mutually exclusive.  
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Studies have shown fibrinogen or fibrin are ligands for ICAM-1 (318), CD11c/CD18 
(319) and CD11b/CD18 which are expressed on macrophages, neutrophils and 
subsets of DCs. Hence this suggests fibrin’s involvement in leucocyte adhesion and 
accumulation at sites of inflammation.  Additionally fibrin also appears to induce 
expression of a number of adhesion molecules on a variety of cells including IL-1β 
from human PBMCs (320), IL-8 (321) and MCP-1 from EC (322) and ICAM-1 from 
human fibroblasts (323).  Of note, fibrinogen was found to induce macrophages to 
secrete MIP-1α, MIP-1β, MIP-2 and MCP-1, which attracts T cells, neutrophils and 
additional macrophages.  This effect did not appear to occur by fibrinogen binding 
with integrins but required the presence of TLR-4, possibly through direct binding, 
suggesting a role for fibrinogen to act as a danger signal in response to tissue damage 
(129).  
 
FDPs have also been shown to have chemoattractant and inflammatory modulating 
properties, which includes the induction of cytokine release (324, 325).  
Fibrinogen-like protein 2  
The gene for fibrinogen-like protein-2 (fgl-2) was originally cloned from cytotoxic 
CD8+ T cells (326) but fgl-2 has subsequently been detected in murine macrophages, 
as an IFN-γ inducible gene (327), ECs (328), CD4+ and CD8+ T cells (329).  As the 
name suggests it shares homology with the carboxyl terminus of the beta and gamma 
subunits of fibrinogen.  The transmembrane form has been found to act as a 
prothrombinase by directly converting prothrombin to thrombin, bypassing the need 
for initiation of the coagulation cascade by TF.  However reports of this pro-coagulant 
effect is controversial as others have not been able to reproduce it (330).  The 
pathological importance of fgl-2 was first described in a mouse model of viral 
hepatitis (331).  Studies went on to find that fgl-2 KO mice had increased survival 
when infected with mouse hepatitis virus strain 3 (MHV-3) compared to WT mice, 
with less hepatic fibrin deposition and liver necrosis (332).  Macrophages from the 
fgl-2 KO mice also failed to show increased pro-coagulant activity when infected with 
MHV-3 compared to infected WT macrophages, in which pro-coagulant activity was 
enhanced compared to uninfected controls. On the other hand response to LPS was 
not modified in fgl-2 KO mice with an equivalent effect in WT mice. 
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Thrombosis is a prominent feature of acute humoral xenograft rejection (AHXR) and 
studies have suggested the importance of fgl-2 in this setting (333).  Pig-to-baboon 
kidney xenografts undergoing AHXR reveal induction of porcine fgl-2 expression on 
graft vascular ECs.  Furthermore in vitro porcine ECs activated by human TNF-α 
induced fgl-2 expression with enhanced conversion of prothrombin to thrombin (334).  
A role for fgl-2 in allograft rejection has also been suggested by the finding of marked 
expression of fgl-2 in rejecting human renal allograft tissue biopsies plus co-
localisation with fibrin deposition and prolonged survival of cardiac allografts in fgl-2 
deficient mice with diminished fibrin deposition (335).  
 
Soluble fgl-2 (sfgl-2) has been shown not to possess pro-coagulant activity (329) and 
appears to exhibit immunosuppressive properties by binding to T cells and DCs, 
although the receptor has not been identified. When added to culture, it appears to 
inhibit T cell proliferation stimulated by alloantigen, con-A and CD3/28 Ab in a dose 
dependent manner.  This is not due to an apoptotic or cytotoxic effect, and causes 
polarisation towards a Th2 profile with enhanced IL-4 and IL-10 and reduced IFN-γ 
levels in the sfgl-2 treated allogeneic cultures.  It also appears to inhibit LPS 
maturation of DCs by inhibiting NKκB translocation and abrogating upregulation of 
CD80 and MHCII molecules.  These sfgl-2 incubated DCs had a reduced capacity to 
stimulate allogeneic T cells (336).  
 
Cardiac grafts from fgl-2 KO mice transplanted into rats appear to be resistant to 
thrombosis but suffer from accelerated T cell mediated rejection (333) suggesting a 
pro-coagulant and possibly an immunomodulatory function of fgl-2.  However others 
have suggested that deletion of the fgl-2 locus in mice does not modify earlier on T 
helper 1 (Th1) immune responses with no abnormalities of coagulation (337). 
Use of anti-coagulants to inhibit inflammation 
In view of the role of coagulation in inflammation, anti-coagulants have been used in 
attempts to counter these effects.  Heparin’s protective effects in experimental 
immune nephritis were documented as far back as 1965 (338).  More recently various 
anti-coagulants have been shown to ameliorate inflammation associated with 
endotoxic shock.  Some of these have already been discussed in detail and suggest 
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that inhibition of coagulation proteins reduces pro-inflammatory chemokine and 
cytokine secretion resulting in a diminished inflammatory response. The dramatic 
effect of anti-coagulants in animal studies led to phase III clinical trials in human 
sepsis.  aPC was associated with significant reduction in 28 day mortality in treated 
patients (339).  However in other studies AT and TFPI failed to show a significant 
difference in clinical outcome (340, 341).  
 
Studies on the cellular effects of coagulation proteins, many of which are thought to 
act through the family of PARs, have revealed complexity in the system.  Examples 
include redundancy between receptors and activation of the same receptor, leading to 
either anti- or pro-inflammatory effects depending on the interacting ligand and the 
fibrinolytic system influencing the inflammatory response.  This complexity may be 
one of the reasons for the lack of benefit seen in the human sepsis trials although there 
are other potential explanations including the concomitant use of low dose heparin, 
which apart from exerting its own action also directly interacts with AT and TFPI and 
so may interfere with their effects. 
 
A number of studies have used anti-coagulants as immunomodulatory agents in 
animal models of transplantation.  Heparin has been used effectively in skin allografts 
(342) and rat skin and cardiac allografts (343).  Doses of 1mcg and 20 mcg were used 
in three different protocols, which varied in the timing and frequency of the heparin.  
An increase in graft survival was seen in all treatment groups in the cardiac allografts 
and in some of the treatment groups in the skin allografts. This effect was sensitive to 
changes of dose and schedule. The most effective treatment was of 20mcg 
administered every seven days starting one week prior to transplantation, which 
achieved a greater than twofold increase in graft survival. Daily administration of 
heparin reduced efficacy for both doses with the least effective treatment being 1mcg 
administered daily.  Although the mechanism was not specifically investigated the 
most efficacious regimen suggests it is different from an anti-thrombotic effect, which 
would be dependent on more frequent administration and possibly higher doses of 
heparin.  
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AT has also been used with benefit in experimental allograft rejection.  In a highly 
histo-incompatible model of rat lung allograft rejection, administration of high dose 
(500U/kg) AT on days two and four post-transplant led to a reduction in acute 
rejection with less oedema, haemorrhage and necrosis although no significant 
difference in fibrin deposition implying the reduction in inflammation was not due to 
an increased anti-thrombotic effect (344).  High dose AT was also shown to induce 
indefinite survival of fully allogeneic cardiac grafts in mice when given on the day of 
transplantation, compared to mean graft survival time of nine days in the control 
group (345).   
 
The mechanisms by which anti-coagulants promote graft survival are not clear but 
there are a number of possibilities.  One is that clotting factors enhance T-cell 
activation through non specific amplification of cytokine secretion, as has been shown 
with a number of cell types in vitro. Another possibility is that TF and other clotting 
factors have a specific role in regulating T lymphocyte responses.  Evidence for the 
latter includes one study in mice in which the use of high dose AT led not only to 
indefinite survival of fully allogeneic cardiac grafts but also suggested the generation 
of Tregs.  The presence of these cells was shown by injecting splenocytes from 
primary recipients into syngeneic naïve recipients immediately prior to transplantation 
of a fully allogeneic cardiac allograft.  This led to an indefinite survival of the grafts 
and is an example of tolerance transfer by cells from within the splenocyte population. 
In vitro mixed leucocyte reaction (MLR) studies confirmed that the proliferation of 
splenocytes from recipients of high dose AT was markedly suppressed, as was IL-2 
production, although no differences were noted in the production of IL-4, IL-10 and 
IFN-γ (345). 
 
A third possibility is that anti-coagulants act directly on T cells or antigen presenting 
cells to modify their response, rather than indirectly by inhibiting coagulation 
proteins.  Evidence for this includes studies which show that in vitro AT reduces 
proliferation of rat spleen cells in response to con A in a dose dependent manner (344) 
with reduction in T cell cytokines IL-2, IFN-γ and IL-4 but no change in TGF-β, IL-6 
or IL-2R.  The reduction of proliferation by addition of AT was also seen with human 
PBMCs in response to a number of stimuli including alloantigen and 
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phytohaemagglutinin (PHA) (346) in serum-supplemented and serum-free medium.  
This in vitro set-up largely excludes an inhibitory role for AT on coagulation proteins 
and points towards a direct effect of AT, in view of the complete absence of 
coagulation proteins in serum free medium.   
 
Other direct effects of AT that have been described include the inhibition of TNF-α 
production from monocytes stimulated by LPS following AT treatment.  This effect 
of AT appears to be mediated through inhibition of a number of transcription factors 
including NFκB (347), ERK1/2 phosphorylation and early growth response (egr) 
expression (348). AT has been shown to induce prostacyclin release from ECs (349), 
which partly explains the amelioration of pulmonary vascular injury in rats challenged 
with LPS following AT treatment (350).  Finally AT has been shown to inhibit LPS 
mediated NFκB activation of TLR4 (351). 
 
The direct effects of AT are more likely to be mediated through a cell surface receptor 
rather than through inhibition of coagulation proteins.  With this in mind AT has been 
shown to bind to syndecan-4 on ECs and leucocytes (352) and affect cell function and 
migration (353).  Syndecan-4 is a member of the heparan sulphate proteoglycan 
(HSPG) family and possesses extracellular glycosaminoglycans (GAGs) containing 
pentasaccharides, similar to those present on heparin.  Initially it was thought that the 
HSPG family acted mainly as co-receptors but growing evidence suggests the 
capability of intrinsic signalling (354) and so indicates a mechanism through which 
AT can directly mediate its effects.   
Use of anti-coagulants in transplantation 
Chronic rejection 
The pathophysiology of chronic rejection (CR) is far from being understood but 
appears to involve immune and non immune mechanisms.  Evidence implicates a role 
for coagulation proteins in the development of this condition.  Fibrin deposition is 
found within arteriosclerotic vessels in human renal CR (355) And the administration 
of low dose heparin to patients with biopsy proven CR has been found to have a 
beneficial effect on renal function (356).    However this finding should be taken in 
the context of the study being neither randomised nor placebo controlled.  Hirudin, as 
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a specific thrombin inhibitor, has been shown to attenuate experimental cardiac CR in 
rats (357) and low molecular weight heparin has also been shown to suppress chronic 
vascular disease in the same model (358).  
Acute humoral rejection 
Venular thrombosis is now seen as an early and consistent marker of Ab mediated 
humoral rejection in the heart (359). To illustrate this point, results from this 
laboratory using a rodent model of acute humoral xenograft rejection has shown 
inhibition of thrombin completely prevents humoral rejection (360) suggesting a 
critical role for the coagulation proteins in mediating inflammatory effects initiated by 
the humoral response.  
Ischaemia- reperfusion injury 
TF expression has found to be enhanced during experimental IR in rabbit heart (262), 
rat kidney (260) and following cold storage of organs (361).  In some of these models 
inhibition of TF diminished tissue necrosis, inflammation and prevented leucocyte 
recruitment.  Similarly AT also prevents and rapidly reverses leucocyte recruitment in 
IR of the feline mesentery and this has been shown to be related to thrombin 
inhibition (362).  Finally another study showed that thrombin dependent PAR 
signalling was more important than fibrin deposition in IR injury (263). 
 
Many studies, some of which have been outlined above, have suggested the potential 
benefit of inhibiting the coagulation system to regulate inflammation and modulate 
the immune response.  However, apart from the use of aPC in sepsis, this has not 
translated into clinical success.  It may in part be due to a lack of insight in to the 
systems at play and more work is required to gain better understanding about the 
mechanisms involved.  
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Chapter 3: Experimental aims 
Background  
It is now clear that the DC is equipped with unique properties as an antigen presenting 
cell to sample and respond to its environment and subsequently initiate and shape the 
T cell response.  These properties are well documented and have been discussed in 
some detail in chapter one.  The immature DC acts as the immunological sentinel as it 
samples and responds to its environment.  It recognises activating signals, which leads 
to a series of changes from primarily antigen processing to antigen presentation, 
migration to lymphoid tissue and subsequent interaction with T cells and the resultant 
immune response.  
  
Initially it was thought that activating signals in the environment were mainly related 
to microbial invasion and involved the recognition of exclusive microbial signature 
patterns by PRRs on DCs.  TLRs are the archetypal PRR and up to now have been the 
main focus of research.   
 
Mounting evidence however suggests that endogenous molecules also play an 
important role in DC activation.  These data are compatible with the danger 
hypothesis that molecules derived from self, which are stimulated or released in 
situations such as infection, transplantation and cancer, and alert the immune system 
to a change in the environment by working as activating signals to DCs.  Emerging 
evidence, outlined in chapter one, has identified some of the specific molecules 
released from necrotic cells that function as DC activators.  However work is still 
required to elucidate many aspects of this system such as the key receptors and their 
effector mechanisms. 
 
Endogenous activating molecules also include innate factors such as complement.  
Initial work showed that donor kidney synthesis of complement played a contributory 
role in allograft rejection and more recent work has shown that lack of C3 production 
on antigen presenting cells results in an impaired anti-donor Th1 response with 
expansion of Tregs.  Further work to investigate the potential mechanism of action 
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has found that DCs express a functional set of complement components and receptors. 
Therefore it appears that DCs are able to generate complement and subsequently to 
respond through C3a and C3aR signalling.  This then mediates upregulation of MHC 
and co-stimulatory molecules on antigen presenting cells, which contributes to more 
aggressive rejection.  These findings clearly indicate that complement, as an 
endogenous molecule, plays a role in DC activation.   
 
Some of the components of the coagulation system, also classically viewed as the 
innate system, have been directly implicated in acting as danger signals to the immune 
system.  Fibrinogen has been reported to stimulate chemokine secretion from 
macrophages possibly through direct binding to TLR4.  Inhibition of this leads to less 
macrophage activation and reduced cytokine release as seen in a model of peritoneal 
inflammation in fibrinogen KO mice.  Although soluble fgl-2 has not been found to 
have pro-coagulant activity, it exhibits immunosuppressive properties by binding to T 
cells and DCs.  It appears to inhibit LPS maturation of DCs and so abrogate 
upregulation of MHC and co-stimulatory molecules, thereby acting as an 
immunomodulatory agent in part by opposing other danger signals.   
 
Tissue factor is the initiator of the coagulation cascade leading to the generation of 
downstream coagulation proteases including thrombin and subsequent fibrin 
deposition.  The role of the coagulation cascade in haemostasis and thrombosis is well 
characterised but more recently its role in other biological systems including 
inflammation has been appreciated.  Some of these effects on inflammation are 
through fibrin generation as outlined above, but many are mediated in a fibrin-
independent manner through surface receptors called PAR. Activated coagulation 
proteins act on PARs to produce cellular effects which have been described in chapter 
two.  
 
Apart from initiating the coagulation cascade, TF is induced upon several types of 
inflammatory cells and has been found to play a role in the diverse settings of 
angiogenesis and inflammation.  Inhibiting TF in animal models of sepsis has been 
found to be protective.  TF has also been shown to a play a role in other inflammatory 
conditions including GN, ischaemia-reperfusion injury and arthritis.  Much of this 
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work has been reviewed in chapter 2.  The mechanism of action appears to be through 
PAR although signalling through TF’s cytoplasmic tail has also been implicated in 
some of these effects. 
 
PAR expression has been described on a number of innate cells and it has been 
suggested that thrombin and other PAR ligands have a role in inflammatory 
conditions including sepsis and GN.  The literature reviewed in chapter two suggests 
that PAR activation through its ligands, which are mainly activated coagulation 
proteins, has largely pro-inflammatory effects but that in some settings, primarily 
through aPC, it also leads to anti-inflammatory effects. 
 
In view of the role of coagulation in inflammation, anti-coagulants have been used in 
attempts to counter these effects.  Only one of three anti-coagulants tested has led to a 
positive result in phase III clinical trials in human sepsis.  The other two failed to 
show a significant difference in clinical outcome, which may be due to incompletely 
understood mechanisms as well as an increased risk of bleeding in the treatment arms.  
 
Anti-coagulants have also been used as successful immunomodulatory agents in 
animal models of transplantation.  One study used high dose AT which led to 
indefinite survival of fully allogeneic cardiac grafts and also suggested the generation 
of regulatory T cells through tolerance transfer.  The mechanism of action in this 
study and others is not clear but a number of possibilities exist.  It may that the anti-
coagulants inhibit the action of coagulation proteins on the immune response whether 
through PAR activation, fibrin generation or other mechanisms.  Alternatively it may 
be that anti-coagulants act directly on T cells or antigen presenting cells as suggested 
by literature reviewed towards the end of chapter two.     
Hypothesis 
Coagulation proteins modify T cell responses by several independent mechanisms: 
- through non-specific amplification of cytokine production 
- via specific interaction with PAR on T cells and/or DCs 
- through expression of TF on DCs 
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These mechanisms are inhibited by the action of anti-coagulants preventing 
generation of coagulation proteins.  However anti-coagulants can also have direct 
effects on T cells or antigen presenting cells, which in turn influence the immune 
response. 
Aims 
This project aims to investigate the precise effects of coagulation factors and AT on 
alloimmunity with the following specific objectives: 
- to analyse TF expression on murine DCs and determine the conditions that 
promote  and inhibit its expression on this cell type 
- to assess whether TF influences T cell activation and tolerance in vitro and in 
vivo 
- to analyse the influence of TF expression on T cell sensitisation in vivo 
- to determine the effect of activated coagulation factors on T cell proliferation 
and cytokine production  
- to determine the mechanism of action of coagulation factors on the T cell 
response, whether through PAR signalling on T cells or DCs 
- to determine the effect of AT on T cell sensitisation in vivo  
- to investigate the effect of AT on DCs with regard to T cell activation and 
cytokine production. 
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Chapter 4: Methodology 
Animals 
Female BALB/c (H-2d), CBA and C3H (H-2k) and female and male C57BL/6 (H-2b) 
mice aged between six and eight weeks were purchased from Harlan Laboratories.  
Marilyn and DO11.10 mice were kind gifts from Dr Jian Guo Chai and Miss Jeni 
Harper respectively.  Animals were treated in strict accordance with the Home Office 
Animals (Scientific Procedures) Act of 1986.  
Cell culture  
Cells were cultured and maintained in RPMI complete medium except when stated 
otherwise. Complete medium consisted of RPMI medium (Sigma-Aldrich, UK) 
supplemented with 10% foetal calf serum (FCS) (, 100U/ml penicillin and 100mg/ml 
streptomycin (Gibco, UK), 1mM L-glutamine and 2-mercaptoethanol (2-ME) 
(Invitrogen, UK).  293T (363) and DAP.3 cells (364) were maintained in DMEM 
supplemented with 5% FCS, 100U/ml penicillin, 100mg/ml streptomycin and 1mM 
L-glutamine.  GM-CSF producing hybridoma (365) (kind gift from Miss Jeni Harper) 
was maintained in selection medium consisting of DMEM supplemented with 10% 
FCS, sodium pyruvate, pyridoxine, and 10mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 100U/ml penicillin, 100ng/ml streptomycin 
and L-glutamine with 1mg/ml G418.  The G418 was omitted from the medium once 
the supernatant was due to be harvested.   
 
Adherent cells were grown in plastic tissue culture flasks and sub-cultured just before 
confluent monolayers developed.  The cells were washed in PBS then incubated in 
either PBS, for B16-F10 cells (366), or 0.1% trypsin (Gibco, UK), for all other 
adherent cells, to disrupt cell adhesion prior to re-seeding in a new flask.  Non-
adherent cells were sub-cultured when the indicator dye included in the medium 
suggested the pH of the supernatant was falling.  Cell lines used in this work are listed 
in table 1.1. 
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Table 4.1 The cell lines used in this work
Cell name Origin Details Reference 
DAP.3 mouse 
fibroblast
adherent
DMEM complete medium
[363]
B16-F10 mouse
melanoma
adherent
RPMI complete medium
[365]
293T renal epithelial cell adherent
DMEM complete medium
[362]
GM-CSF 
producing 
hybridoma
transfected
myeloma cell
non-adherent
G418 selection
DMEM complete medium
with Na pyruate
[364]
 
Cryopreservation  
For long term storage cells, 2-5x107 cells were suspended in a solution of 10% DMSO 
and 90% FCS.  Aliquots of cells were first placed overnight at -80°C to prevent too 
rapid cooling before placement in liquid nitrogen. 
T cell purification 
Spleen and lymph nodes were removed from mice and the cells were passed through a 
nylon mesh.  The red cells were lysed and the cells washed.   The cells were incubated 
with an antibody cocktail supplied by the manufacturer (Invitrogen, UK) containing 
rat anti-mouse CD16/32, MHCII and CD8 Abs for 30 minutes at 4°C.  For CD8+ T 
cell purification the antibody cocktail contained rat anti-mouse CD16/32, MHCII and 
CD4 Abs.   The cells were washed and then incubated with sheep anti-rat magnetic 
beads (Invitrogen, UK) for 30 minutes at 4ºC.  The T cells were then negatively 
selected by retaining the antibody coated cells on a Dynal magnet, according to the 
manufacturer’s instructions, and collecting the remaining T cells.  Purity of between 
80-90% was achieved using this technique with no evidence of MHCII expressing 
cells as assessed by flow cytometry.  Purity could be improved to be consistently 
above 95% by performing a second round of depletion with the magnetic beads.  
Representative profiles are shown in figure 4.1A.  
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Purity of the T cells was also assessed functionally using a con A (Sigma-Aldrich, 
UK) assay. Results were variable and did not always correlate with purity as assessed 
by flow cytometry.  At best the proliferation of the T cells with con A was 25% of the 
proliferation seen with both T cells and irradiated syngeneic splenocytes with con A 
as shown in figure 4.1B.  The discrepancy between this functional assay and flow 
cytometric analysis was probably due to the more sensitive nature of the con A assay 
in assessing the presence of antigen presenting cells.  It seems that the presence of 
very few antigen presenting cells allowed for significant T cell proliferation in the 
presence of con A.  
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Figure 4.1 T cell purity
CD4+ T cells were purified from lymph nodes and spleen by negative selection and analysed
for purity (CD4) following one ([x1]) or two ([x2]) rounds of negative depletion using dynal
beads. MHCII (MHCII) and CD8 (CD8) expression was also analysed using flow cytometry
(A). Numbers shown are percentage positive cells. Purified CD4+ T cells (CD4) were
assessed for purity in a functional assay by comparing proliferation of CD4+ T cells plus con A
(CD4+con A) with CD4+ T cells plus irradiated syngeneic splenocytes (S) plus con A
(CD4+S+con A). Irradiated splenocytes plus con A (S+con A) and CD4+ T cells alone (CD4
alone) are shown as controls. Two days later T cell proliferation was measured by 3H
incorporation. Mean +/- SE are shown of triplicate wells.
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Dendritic cell culture 
Bone marrow derived DCs were cultured as described elsewhere (39).  Briefly muscle 
and tissue were removed from the femurs and tibiae of mice.  Bone marrow cells were 
flushed out.  The cells were passed through a nylon mesh to remove debris and bone 
particles and the red cells were lysed.  The cells were washed and seeded in tissue 
culture flasks or 6 well plates at concentration of 1x106/ml in complete medium plus 
5% supernatant from a GM-CSF producing hybridoma cell line .  On day three, non 
adherent cells were discarded and fresh supplemented medium was added.  On day six 
half the medium with non adherent cells was removed from culture and centrifuged, 
the medium was discarded and cells were resuspended in fresh supplemented medium 
with 2.5% GM-CSF hybridoma supernatant and added back to the rest of the culture.  
On day 5, 1µM dexamethasone (Sigma-Aldrich, UK) was added to the culture 
medium to attain immature DCs as previously described (367).  On day six, 1μg/ml 
LPS (Escherichia coli serotype 0128:B12) (Sigma-Aldrich, UK), unless otherwise 
stated, was added to the culture medium for 16 hours to attain mature DCs.  DCs were 
harvested on day seven unless otherwise stated. 
 
In some experiments human α-thrombin (Haematologic Technologies Inc., USA), 
inactive thrombin (human α-thrombin-FPRCK) (Haematologic Technologies Inc., 
USA), PAR-1, -2 or -4 agonists (Peptides International, USA), anti-thrombin (AT) 
(Enzyme Research, UK) at stated concentrations or an equivalent volume of medium 
or AT followed by 100ng/ml LPS, or 100ng/ml LPS alone were added to DCs at 
stated time points before harvesting.  The DCs were then washed prior to further 
analysis. 
 
In some experiments DCs were incubated with anti-TF Ab at the stated concentration 
or an equivalent concentration of rabbit Ig and then washed prior to further analysis.  
Endothelial cell culture 
Vascular ECs were isolated as previously described (368) with a few minor 
modifications.  Hearts from mice were rinsed thoroughly with serum free DMEM, 
dissected into 1mm3 blocks and incubated with collagenase (diluted in 10% FCS-
DMEM) for 30 minutes at 37°C.  The digested tissue was passed through a cell 
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strainer to obtain a single cell suspension, which was then washed and resuspended in 
0.5% FCS-DMEM at a volume of 200µl per heart.  The cells were incubated with rat 
anti-mouse CD31 Ab (BD Pharmingen, USA) at a final concentration of 10ng/ml for 
30 minutes at 4°C.  Cells were then washed and resuspended in 0.5% FCS-DMEM 
with goat anti-rat IgG coated magnetic microbeads (Miltenyi Biotech, Germany) for 
15 minutes at 4°C following which they were again washed and resuspended in 0.5% 
FCS-DMEM at a volume of 500µl per heart.  The CD31 cells were positively isolated 
using MACS MS separation columns (Miltenyi Biotech, Germany) according to 
manufacturer’s instructions and eluted using 1ml 0.5% FCS-DMEM.  Cells were 
cultured in gelatin-coated flasks (Sigma-Aldrich, UK) in endothelial medium, which 
consisted of DMEM supplemented with 20% FCS, 10 units/ml heparin, non-essential 
amino acids, 10mM HEPES, 1mM sodium pyruvate, 50µM 2-ME and 30µg/ml EC 
growth factor.  Flow cytometric analysis of characteristic surface molecules was 
performed to confirm EC phenotype.  Representative profiles are shown in figure 4.2 
 
Figure 4.2 Endothelial cell phenotype
Vascular EC were isolated from cardiac tissue by positive selection using
CD31 Ab. Following culture the cells were analysed by flow cytometry.
Shaded profiles show isotype control and open profiles show specific
binding.
CD31 CD105
CD106e-selectin
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Assays for T cell proliferation 
Assays were performed in triplicate in 96 well U bottom plates unless otherwise 
stated in humidified atmosphere with 5% CO2 at 37° C.  Complete medium consisted 
of RPMI supplemented with 10% heat inactivated FCS, 100U/ml penicillin, 
100mg/ml streptomycin and 1mM L-glutamine. 
Response to con A  
2x105 purified T cells were stimulated with 5μg/ml con A with or without 2x105 
irradiated syngeneic splenocytes in 200μl of complete medium. The cells were pulsed 
with 3H thymidine (Amersham GE Healthcare, UK) on day two and harvested 16 to 
18 hours later to determine T cell proliferation as assessed by incorporated 
radioactivity. 
CD3/CD28 stimulation 
Two methods were tried. In the first, 0 to 5µg/ml as specified, of anti-CD3 Ab (clone 
37.51.1) (Caltag, UK) and anti-CD28 Ab (clone 500-A2) (Caltag, UK) in phosphate 
buffered saline (PBS) were added to wells of a flat bottomed 96 well plate and 
incubated at 37°C overnight.  The following day the wells were washed with PBS.  
2x105 BALB/c CD4+ T cells were then added to the Ab coated wells in triplicate.  
The cells were pulsed with 3H thymidine on day two and harvested 16 to 18 hours 
later to determine T cell proliferation as assessed by incorporated radioactivity. 
 
In the second method, which was used for the experimental conditions, 2x105 purified 
BALB/c T cells in 200μl complete medium were stimulated with a specified ratio of 
CD3/CD28 coated beads (Invitrogen, UK) with or without the addition of thrombin or 
inactive thrombin at a final concentration as stated.  The cells were pulsed with 3H 
thymidine on day two of culture and harvested 16 to 18 hours later to determine T cell 
proliferation as assessed by incorporated radioactivity. 
Alloantigen stimulation 
2x105 BALB/c T cells were stimulated with 1x104 irradiated C57BL/6 DCs in 200μl 
complete medium unless otherwise stated.  In some experiments thrombin (ranging 
from a final concentration of 0 to 1500nM) was added at the beginning of the assay.  
Proliferation was measured by adding 3H on day four of culture and harvesting 16 to 
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18 hours later to determine T cell proliferation as assessed by incorporated 
radioactivity. 
Antigen specific stimulation 
2x105 female Marilyn CD4+ T cells were stimulated with 1x104 male C57BL/6 DCs 
in 200µl complete medium.  Proliferation was measured by adding 3H on day two of 
culture and harvesting 16 to 18 hours later to determine T cell proliferation as 
assessed by incorporated radioactivity. 
Two step anergy assay 
1x106 purified BALB/c CD4+ T cells were co-cultured with 2x105 C57BL/6 DCs in 1 
ml complete medium per well of a 24 well plate.  Cells were recovered on day five 
and washed by slow centrifugation to remove any dead cells.  The cells were then 
rested in fresh complete medium for a further 96 hours before they were recovered 
and washed again.  2x104 recovered T cells in 100µl complete medium were then co-
cultured with 4x104 C57BL/6 DCs or CBA DCs as a third party control in 100µl 
complete medium per well in a 96 well U-bottom plate in triplicate.  T cell 
proliferation was measured by adding 3H on day three, five and seven of separate 
cultures and harvesting 16 to 18 hours later in order to ascertain the pattern of T cell 
response.  Figure 4.3 shows a schematic of the experimental protocol. 
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Figure 4.3 Protocol for two step anergy assay
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In vivo rechallenge 
5x106 C57BL/6 DCs were injected intravenously via the tail vein into BALB/c mice.  
Ten days later CD4+ T cells were purified from the spleen and lymph nodes of the 
mice and rechallenged with C57BL/6 irradiated splenocytes or CBA irradiated 
splenocytes as a third party control.  2x105 T cells were co-cultured with 2x105 
irradiated splenocytes in triplicate.  T cell proliferation was measured by adding 3H on 
days three, five and seven of separate cultures and harvesting 16 to 18 hours later in 
order to ascertain the pattern of T cell response.  Figure 4.4 shows a schematic of the 
experimental protocol. 
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Figure 4.4 Protocol for in vivo rechallenge
 
T cell suppressor assay 
1x106 purified BALB/c CD4+ T cells were co-cultured with 1x105 C57BL/6 DCs in 1 
ml complete medium per well of a 24 well plate.  Cells were recovered on day five 
and washed by slow centrifugation to remove any dead cells.  The cells were then 
rested in fresh complete medium for a further 96 hours before they were recovered 
and washed again following which they were irradiated and titrated into a primary co-
culture at specified ratio as indicated.  The primary co-culture consisted of 2x105 
purified naive CD4+ BALB/c T cells and 1x104 C57BL/6 DCs in 200µl complete 
medium per well of a 96 well U-bottom plate. This was performed in triplicate.  
Proliferation was measured by adding 3H on day four of culture and harvesting 16 to 
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18 hours later to determine T cell proliferation as assessed by incorporated 
radioactivity. 
Enzyme linked immunosorbent assay 
For IL-12, IL-6, IFN-γ and IL-4, supernatants were collected from DC culture and DC 
and T cell co-culture and stored at -80°C until ready to be analysed.  Cytokine 
production was assayed by double sandwich ELISA using a cytokine-specific purified 
Ab paired with an Ab specific for another epitope of the cytokine.  Commercial 
ELSIA kits (Insight, UK) were used according to manufacturer’s instructions.  
Briefly, 96 well ELISA plates (Corning Costar 9018) were coated with capture Ab by 
incubating them overnight at 4°C.  The next day the plate was washed three times in 
0.1% Tween in PBS (wash buffer).  The wells were then incubated with assay diluent 
at room temperature for one hour as a blocking step and then washed thoroughly, 
which involved soaking the wells in wash buffer for 1-2 minutes prior to removal and 
repeating five to seven times.  Standards of the cytokine being measured were made 
up; four fold dilutions of the standard, negative control and supernatant samples were 
plated in triplicate.  The plate was incubated at room temperature for two hours 
following which the wells were again washed thoroughly.  Detection Ab was then 
added to the wells and the plate incubated at room temperature for one hour before 
thorough washing of the wells.  Avidin-HRP was then added to the wells and the plate 
incubated at room temperature for 30 minutes.  Again the wells were washed 
thoroughly and then substrate solution was added to each well.  The plate was 
incubated at room temperature for approximately 15 minutes, until an appropriate 
intensity of colour was obtained, before stop solution was added to each well.  The 
plate was read immediately on an ELISA plate reader at 450nM.  A standard curve 
was generated and cytokine levels of the samples were read from this. 
Flow cytometric analysis 
All flow cytometry was performed on a FACSCalibur flow cytometer and analysed 
using Cellquest (BD BioSciences, UK) or Flojo (Treestar, USA) software. 
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Surface marker expression 
Cells were analysed for surface marker expression with the use of specific Abs and, 
when appropriate, the use of a relevant secondary Ab.  The relevant isotype matched 
Abs were used as negative controls.   
 
2x105 cells were washed in PBS containing 5% heat inactivated FCS (FACS buffer) 
then stained with the appropriate concentration of Ab in 50 or 100µl FACS buffer in 
96 well V-bottom plates and incubated for thirty minutes in the dark at 4°C.  The cells 
were then washed three times and when appropriate stained with a relevant secondary 
Ab before washing three times again.  The cells were then resuspended in 300µl 
FACS buffer and analysed immediately or fixed by incubation with 2% 
paraformaldehyde in PBS and analysed within three days. 
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Table 4.2 Primary antibodies used for flow cytometry and immunocytochemistry
N/A not available, * used in immunocytochemistry.
Specificity Clone Source Isotype
CD4 RM4-5 e-Bioscience, USA rat IgG2a
CD8 53-6.7 e-Bioscience, USA rat IgG2a
FITC-CD3 145-2C11 e-Bioscience, USA hamster IgG
CD11b M1/70 e-Bioscience, USA rat IgG2b
CD68 FA-11 Serotec, UK rat IgG2a
F4/80 CI:A3-1 Serotec, UK rat IgG2b
FITC-CD11c N418 Serotec, UK hamster IgG
MHCI 2G5 Caltag, UK mouse IgG2b
FITC-MHCII M5/114.15.2 e-Bioscience, USA rat IgG
FITC-CD80 RM80 Serotec, UK rat IgG2a
FITC-CD86 GL1 Becton Dickinson, USA rat IgG2a
CD40 IC10 e-Bioscience, USA rat IgG2a
ICOSL HK5.3 e-Bioscience, USA rat IgG2a
PDL1 MIH1 e-Bioscience, USA rat IgG2a
PDL2 TY25 e-Bioscience, USA rat IgG2a
ICAM YN1/1.7.4 e-Bioscience, USA rat IgG2b
TF N/A American Diagnostica, USA rabbit Ig
PDI* N/A Affinity Bioreagents, USA mouse IgG2a
TFPI N/A American Diagnostica, USA rabbit Ig
PAR-1 14 Becton Dickinson, USA mouse IgG1
PAR-2 SAM-11 Santa Cruz, USA mouse IgG2a
PAR-3 H-103 Santa Cruz, USA rabbit Ig
PAR-4 H-120 Santa Cruz, USA rabbit Ig
PE-foxp3 FJK-16s e-Bioscience, USA rat IgG2a
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Table 4.3 Secondary antibodies used for flow cytometry and immunocytochemistry
* Used in immunocytochemistry.
Description Source
FITC swine anti-rabbit Ig Dako, Denmark
FITC goat anti-rabbit Ig Sigma-Aldrich, UK
PE goat anti-rabbit Ig Sigma-Aldrich, UK
FITC mouse anti-rat IgG e-Bioscience, USA
FITC goat anti-mouse IgG* Dako, Denmark
 
  
When DCs were stained with anti-TF Ab followed by a goat anti-rabbit phycoerythrin 
(PE) conjugated secondary Ab no specific staining was seen, which contrasted with 
what was seen when a swine anti-rabbit fluorescein isothiocynate (FITC)-conjugated 
secondary Ab was used as shown in figure 4.5A-D.  The lack of specific binding was 
likely to be due to the degree of non-specific binding of the secondary Ab as 
confirmed by the difference in profiles seen when unstained DCs were compared with 
DCs stained with the FITC-conjugated secondary Ab and the PE-conjugated 
secondary Ab as shown in figure 4.5E-F.  The non-specific binding of the PE-
conjugated Ab was overcome by incubating the cells with goat serum (Sigma-Aldrich, 
UK) prior to staining with the secondary Ab as shown in figure 4.5F.  This step was 
used for all further staining involving the PE-conjugated secondary Ab.  
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Figure 4.5 Effective blocking of non specific binding of goat anti-rabbit PE-conjugated 
secondary Ab
C57BL/6 DCs were analysed for expression of TF by flow cytometry.  Cells were stained with 
anti-TF Ab (B, D) or isotype control (A, C) and then with swine anti-rabbit FITC-conjugated 
secondary Ab (A, B) or goat anti-rabbit PE-conjugated secondary Ab (C, D).  Numbers shown 
are percentage of positive cells in upper gate. Untreated C57BL/6 DCs were unstained (untx) or 
stained with  swine anti-rabbit FITC-conjugated secondary Ab (FITC) (E) untreated C57BL/6 
DCs were unstained or stained with goat anti-rabbit PE-conjugated secondary Ab (PE) or goat 
serum followed by goat anti-rabbit PE -conjugated secondary Ab (goat serum + PE) (F). 
Key Name
untx not stained.001
untx 2 FITC sw a-rab.004
Key Name
untx not stained.001
untx 2 PE gt a-rab.005
untx 2 PE gt a-rab+gt serum.006
untx
untx
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PE
goat serum + PE
PE
C D
TF isotype 
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TC
A
2.5%
TFB
20%
2.5% 2.5%
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F
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Intracellular cytokine staining 
Cells were prepared and stained using a method as described elsewhere (369).  Cells 
were stimulated with PMA (Sigma-Aldrich, UK) at 50ng/ml plus ionomycin 
(Calbiochem, Germany) at 500ng/ml for four hours.  At two hours before cell harvest 
brefeldin A (Sigma-Aldrich, UK) was added at 10µg/ml using a stock of 1mg/ml in 
ethanol.  Cells were harvested, washed with FACS buffer and when required stained 
for surface markers at this point.  Following further washing, the cells were 
resuspended in 2% paraformaldehyde in PBS.  After fixing for twenty minutes at 
room temperature the cells were washed in FACS buffer and either stored in FACS 
buffer containing a final concentration of 0.1% sodium azide, for up to 48 hours, or 
stained immediately.  For intracellular staining all washes and incubations were done 
in FACS buffer containing 0.5% Saponin (Sigma-Aldrich, UK) (permeabilisation 
buffer) unless otherwise stated.  The cells were incubated in permeabilisation buffer 
for ten minutes in 96 well V-bottom plates.  The cells were then stained with the 
appropriate concentration of Abs (Table 4.3) in 50µl permeabilisation buffer or the 
relevant isotype controls and incubated for thirty minutes in the dark at 4°C.  The cells 
were washed twice, then once with FACS buffer before resuspending in FACS buffer 
and analysing immediately. 
 
Table 4.4 Antibodies used for flow cytometric analysis of cytokine secretion
Specificity Clone Source Isotype
IFN-γ XMG1.2 BD Pharmingen, USA rat IgG1K
IL-4 11B11 BD Pharmingen, USA rat Ig1K
IL-10 JES5-16E3 BD Pharmingen, USA rat Ig2b
 
Immunocytochemistry  
Cells were suspended at 1x105/ml in complete medium and ~20µl placed in each well 
of a glass slide and allowed to dry.  Once completely dried 20µl of cold 4% 
paraformaldehyde in PBS was added to each well and left for fixing for ten minutes at 
room temperature.  The slides were then washed gently in PBS and air dried before 
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being either wrapped in aluminium foil and stored at -70°C or stained immediately.  
When staining stored slides, each well was first resuspended in 20µl PBS and left for 
ten minutes at room temperature before being washed and stained.  For staining, 0.5% 
triton in PBS was added to each well and incubated for 20 minutes at room 
temperature.  The slides were then washed in PBS and cells in the wells incubated for 
one hour in 1% BSA in PBS as a blocking step.  Next, the slides were washed in PBS 
and stained by incubating the cells for one hour in the appropriate concentration of Ab 
suspended in 20µl 1% BSA in PBS.  The slides were washed three times in PBS and 
the cells were then stained with the relevant fluorescent secondary Ab and incubated 
for one hour in the dark at room temperature.  Abs used are shown in table 4.1 and 
4.2. The slides were finally washed in PBS and allowed to dry completely before 
adding mounting medium with 4'-6-Diamidino-2-phenylindole (DAPI) (Vector 
laboratories, UK) to each well.  A coverslip was placed over the slide and analysed on 
an immunofluorescence microscope (Axiovert S100 TV; Zeiss, Welwyn Garden City, 
UK) with Plan-NEOFLUAR objectives using a KTL/CCD-1300/Y/HS camera from 
Princeton Instruments (Trenton, NJ, USA). Images were analyzed using the 
MetaMorph imaging system (Universal Imaging, Downingtown, PA, USA). 
RNA extraction 
Between 5x106 and 10x106 cells were washed thoroughly with PBS before RNA was 
extracted using phenol and chloroform.  Briefly, cells were pelleted and resuspended 
in 1ml TRI-Reagent (Invitrogen, UK), followed by incubation at room temperature for 
five minutes.  200µl chloroform was then added and the sample was shaken 
vigorously for 15 seconds before being allowed to stand at room temperature for five 
minutes.  Samples were then centrifuged again before the aqueous, upper phase was 
transferred to a new 1.5ml tube.  500µl isopropanol was added to the aqueous phase 
and the two solutions were mixed thoroughly prior to 30 minutes incubation at room 
temperature.  Samples were then centrifuged at 4˚C and the supernatants carefully 
removed.  RNA pellets were washed with 1ml of 75% ethanol and then samples were 
centrifuged at 4˚C.  Supernatants were removed and pellets were allowed to air dry 
before being resuspended in RNase free water (Sigma-Aldrich, UK).  RNA was 
assessed using agarose gel analysis and Quanti-iT Ribogreen RNA reagent and kit 
(Invitrogen, UK). 
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Reverse transcription-polymerase chain reaction 
A two-step protocol was used for RT-PCR.  Initially cDNA was produced from 1µg 
RNA.  The reagent mix consisted of deoxynucleotides (dNTPs), random primers and 
reverse transcriptase as well as reaction buffer, MgCl2, RNA polymerase inhibitor and 
water (Applied Biosystems, USA).  The conditions used were: 10 minutes at 25°C, 
then 60 minutes at 42°C followed by 5 minutes at 99°C and finally 5 minutes at 4°C.  
Samples were run in triplicate for the second step.  Specific primers were selected 
from ‘assays on demand’ Taqman gene expression assays (Applied Biosystems, USA) 
and are listed in table 4.4.  Taqman FAM dye labelled probe was used with Taqman 
universal mastermix (Applied Biosystems, USA).  Amplification and detection were 
performed under the following conditions: 2 minutes at 50°C, then 10 minutes at 95°C 
followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C.  A DNA engine 
Opticon 2 system (Bio-Rad, UK) was used for both steps.  All PCR products were run 
on 1% agarose gel. 
 
Table 4.5 Primers used for RT-PCR
Specific primers used in RT-PCR were selected from
Taqman gene expression assays (Applied Biosystems,
USA).
Primer Assay identification details
PAR-1 Mm00438851
PAR-2 Mm00433160
PAR-3 Mm00438852
PAR-4 Mm00433161
β-actin 435231
 
Clotting assay 
A range of known concentrations of TF from mouse acetone brain extract were 
suspended in a solution of 50mM Tris-HCl, 150mM NaCl and 1mg/ml human 
albumin pH 7.4 (TBS-A).  For test samples, cells were suspended at a concentration 
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of 10x106/ml in TBS-A.  For some samples, cells were incubated with a specified 
concentration of anti-TF Ab or relevant isotype control. 
 
For the clotting assay known concentrations of TF in 80µl TBS-A or 10x106/ml cells 
in 80µl TBS-A in a glass tube ( ) was mixed with 80µl phospholipid and 80µl pooled 
normal mouse plasma.  The tube was incubated in a water bath at 37°C for one 
minute.  To start the clotting assay 80µl CaCl2 was added, then the tube was 
continuously agitated by tilting and the time for a clot to form measured.  Triplicates 
were done for all conditions and a mean was calculated.  In this way a standard curve 
was generated from the samples with known concentrations of TF and a measure of 
the level of TF in the test samples could be read from this.  
 
Figure 4.6 shows a standard curve generated for one of the experiments performed.  
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Figure 4.6 Standard curve for clotting assay
80µl TF from mouse brain extract in 50M TBS-A was mixed in a pyrex tube with 
80µl phosopholipid and 80µl mouse plasma.  The sample was incubated for one 
minute at 37°C before starting the clotting assay by adding 80µl CaCl2 and mixing.  
Time to clot was measured for each sample in triplicate and the mean time plotted 
to generate a standard curve as shown.
 
In vivo antigen specific T cell sensitisation 
Cells from lymph nodes and spleen of naive DO11.10 mice were stained with 2.5µM 
carboxyfluorescein succinimidyl ester (CFSE from Cambridge Biosciences, UK) by 
incubating in warm PBS on a roller for 15 minutes in the dark at room temperature.  
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5% FCS in PBS was then added to stop the reaction and the cells were washed twice 
with PBS.  10x106 cells were then injected via the tail vein into BALB/c recipient 
mice.  24 hours later, in some experiments the mice were given an intraperitoneal 
injection of 3mg or 10000U/kg AT or an equivalent volume of saline followed by 
5mg ovalbumin plus 25µg LPS (Escherichia coli serotype 0127:B8) (Sigma-Aldrich, 
UK) (sensitised) or 25µg LPS alone (control).  In some experiments the mice were 
given an intraperitoneal injection of 250µg anti-TF Ab or its isotype control followed 
by 5mg ovalbumin (tolerised) or saline (control).  72 hours after the intraperitoneal 
injection the mice were killed and cells from the lymph nodes (cervical, axillary, 
brachial and inguinal) were harvested for analysis of proliferation and IFN-γ, IL-4 and 
IL-10 production by flow cytometry.  
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Chapter 5: Tissue factor 
TF is found both constitutively and following induction on a number of different cell 
types.  Interaction of FVII with TF initiates the coagulation cascade resulting in the 
formation of thrombin, which leads to haemostasis and thrombosis through clot 
formation.  It is now clear that TF additionally exerts cellular effects following 
binding of its ligand FVII.  This is through interaction with another cell surface 
receptor, namely PAR-2, as well as generation of downstream coagulation proteins, 
which also act through members of the PAR family.  Additionally signalling can 
occur directly through the cytoplasmic tail of TF following binding of its ligand. 
 
TF expression has been found on a number of cells of the immune system raising the 
possibility of a role in the immune response.  Data already implicates its role in other 
biological systems including angiogenesis through cell growth and vascular 
remodelling and inflammation, through increased cytokine production, cell migration 
and activation.  
 
Experiments in this chapter focus on the hypothesis that TF plays a role in the 
adaptive immune response. 
 
The adaptive immune response is initiated by the encounter of T cells with antigen 
presented in the context of MHC by antigen presenting cells.  This response is 
influenced by environmental factors through their effects on the antigen presenting 
cell.  The dendritic cell is the most important antigen presenting cell, which possesses 
specialised functions for this purpose, and for these reasons was chosen as the main 
cell type to study, along with T cells.   
 
Specific experimental aims in this chapter are: 
- To isolate and characterise mouse DCs 
- To confirm and characterise TF expression on mouse DCs  
- To examine regulatory factors of TF expression on DCs 
- To determine whether TF is expressed on T cells 
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- To characterise the function of TF on these cell types and its influence on the 
T cell response in vitro and in vivo 
- To determine the mechanism of action of the effects of TF on the T cell 
response 
Generation of dendritic cells  
Immature, untreated and mature murine bone marrow derived DCs were cultured as 
described in chapter 4. It was important to confirm that these cells displayed a 
characteristic DC phenotype and this was assessed by flow cytometry and their ability 
to act as stimulators for allogeneic naïve T cells in a MLR.  Flow cytometry was used 
to detect the presence of a specific DC marker, CD11c, plus CD4, CD8, MHCII and 
co-stimulatory molecules CD80 and CD86.  
 
As shown in figure 5.1 there was high purity of the DCs with over 85% expressing 
CD11c.  To attain either immature or mature DCs 1µM dexamethasone or 1µg/ml 
LPS was added on day five of culture or overnight before the day of harvest 
respectively.  As expected immature DCs had low level expression of MHCII and co-
stimulatory molecules whilst mature DCs had high level expression of these 
molecules with untreated DCs having an intermediate phenotype.  
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Figure 5.1 Phenotype of DCs
C57BL/6 DCs were harvested on day seven of culture and analysed by flow cytometry.
Immature (dex) and mature DCs (mature) were attained by adding 1µM dexamethasone and
1ng/ml LPS on day five and six of culture respectively. Shaded profiles show isotype control and
the open profiles show specific binding.
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The differential expression of surface molecules was reflected in the DCs ability to 
stimulate allogeneic T cells as shown in figure 5.2. Maximal T cell proliferation was 
seen with LPS treated DCs, which correlates with their mature phenotype, with robust 
proliferation at a ratio of one DC for every 100 T cells emphasising their potency as 
an antigen presenting cell. Minimal T cell proliferation was seen with immature DCs, 
which correlated with their low surface expression of MHCII and co-stimulatory 
molecules. T cell proliferation with untreated DCs was between these two levels.  A 
ratio of one DC for every twenty T cells was used for further experiments to ensure 
that either a reduction or enhancement of T cell proliferation would be detected. 
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Figure 5.2 Titration assay of the T cells response to allogeneic DCs
Dexamethasone treated (dexDC), untreated (uDC) or LPS matured (mDC)
C57BL/6 DCs were co-cultured with 2x105 purified BALB/c CD4+ T cells at
the specified ratio. T cells (T) and DCs (DC) alone are shown as negative
controls. Mean shown +/- SE of triplicate wells.
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Figure 5.3 shows further analysis of the DCs, which revealed that they did not express 
CD8 or CD4.  To exclude the presence of macrophages, which would be important as 
they are known to express TF on activation, a panel of three markers was used.  
Although CD11b was found there was no expression of CD68 or F4/80, which are 
thought to be more specific for macrophages. 
 
CD4 CD8
F4/80CD11b CD68
Figure 5.3 Phenotype of DCs
C57BL/6 DCs were harvested on day seven of culture and analysed by flow
cytometry. The shaded profiles show isotype control and open profiles show
specific binding.
 
Optimisation of anti-tissue factor antibody use 
A number of antibodies against TF was tested on B16-F10, which is a mouse 
melanoma cell line with high TF expression, using flow cytometry.  The results are 
shown in figure 5.4. Neither the anti-mouse Ab in crude rabbit serum, which was 
generated by the McVey laboratory, nor the commercially available goat anti-human 
TF Ab, stained the B16-F10 cells.  Concentrated anti-mouse Ab, generated from a 
DNA vaccine in rabbit, stained the cells at saturating levels for all the dilutions tested. 
The commercially available rabbit anti-mouse TF also stained the B16-F10 cells and 
titration of this Ab showed saturation at doses of between 50 and 100mcg/ml with 
suboptimal saturation at doses of 25 and 5mcg/ml. This Ab was used for further 
experiments in flow cytometry at a dose of 100mcg/ml unless otherwise stated.  The 
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antibody was functionally inhibitory and was used for this purpose in clotting assays 
and MLRs. 
 
Figure 5.4 Assessment of mouse anti-TF Ab by flow cytometry
Different preparations of anti-TF Ab were tested by flow cytometry on B16F10, a murine melanoma cell
line. Crude rabbit serum anti-mouse Ab (A), goat anti-human Ab (B), rabbit anti-mouse DNA vaccine Ab
1:5 (C), 1:2 (D), neat (E) dilution, rabbit anti-mouse Ab 100µg/ml (F), 50µg/ml (G), 25µg/ml (H), 5µg/ml (I).
Shaded profiles show isotype control and open profiles show specific binding.
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On testing this Ab for use in western blotting (WB) it was only able to detect the 
purified recombinant TF protein but not TF in protein lysate from B16-F10 cells upto 
a loading protein amount of 70µg.  Possible explanations for this may be due to the 
low affinity properties of the Ab in this application, such that it only works with high 
concentrations of highly purified protein.  Another explanation would be that the TF 
protein was lost from the lysate preparation.  TF is a transmembrane protein and so it 
is possible that it remained within the lipid portion when the cells were lysed with a 
detergent based lysis buffer. 
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Tissue factor expression on T cells and bone marrow progenitor cells 
Figure 5.5 shows that no TF expression was found on CD4+ or CD8+ T cells isolated 
from the spleen and lymph nodes of BALB/c, as described in the methodology. 
 
Figure 5.5 TF expression on CD4+ and CD8+ T cells
T cells were purified from spleen and lymph nodes of BALB/c mice by negative depeletion.
They were analysed by flow cytometry for purity of CD4+ (CD4) and CD8+ (CD8) T cells,
shown as a percentage, and for expression of TF (TF). Shaded profiles show isotype
controls and open profiles show specific binding.
60% 35%
T cells
CD4 CD8 TF
 
Tissue factor expression on dendritic cells 
Previous work has shown that human monocyte-derived DCs express TF (232, 233) 
as outlined in chapter 2.  Other work has suggested the expression of TF on murine 
DCs but have not shown this directly  (234). 
 
Flow cytometry was used to determine whether immature, untreated and LPS treated 
murine bone marrow derived DCs expressed TF.  All three subtypes of DCs from 
C57BL/6 and BALB/c mice, were found to have a subpopulation of TF positive cells. 
This varied between experiments from 5 to 20%.  A representative profile of TF 
staining of untreated C57BL/6 DCs is shown in figure 5.6B.  This was in contrast to 
freshly isolated bone marrow progenitor cells, as shown in figure 5.6A, which had no 
TF expression. 
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Figure 5.6 TF expression on bone marrow progenitor cells and DCs
Freshly isolated mouse bone marrow progenitor cells (A) and cultured C57BL/6 untreated 
DCs (B) were analysed for expression of TF by flow cytometry.  R1 and R2 represent the 
two populations seen on the forward and side scatter profiles for the bone marrow progenitor 
cells.  Dot plots for TF staining and TF isotype controls are shown for the C57BL/6 DCs
with percentage positive staining.  Shaded profiles show isotype controls and open profiles 
show specific binding for the histogram profiles.
 
 
To ensure that the TF expressing cells were DCs, and not contaminating cells, double 
staining was undertaken with anti-CD11c Ab conjugated to FITC, a specific DC 
marker, and anti-TF Ab followed by anti-rabbit secondary Ab conjugated to PE.   
 
Figure 5.7 shows that the TF expressing cells co-expressed CD11c and so confirms 
that a subpopulation of DCs, not contaminating cells, express TF.  These results 
indicate that immature, untreated and mature murine DCs within the same experiment 
all had a similar percentage of TF expressing cells and levels of antigenic TF 
expression as indicated by the median fluorescence index (MFI) of the these three 
different subtypes of DCs. 
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Figure 5.7 TF and CD11c co-expression on DCs
Untreated (untx), dexamethasone treated (dex) and LPS matured (LPS) C57BL/6 DCs
were harvested on day seven of culture and analysed by flow cytometry for co-
expression of CD11c and TF. profiles show isotype control (A) and specific binding (B).
Numbers in quadrants are percentage of positively stained cells within quadrant. MFI=
median fluorescence index. Profiles shown are one of four experiments.
 
Functional activity of tissue factor on dendritic cells 
The next experiments addressed whether the TF present on DCs was functionally 
active in terms of its ability to initiate the coagulation cascade by performing a 
clotting assay as described in chapter 4.  DCs, as a source of TF, were added to 
recalcified mouse plasma and the time to clot measured.  
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Figure 5.8 Functional assessment of TF on DCs using clotting assay
Dexamethasone treated (dex DC) untreated (untx DC) or LPS matured DCs (LPS DC), 
B16F10 cells as a positive control, and no cells as a negative control, were added to 
recalcified mouse plasma and the time to clot measured (A).  To confirm the time to clot 
was TF dependent, the respectiver DCs were incubated with increasing doses of anti-TF 
Ab (α-TF) or isotype control (isotype) and then added to recalcified mouse plasma and 
the time to clot measured (B).  Mean shown  +/- SE (too small to visualise) of triplicates.  
Data representative of two experiments.
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As shown in figure 5.8A, when no cells were added to the assay, which served as the 
negative control for TF dependent clotting, a clot eventually formed but took a 
relatively long time. When B16-F10 cells, which have a high level of TF expression, 
were added to the assay the time to clot was short. Clotting times for the same 
condition varied between assays as shown in table 5.1.  This may in part be due to 
varying levels of TF between assays but the negative control also differed suggesting 
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that factors other than TF also played a role.  The same batch of mouse plasma was 
used throughout these series of experiments however it is likely that over time non-TF 
factors led to low level activation of the coagulation factors in the plasma and so less 
time was required for TF dependent activation to lead to clot formation.  
 
Figure 5.8A shows that the clotting assays with DCs were shorter than the negative 
control suggesting functionally active TF is present on DCs.  Furthermore the time to 
clot was significantly different depending on whether immature, untreated or mature 
DCs were added to the assay.  Immature DCs consistently took the longest time to 
initiate clot formation followed by untreated DCs, with mature DCs leading to the 
shortest time to clot.  
 
To confirm that the pro-coagulant activity was due to the presence of TF on the cells, 
inhibitory anti-murine TF Ab was used to block the effect of TF up to a dose of 
100µg/ml.  As shown in figure 5.8B-D incubation of the cells with this Ab, but not 
with the rabbit Ig isotype control, led to a significant increase in the clot time in a 
dose dependent fashion.  However the time to clot, when anti-TF Ab was added to the 
assay, was still shorter than the time to clot of the negative control, when no TF was 
present in the assay.  An explanation for this would be that the anti-TF Ab was not at 
a completely saturating dose and, due to the sensitivity of the clotting assay, even a 
small amount of active TF present reduced the clot time compared to the negative 
control.   
 
When anti-TF Ab was incubated with mature DCs, at the maximal dose of 100ug/ml, 
the time to clot was increased, compared to that of mature DCs alone, and equivalent 
to the time to clot of untreated DCs alone.  This incremental increase in the time to 
clot was also observed for untreated DCs when incubated with anti-TF Ab, which was 
equivalent to the time to clot of immature DCs alone.  This confirms that the pro-
coagulant activity of DCs at all levels of activation was in part due to the presence of 
TF although the functional level of TF activity appeared to vary. 
 
For each experiment a standard curve was generated by adding known amounts of 
murine TF, in the form of homogenised brain extract, to recalcified mouse plasma and 
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measuring the clotting time. In this way a relative measure of the amount of TF 
present could be given to each sample.  Table 5.1 shows mean time to clot of the 
samples within the four experiments with the corresponding measurement of TF, as 
deduced from the standard curve generated for each experiment.  This consistently 
shows that the amount of active TF is highest on mature DCs, followed by untreated 
and then immature DCs.  
 
Table 5.1 Correlation of antigenic TF expression and pro-coagulant functional activity of DCs
Mean time to clot of samples within four experiments with the corresponding measure of TF and
antigenic expression of TF, as expressed by % TF expression and median fluorescence index (MFI)
for three of the four experiments.
Experiment Cell type Mean clot 
time (secs)
TF 
(units/ml)
% TF 
expression
MFI of 
TF
1 none 229
B16F10 27.5 22
immature DCs 156 0.15 10 690
untreated DCs 107 1 7 550
mature DCs 81 2.75 5 602
2 none 145.5
immature DCs 95 0.56
untreated DCs 66 2.1
mature DCs 58 4.46
3 none 117
immature DCs 95 0.21 14 783
untreated DCs 72.5 1.29 24 726
mature DCs 40.5 16.8 25 590
4 none 115
immature DCs 73 1.25 10 1012
untreated DCs 53.5 5.4 15 1063
mature DCs 34 23 13 1184
 
 
Corresponding antigenic expression of TF as assessed by flow cytometry was done on 
DCs from three of the four clotting assay experiments.  The percentage of TF-
expressing cells and MFI are shown in table 5.1 and are similar between DCs at 
different levels of activation. This highlights the discrepancy between the similar 
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levels of antigenic expression of TF but increasing levels of active pro-coagulant TF 
with increasing maturity of DCs. 
 
TF is known to exist in an encrypted or inactive form that has the ability to become 
pro-coagulant.  The discrepancy between similar levels of antigenic TF and increasing 
levels of functionally active TF with increasing maturity of the DCs, suggests that 
more TF exists in this encrypted form on immature DCs but as the DC matures this is 
converted into the active pro-coagulant form of TF.  The control of this regulation is 
unknown but there are several proposed mechanisms as outlined in the introduction.  
The next section addresses whether some of these mechanisms are involved as a way 
to regulate the differential functional activity of TF on immature, untreated and 
mature DCs.  
Regulation of tissue factor pro-coagulant activity on dendritic cells 
Phosphatidylserine exposure on plasma membrane 
TF pro-coagulant activity is sensitive to phospholipid composition and so the 
regulated degree of exposure of phosphatidylserine (PS) on the outer leaflet of the 
plasma membrane is a potential mechanism to control the activity of TF present. 
Dexamethasone treated, untreated and LPS matured DCs were analysed for PS 
exposure and the levels compared.  One would expect more PS exposure with more 
TF pro-coagulant activity if this was the mechanism at play. 
 
Annexin-V is known to bind to PS and this property was utilised to assess the level of 
PS exposure on the DCs.  They were stained with FITC conjugated annexin-V and 
analysed by flow cytometry.  Figure 5.9 shows results from one of two experiments, 
in which there was some binding of the FITC-annexin-V as detected by a shift in the 
fluorescence in dexamethasone treated and untreated DCs compared to unstained 
cells. Importantly there was no significant difference between the level of PS 
exposure of DCs with increasing maturity as assessed by the percentage positivity of 
20% and similar MFI in dexamethasone treated and untreated DCs.  In the second 
experiment the degree of binding of FITC-annexin-V was less than in this experiment.   
However, again it was similar between the DCs at different levels of maturity. Overall 
these results indicate that PS exposure can occur on DCs but that it is similar on DCs 
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at different levels of maturity within any one experiment and so cannot account for 
the differences in TF pro-coagulant activity.  The difference in PS exposure between 
experiments was likely to be due to variable degrees of apoptosis.  
 
 
Figure 5.9 Surface expression of phosphatidylserine on DCs
Dexamethasone treated (dex) and untreated DCs (untx) were analysed by flow
cytometry for exposure of phosphatidylserine on the cell surface by staining with
annexin-V or nothing (unstained) as a negative control as indicated. Numbers
represent percentage positive cells within gate and (numbers) represent mean
fluorescence index. Data are one of two independent experiments.
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Protein disulphide isomerase 
Recent but controversial data suggest an allosteric disulphide bond by PDI as a 
control mechanism for TF activation (243, 246). PDI is a protein normally resident in 
the endoplasmic reticulum of eukaryotic cells, however it has also been described in 
other locations including the cell surface (245), where it would be predicted to be 
present if it played a role in controlling TF activation.  Anti-PDI Ab was used to 
address whether PDI was present on the surface of DCs.   
 
Fig 5.10A-D shows immunocytochemistry of 293T cells, which is a positive control 
cell line for PDI.  The Ab stains the surface as well as the cytoplasm, confirming that 
the Ab works in this application. Figure 5.10E-J shows there is no staining on the 
surface of immature, untreated or mature DCs. 
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Figure 5.10 Expression of protein disulphide isomerase (PDI) on DCs
293T cells (293T), as a positive control, dexamethasone treated (dex), untreated (untx) or LPS
matured DCs (LPS) were fixed on glass slides for analysis of surface expression of PDI. 293T
cells were also fixed and permeabilised for analysis of intracellular expression of PDI (293T
intra). Cells were stained with an anti-rat PDI Ab (B, D, F, H, J) or its isotype control (A, C, E,
G, I) and then with a FITC conjugated secondary Ab prior to analysis. x20 magnification.
Data are representative of two experiments.
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I J
293T
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Use of the same anti-PDI Ab clone has been previously described with WB on murine 
cells (370), therefore WB was performed on DCs.  No band was seen at the 
anticipated size, which indicated no expression of PDI in DCs. 
 
Finally the anti-PDI Ab was used in flow cytometry and again no expression was seen 
on DCs.   
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In summary the anti-PDI Ab used has previously been shown to work in murine cells 
with immunocytochemistry (371) and WB.  These results have been confirmed and, 
using similar methods, demonstrated that immature, untreated and mature DCs do not 
express PDI.  Furthermore, flow cytometry using this Ab corroborated this finding. 
Tissue factor pathway inhibitor 
As discussed in chapter two, TFPI is the natural inhibitor for TF and is known to be 
expressed on cells which can be induced to express TF such as ECs and fibroblasts. 
TFPI inhibits the pro-coagulant function of TF by binding to it and preventing 
interaction with downstream coagulation proteins. Therefore it is feasible that 
variations in the level of TFPI expression may affect the function of TF on that cell 
type.  Figure 5.11 shows there was no expression of TFPI on mouse DCs. 
  
dex untx LPS
TFPI
Figure 5.11 Expression of tissue factor pathway inhibitor on DCs
Dexamethasone treated (dex), untreated (untx) and LPS matured (LPS) DCs
were analysed by flow cytometry for expression of tissue factor pathway
inhibitor (TFPI). Shaded profiles show isotype control and open profiles show
specific binding. Data are representative of two experiments.
 
In vitro assessment of the function of tissue factor 
Next the function of the TF found on DCs was investigated.  As detailed in chapter 
two, TF binds to FVII/VIIa to either initiate the coagulation network or activate PAR-
2 leading to cellular signalling (272).  Evidence suggests this differential function of 
TF depends on the nature of TF present on the cell.  If TF is encrypted cellular 
signalling is more likely to occur, whereas initiation of coagulation is more likely with 
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the pro-coagulant form.  As TF appears to be present in its different forms on 
immature and mature DCs it would suggest that they have differential functions. 
 
The function of TF on DCs was addressed by, firstly, adding the inhibitory anti-TF 
Ab into an MLR with immature, untreated or mature DCs as stimulators and 
allogeneic CD4+ T cells as responders, and then measuring T cell proliferation as 
assessed by 3H incorporation as described in chapter four.  
 
There was no change in T cell proliferation with the addition of anti-TF Ab in to the 
MLR compared to controls, when either untreated or LPS matured DCs were used as 
stimulators.  In contrast, there was significant enhancement of T cell proliferation 
when anti-TF Ab was added into the MLR with dexamethasone treated DCs.  These 
results are shown in figure 5.12.   
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Figure 5.12 Effect of inhibiting TF on T cell proliferation in co-culture with
allogeneic DCs
Anti-TF Ab (α-TF), isotype control Ab (α-TF isotype) or nothing was added to
co-culture of C57BL/6 dexamethsone treated (dex) or untreated (untx) DCs
with BALB/c CD4+ T cells. T cell proliferation was measured by 3H
incorporation on day five. Mean shown +/- SE of triplicate wells. Comparison
of anti-TF Ab with control isotype Ab *p<0.002. Results are representative of
two experiments.
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Secondly, DCs were incubated with anti-TF Ab to block TF function prior to co-
culture with allogeneic CD4+ T cells.  A similar pattern was noted as seen in figure 
5.13.  Namely that the ability of untreated or mature DCs, which had been incubated 
with anti-TF Ab, to stimulate allogeneic CD4+ T cells, was unaltered compared to 
control DCs.  However dexamethasone treated DCs, which had been pre-incubated 
with anti-TF Ab, had a greater ability to stimulate allogeneic CD4+ T cells compared 
to those incubated with the relevant isotype control.  There was no significant 
difference in T cell proliferation when T cells were stimulated with either DCs alone 
or DCs incubated with relevant isotype control. This excluded the possibility that a 
non-specific effect of the Ab on the DCs caused the change in their ability to stimulate 
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allogeneic T cells.  It strengthens the case that the effect seen was due to specific 
binding of the Ab, and hence inhibition of TF, on the dexamethasone treated DCs. 
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Figure 5.13 Effect on CD4+ T cell proliferation of inhibiting TF on DCs in an
allogeneic co-culture
C57BL/6 dexamethasone treated (dex), untreated (untx) or LPS matured (LPS) DCs
were incubated with nothing, anti-TF Ab (α-TF) or isotype control Ab (α-TF isotype)
and co-cultured with purified BALB/c CD4+ T cells. T cell response was measured by
3H incorporation on day five of culture. Mean shown +/- SE of triplicate wells.
Comparison of anti-TF Ab with control isotype Ab *p<0.05. Results are representative
of three experiments.
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Allogeneic CD8+ T cells were co-cultured with dexamethasone treated DCs pre-
incubated with anti-TF Ab and figure 5.14 shows that there was no change in T cell 
proliferation compared to co-culture with control DCs.  This contrasts to the findings 
of the same DC condition co-cultured with allogeneic CD4+ T cells.  However this 
experiment was only done once. 
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Figure 5.14 Effect on CD8+ T cell proliferation of inhibiting TF on DCs in
an allogeneic co-culture
C57BL/6 dexamethasone treated (dex) DCs were incubated with nothing, anti-
TF Ab (α-TF) or isotype control Ab (α-TF isotype) and co-cultured with
purified BALB/c CD8+ T cells. T cell response was measured by 3H
incorporation on day five of culture. Mean shown +/- SE of triplicate wells.
Data are from one experiment.
 
 
An antigen specific system was used in the form of Marilyn mice, which have a 
C57BL/6 background and possess a transgenic TCR that recognises the male HY 
antigen restricted by MHCII. Therefore when Marilyn female CD4+ T cells are 
cultured with male C57BL/6 DCs there will be HY specific T cell proliferation.  Due 
to the high frequency of the antigen specific TCR, proliferation can be measured early 
on day three of culture.  Male dexamethasone treated C57BL/6 DCs were pre-
incubated with anti-TF Ab and co-cultured with female Marilyn CD4+ T cells.  Figure 
5.15 shows that T cell proliferation was significantly enhanced when stimulated with 
immature DCs incubated with anti-TF Ab, compared to control DCs. This is in 
keeping with results from the allogeneic system. 
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Figure 5.15 Effect on female Marilyn CD4+ T cell proliferation of
inhibiting TF on male C57BL/6 DCs in an antigen specific co-culture
C57BL/6 male dexamethasone treated (dex) DCs were incubated with nothing,
anti-TF Ab (α-TF) or isotype control Ab (α-TF isotype) and co-cultured with
purified Marilyn female CD4+ T cells. T cell response was measured by 3H
incorporation on day three of culture. Mean shown +/- SE of triplicate wells.
Comparison of ani-TF with control isotype Ab *p=0.05. Data are
representative of two experiments.
 
 
Cytokine profiles from the co-cultured T cells in the antigen specific system were 
analysed using intracellular staining with Abs to IFN-γ, IL-4 and IL-10 as described 
in chapter four.  This was done once towards the end of the project.  Figure 5.16 
shows there is a higher frequency of IFN-γ compared to IL-4 secreting T cells in all 
conditions.  This suggests that there is Th1 polarisation of T cells, which is to be 
expected in C57BL/6 mouse strain.  Polarisation is not changed by blocking TF on the 
DCs acting as stimulators. The frequency of IL-4 is similar in all the experimental 
conditions however there does seem to be an increase in the number of IFN-γ and IL-
10 secreting T cells when they are stimulated with immature DCs preincubated with 
anti-TF Ab compared with isotype control Ab. 
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Figure 5.16 Effect on the CD4+ T cell cytokine profile of inhibiting TF on
dexamethasone treated DCs in an allogeneic co-culture
Female Marilyn T cells were cultured with male C57BL/6 dexamethasone treated
DCs, which were incubated with medium alone (dex DC), anti-TF Ab (TF-dex DC)
or its isotype control Ab (iso-dex DC). Following seven days of culture the T cells
were harvested and stimulated with PMA and ionomycin for 4 hours with brefeldin
added for the last 2 hours prior to intracellular staining for IFN-γ (IFN gamma), IL-
4 and IL-10. Cells were analysed by flow cytometry and profiles are shown.
Numbers represent percentage positive cells within the quadrant.
 
 
This series of experiments has shown that inhibiting TF on immature but not on 
untreated or mature DCs appear to enhance their ability to stimulate CD4+, but not 
CD8+ T cells, in an allogeneic and antigen specific system.  The last experiment 
assessing the cytokine profiles of the cultured T cells has only been done once but 
suggested that there was enhanced T cell cytokine production when stimulated with 
dexamethasone treated DCs on which TF had been inhibited, although there was no 
change in the overall cytokine pattern of polarisation.  These last results should be 
treated with caution until repeated for confirmation. 
 
Overall the results suggest that the presence of TF keeps the DCs in a more immature 
state and this is lost when TF is inhibited.  
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There are a number of possible mechanisms by which TF could act on the DCs as 
outlined in figure 2.2 shown in chapter two.  The effect of TF could be through the 
generation of downstream coagulation proteins, which in turn act on PAR-1 or -4 or 
generate clot; alternatively the effect of TF may be through direct signalling via PAR-
2.  The latter would be more in keeping with the form of TF present on immature DCs 
as it is less functionally active in a clotting assay, whilst the former would be more in 
keeping with pro-coagulant TF found on more mature DCs.  To address these 
possibilities, PAR-1 and -4 or PAR-2 agonists were added to anti-TF Ab incubated 
DCs, which were then co-cultured with T cells and the T cell response measured. A 
the third possibility is that the effect of TF occurs through signalling via its 
cytoplasmic tail, which has been shown to occur on other cell types (254-256). 
 
Figure 5.17A shows that the addition of PAR-1 and -4 agonists to dexamethasone 
treated DCs pre-incubated with anti-TF Ab did not change the degree of T cell 
proliferation compared to stimulation with dexamethasone treated DCs pre-incubated 
with anti-TF Ab but without the addition of the PAR-1 and -4 agonists.  The T cell 
proliferation remained enhanced in both these conditions suggesting that the 
downstream effect of TF on these immature DCs is not through generation of 
thrombin and signalling of PAR-1 or PAR-4. 
 
Figure 5.17B is representative of two experiments and shows there was significant 
abrogation of T cell proliferation, when stimulated with anti-TF Ab incubated 
dexamethasone treated DCs with the addition of PAR-2 agonist.  This was back down 
to the level of T cell proliferation found when stimulated with only control DCs.  In 
two other experiments using the same conditions, as shown in figure 5.17C, this was 
not seen and T cell proliferation remained enhanced when TF incubated 
dexamethasone treated DCs were used as stimulators with or without the addition of 
PAR-2 agonist.  The clear difference between the two sets of experiments is the 
degree of T cell proliferation.  In the latter two experiments T cell proliferation was 
much greater than in the former two experiments suggesting a greater stimulatory 
capacity from the DCs.  This may be related to a lesser effect of dexamethasone 
treatment, which could be confirmed by analysis of the DC phenotype. 
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Figure 5.17 Effect on T cell proliferation of inhibiting TF on DCs plus the
addition of PAR-2 or PAR-1 and -4 agonists to the allogeneic co-culture
C57BL/6 immature DCs were incubated with anti-TF Ab (α-TF), isotype control (α-
TF isotype) or medium alone (nothing) plus addition of either PAR-2 agonist (PAR-
2), PAR-1 and -4 agonists (PAR-1&--4) or vehicle (no PAR). DCs were then co-
cultured with purified BALB/c CD4+ T cells and T cell response measured by 3H
incorporation on day five of culture. A is representative of three experiments; B and
C are each representative of two experiments. Mean shown +/- SE of triplicate wells.
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These two sets of experiments produced different results. The first two experiments 
suggest that TF activity is coupled to downstream PAR-2 signalling.  Thus TF may be 
acting through PAR-2 to maintain DCs in an immature state.  The second set of two 
experiments does not support this finding.  However this difference may be related to 
the increased degree of T cell proliferation seen in these latter two experiments.  As 
stated, a likely reason for the difference in T cell proliferation is a difference in the 
stimulatory capacity of the DCs between the two sets of experiments.  Therefore one 
interpretation of these results is that when dexamethasone exerts a maximal effect on 
the DCs to maintain them in an immature state then the effect of TF is solely through 
PAR-2 activation.  However if dexamethasone is less effective in maintaining DCs in 
an immature state there appears to be other factors involved in TF activity.  
Possibilities would be a combination of signalling through PAR-2 as well as 
generation of thrombin leading to signalling through PAR-1 and -4 or signalling 
through the cytoplasmic tail of TF. 
In vivo assessment of the role of tissue factor on the T cell response 
To determine if TF plays a role in T cell sensitisation or on the T cell response in vivo, 
an antigen specific system was used.  Cells from the lymph nodes and spleen of 
DO11.10 transgenic mice were isolated and CFSE labelled.  T cells from these mice, 
which are bred on a background of BALB/c, possess a transgenic T cell receptor that 
recognises a peptide derived from ovalbumin (i.e. OVA323-339) restricted by H-2Ad 
(372).  In these mice 50-70% of the naive T cells are specific to ovalbumin.  The 
CFSE labelled cells were injected intravenously into naive BALB/c mice and 24 
hours later these mice were given an intraperitoneal injection of ovalbumin without an 
adjuvant.  Prior to this, mice were given anti-TF Ab or isotype control as an 
intraperitoneal injection to address whether inhibiting TF would affect the T cell 
response.  After 72 hours, lymph nodes from the mice were harvested and examined 
by flow cytometry.  CD4+ T cells were gated and T cell proliferation by CFSE 
dilution as well as cytokine secretion of IFN-γ and IL-4 was assessed.   
 
10x106 CFSE labelled DO11.10 cells were injected into each BALB/c mouse on the 
assumption that there were between 30-40% CD4+ T cells in this population based on 
previous flow cytometric analysis.  This meant that approximately 3.5x106 CFSE 
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labelled DO11.10 CD4+ T cells were injected, which is similar to numbers used 
successfully in other studies (373).  In view of the paucity of DO11.10 mice available 
it was not possible to isolate and use a purified CD4+ T cell population for 
intravenous injection. 
 
Figure 5.18 shows representative profiles of one mouse from each of the groups from 
an optimisation experiment.  As expected there was no antigen specific T cell 
proliferation in the naive control group of mice, which were not sensitised but had 
been given an intraperitoneal injection of LPS adjuvant, as confirmed by the single 
peak and high fluorescence of CFSE+ CD4+ T cells in the profile.  When mice were 
sensitised with ovalbumin plus LPS adjuvant there was proliferation of most of the 
DO11.10 CD4+ T cells with a proportion of these T cells producing IFN-γ, but no 
significant IL-4, which suggests a Th1 differentiation.  When mice were sensitised 
with ovalbumin alone there was still proliferation of most of the DO11.10 CD4+ T 
cells however this was relatively less than when sensitised with an adjuvant and, 
importantly, there was a significant reduction in the frequency of IFN-γ producing T 
cells but still no significant IL-4 production suggesting a loss of Th1 differentiation 
but no skewing to a Th2 pattern.  
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Figure 5.18 Optimisation of an in vivo antigen specific model of T cell activation with and
without adjuvant
10x106 CFSE stained cells from lymph nodes and spleen of naïve DO11.10 mice were injected
intravenously via the tail vein into naïve BALB/c mice. 24 hours later mice were given an
intraperitoneal injection of only 25µg LPS (LPS) as a naive mouse control or 5mg ovalbumin
with 25µg LPS (alb+LPS) or 5mg ovalbumin (alb). 72 hours later the mice were killed and cells
from the lymph nodes of individual mice were stained and analysed for proliferation and IFN-γ
and IL-4 secretion. Representative profiles from one of the three mice from each group are
shown.
LPS
alb
alb +
LPS
 
 
In view of the in vitro data showing that blocking TF on immature DCs enhanced 
proliferation, sensitisation with ovalbumin alone was used as the experimental 
condition to assess if blocking TF in vivo would enhance the T cell response.  An 
intraperitoneal injection of anti-TF Ab or its isotype control Ab was given before 
sensitisation to assess if inhibiting TF would enhance antigen specific T cell 
proliferation and cytokine production.  In vitro, an anti-TF Ab dose of between 50 and 
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100µg/ml was found to be effective both in flow cytometry and, importantly, 
functionally in inhibiting TF in a clotting assay. This dose of Ab also showed an 
effect in the T cell proliferation assays when it was used to block TF on 
dexamethasone treated DCs.  A dose of 250µg Ab was used for each mouse in these 
in vivo experiments, which equates to 85µg/ml if the volume of distribution of each 
mouse is taken to be approximately 3ml.  This was felt to be an adequate dose to 
sufficiently block TF. 
 
The experiment was performed twice with similar results.  There were three mice in 
each group for each experiment and Figure 5.19 shows representative profiles from 
one mouse in each of the groups for one of the experiments.  An additional control 
group was included, which entailed giving an intraperitoneal injection of saline alone 
rather than the sensitisation regime.  This group acted as further naive controls to 
ensure that administering LPS did not affect the adoptively transferred DO11.10 
CD4+ T cells.  The number and percentage of non-proliferating CFSE+ DO11.10 
CD4+ T cells was equivalent in the control groups whether LPS or saline were 
injected confirming that giving LPS had no specific effect on the adoptively 
transferred DO11.10 T cells.  The main difference seen was the increased proportion 
of IFN-γ producing BALB/c cells when mice were given LPS compared to saline.   
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Figure 5.19 Assessment of the effect of inhibiting TF on the T cell response in an in vivo antigen
specific system
10x106 CFSE stained cells from lymph nodes and spleen of naïve DO11.10 mice were injected
intravenously via the tail vein into naïve BALB/c mice. 24 hours later mice were given an
intraperitoneal injection of only 25µg LPS or an equivalent volume of saline as naive mouse controls or
5mg ovalbumin with 25µg LPS (alb+LPS) as a positive control or 250µg anti-TF Ab (α-TF) or the
equivalent dose of rabbit Ig (α-TF iso) followed by 5mg ovalbumin. 72 hours later the mice were killed
and cells from the lymph nodes of individual mice were stained and analysed for proliferation and IFN-γ
and IL-4 secretion. Representative profiles from one of the three mice from each group are shown for
all conditions except for alb+LPS, when one mouse was used.
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When the mice were given anti-TF isotype control Ab followed by sensitisation with 
ovalbumin alone, proliferation of the antigen specific T cells occurred but to a lesser 
degree than when LPS adjuvant was also given.  Furthermore there was a smaller 
proportion of IFN-γ producing T cells as predicted from the optimisation experiment.  
When anti-TF Ab was given prior to sensitisation, antigen specific T cell proliferation 
occurred to the same extent as in the control group with a trend towards a significantly 
higher proportion of IFN-γ producing CD4+ T cells but no significant IL-4 
production. 
 
The number of CFSE+ and cytokine producing CFSE+ T cells were enumerated for 
each mouse.  Fold increase was calculated as the number of CFSE+ T cells to the 
mean number of CFSE+ T cells from mice in the naive control group, which was a 
similar value for mice given LPS alone or saline alone.  This is shown for the number 
of IFN-γ producing CFSE+ T cells in each group in figure 5.20, which was 
significantly higher for the mice sensitised with ovalbumin and LPS compared to 
mice given anti-TF isotype before sensitisation with ovalbumin alone.  When anti-TF 
Ab was given before sensitisation with ovalbumin there was an increase in this 
number compared to giving the isotype control.  There was a wide variation in the 
group, which led to a large standard error for the group and prevented it from being 
statistically significantly different from the control group. 
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Figure 5.20 Analysis of the fold increase in IFN-γ producing CFSE+ CD4+ T cells
when inhibiting TF in an in vivo system of T cell activation
Experiment was performed as described in figure 5.19. The number of IFN-γ
producing CFSE+ CD4+ T cells was enumerated for each mouse. Fold increase was
calculated as the ratio of this number for each mouse to the equivalent number of
CD4+ T cells enumerated for mice given LPS alone. Mean and standard error were
calculated for each group and are plotted except for the one mouse given alb+LPS.
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These results suggest that blocking TF in vivo enhances T cell activation and T cell 
differentiation in this model but does not appear to alter the pattern of cytokine 
production from T cells.  Results appear to concur with data from in vitro experiments 
in which blocking TF on immature DCs leads to an enhanced T cell response. 
In vivo assessment of the function of tissue factor on dendritic cells 
In the previous set of experiments inhibition of TF was not limited to a particular cell 
type since the intraperitoneal administration of blocking Ab was probably acting on 
all cell types and locations where TF was expressed.  To determine the significance of 
TF expression specifically on DCs in vivo the following experiments were performed.  
Immature, untreated or mature C57BL/6 DCs were injected into BALB/c mice and ten 
days later T cells were harvested and rechallenged with C57BL/6 stimulators.  T cell 
proliferation was measured by 3H incorporation three, five and seven days later to 
discern primary from secondary responses. To address whether TF expression on DCs 
affected these responses the injected DCs were pre-incubated with anti-TF Ab and 
compared to pre-incubation with isotype control. 
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Optimisation of in vivo protocol 
Intravenous and intraperitoneal injections of DCs were compared as well as different 
numbers of T cells and DCs in the rechallenge MLR. 
 
As shown in figure 5.21, T cell proliferation following rechallenge of T cells from 
mice given intraperitoneal injection of C57BL/6 DCs was greater than from mice 
given PBS, which served as a control for the primary response. The greatest response 
was seen following rechallenge of T cells from mice injected with untreated DCs.  A 
smaller response was seen from mice injected with mature and immature DCs, which 
was out of keeping with the expected result.  Kinetics were also uncharacteristic for a 
secondary response as it was maximal on day seven rather than peaking before the 
primary response, which, in this assay was on day five.  This same pattern was seen 
when either 2x104 T cells were co-cultured with 2x104 DCs or 4x104 DCs in the 
rechallenge MLR.  Challenge of the T cells with third party DCs had the kinetics of a 
primary response and was equivalent in all the groups, confirming an antigen specific 
effect.  Comparable profiles were seen when CBA or C3H DCs were used as the third 
party control. 
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As shown in figure 5.22, similar results to intraperitoneal delivery were seen with 
intravenous injection of the C57BL/6 DCs except that the greater response following 
rechallenge of T cells was from mice given C57BL/6 mature or untreated DCs.  The 
results were similar. Rechallenge of mice given immature DCs led to a much less 
vigorous response.  These results were similar to those of mice given PBS, confirming 
alloantigen hyporesponsiveness.  
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Intravenous rather than intraperitoneal delivery of DCs was used in subsequent 
experiments because of more consistent control groups.  There was no difference 
between using CBA or C3H strains as third party controls, which is not surprising as 
they both share the same haplotype, and so the CBA strain was used thereafter. 
 
With the aim of simplifying the experimental protocol, the rechallenge co-cultures 
were done using splenocytes instead of DCs as stimulators, co-cultured with either 
purified T cells or splenocytes.  (This was done due to problems with contamination 
of DC cultures at the time of these experiments.)  Higher numbers of splenocytes and 
T cells were used in view of the reduced proportion of antigen presenting cells in 
whole splenocytes compared to a pure population of DCs. 
 
The pattern of results with 2x105 T cells or splenocytes as responders co-cultured with 
2x105 irradiated C57BL/6 or CBA splenocytes as stimulators was equivalent to using 
2x104 T cells with 2 or 4x104 DCs.  As would be expected, the level of response was 
greater when T cells rather than splenocytes were used as responders. 
 
In further experiments comparing the sensitisation of mice injected with anti-TF Ab 
incubated DCs with controls, the DCs were injected intravenously.  In the rechallenge 
co-culture, 2x105 T cells were used with the same number of splenocytes, which had 
been irradiated to ensure no proliferation of the stimulators occurred. 
In vivo assessment of the function of tissue factor on dendritic cells 
Figures 5.23 and 5.24 show representative results of these experiments.  In figure 5.23 
mice were injected intravenously with anti-TF incubated DCs and compared with 
mice injected with untreated DCs or PBS as the control for a primary response.  T 
cells from BALB/c mice injected with C57BL/6 DCs had a significantly greater 
response in the rechallenge co-culture compared to T cells from mice injected with 
PBS, in keeping with a secondary rather than a primary response respectively.  The 
kinetics were variable between experiments. Importantly, whether mice were injected 
with anti-TF Ab incubated DCs or untreated DCs, the rechallenge response was 
similar in terms of its magnitude and quality.    
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A similar result occurred when anti-TF Ab incubated dexamethasone treated DCs 
compared with dexamethasone treated DCs alone were injected as seen in figure 5.24.  
However the much greater secondary compared to primary response suggests that the 
DCs were not truly tolerogenic as might be expected from dexamethasone pre-
treatment.  The expected pattern following injection of dexamethasone treated DCs 
would be a similar magnitude and even profile as a primary response, as seen in the 
optimisation experiments in figure 5.22.  Therefore these results showing no effect of 
blocking TF on dexamethasone treated DCs should be interpreted with caution as the 
dexamethasone treated DCs do not appear to be truly tolerogenic. 
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Cytokine profiles of the T cells from the rechallenge co-cultures were assessed by 
harvesting T cells on day five of the co-culture.  Following stimulation with PMA and 
ionomycin the cells were stained for IFN-γ, IL-4 and IL-10.  Due to time constraints 
this was only done once with T cells from BALB/c mice that were initially injected 
intravenously with C57BL/6 untreated DCs and which were incubated with nothing, 
anti-TF Ab or its isotype control.  Data is shown in figure 5.25 and demonstrates that 
the cytokine profile of the T cells from the rechallenge co-culture was a Th2 pattern 
with predominant IL-4 and IL-10 production.  This was not altered by blocking TF on 
the injected DCs.  However the percentage of IL-10 and possibly IL-4 producing 
rechallenged T cells was higher from mice injected with allogeneic DCs on which TF 
was blocked compared to controls. The frequency of IL-4 and IL-10 producing 
rechallenged T cells from control mice injected with untreated allogeneic DCs or with 
untreated allogeneic DCs incubated with TF isotype control Ab was similar.      
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Figure 5.25 Effect of inhibiting TF on untreated DCs on the T cell cytokine 
profile in an in vivo allogeneic model of T cell sensitisation
BALB/c mice were injected intravenously with C57BL/6 DCs, which were 
incubated with nothing (untx DC), anti-TF Ab (TF-untx DC), isotype control Ab 
(TF iso-untx DC).  Ten days later T cells were purified from the spleen and lymph 
nodes of the mice and rechallenged with C57BL/6 irradiated naïve splenocytes.  T 
cells were harvested on day five of co-culture and stimulated with PMA and 
ionomycin prior to intracellular staining for IFN-γ (IFN-γ), IL-4 (IL-4) and  IL-10 
(IL-10).  Numbers represent percentage positive cells within the quadrant.  
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Discussion 
The molecular surface expression and functional properties of cultured mouse bone 
marrow derived DCs, using a modified version of a published method (39), were 
described and confirmed to display the characteristic DC phenotype.  The generated 
DCs were CD11c+CD4-CD8-CD11b+ and were negative for specific macrophage 
markers CD68 and F4/80.  Based on this the cells appear to represent interstitial or 
monocyte derived inflammatory DCs (4).  In keeping with published manipulations, 
addition of  dexamethasone to the culture maintained DCs in an immature state with 
low level expression of MHCII and co-stimulatory molecules (367).  Conversely LPS 
activated the DCs leading to a high level expression of the surface molecules.  This 
directly correlated with their ability to stimulate naive allogeneic T cells.    
 
Anti-mouse TF Ab was not widely available at the beginning of the project and so a 
number of in-house generated Abs was tested along with a commercial Ab, when it 
became available.  Due to ease of availability and defined concentration the 
commercial Ab was used for further experiments. 
 
Using this Ab, TF expression was not seen on T cells or bone marrow progenitor cells 
but was found on a subset of bone marrow derived DCs by flow cytometry.   It would 
be interesting to examine other subsets of mouse DCs for TF expression as it is 
possible that, like other molecules, these vary on different subsets.  Co-staining of 
these cells with TF and CD11c confirmed that the TF expressing cells were DCs and 
not contaminating cells in the culture.  The levels of antigenic TF were found to be 
similar no matter what the degree of maturity of the DCs.  Clotting assays, to assess 
functional activity of the TF, confirmed the presence of pro-coagulant TF on DCs 
however the amount of active TF appeared to increase with increasing maturity of the 
DCs.  Overall these results clearly demonstrate TF expression on mouse DCs but with 
a discrepancy between the antigenic expression and functional activity of the TF.   
 
Other groups have found TF expression on human DCs (232, 233) however this is the 
first report with direct evidence of TF expression on mouse DCs.  Niessen and 
colleagues inferred TF expression on mouse DCs in a model of endotoxaemia, when 
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they found PAR-1 KO mice to have a survival advantage.  Furthermore their results 
suggest that DCs play a pivotal role in dissemination of coagulation and inflammation 
(234).   
 
TF is known to be induced upon activation of cell types such as ECs and macrophages 
(210, 213, 255) demonstrating a direct relationship between inflammatory stimuli and 
coagulation protein expression.  Results from this project support the concept as TF is 
more functionally active upon maturation of the DC.  In contrast, Broussas and 
colleagues found a reduction in the level of TF expression with maturation of human 
DCs.  However the manipulations used to mature the DCs may account for this 
difference (233).  PGE2 and TNF-α were added to DC culture by Broussas and 
colleagues, rather than LPS as used in this project, and the former has been shown to 
inhibit antigenic TF expression (374). 
 
TF is known to exist in an encrypted or inactive form (241), which may explain the 
disparity between TF activity on DCs with increasing maturity despite unchanged 
antigenic expression.  Evidence suggests that TF in its encrypted form is more likely 
to signal through PAR-2 whilst the active form more readily activates FVIIa leading 
to initiation of the coagulation cascade (246).  This is compatible with this project’s 
findings of differential effects on the T cell response by immature compared to mature 
DCs when TF was inhibited by incubation with a blocking Ab. 
 
The control of the different forms of TF is still not fully elucidated but several 
possible mechanisms have been postulated (241-243), which have been discussed in 
chapter two.  The degree of PS exposure and presence of PDI, which are two of the 
possibilities, were both investigated on DCs.  PDI was not found to be expressed on 
the surface of DCs despite using three different methods, which supports the 
controversy around this enzyme and its postulated role in TF regulation (247).  No 
differences were found in the level of PS exposure between DCs at different levels of 
maturity using annexin-V in flow cytometry.   
 
TFPI is the natural inhibitor for TF and is expressed on and released from cells which 
can be induced to express TF such as ECs (197).  This was therefore also examined as 
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a possible mechanism for regulation of TF activity on DCs.  No expression was found 
on mouse DCs by flow cytometry. 
 
The significance of TF on DCs was investigated further.  As DCs are the professional 
antigen presenting cells, their ability to stimulate naive T cells was analysed and in 
particular, whether inhibiting TF affected this response.  In vitro results suggested that 
inhibiting TF on immature but not LPS matured DCs enhanced CD4+, but not CD8+, 
T cell proliferation in an allogeneic and antigen specific system.  Cytokine production 
also appeared to be affected with enhanced IFN-γ secretion examined solely in the 
antigen specific system. This experiment was only performed once and hence the 
results should be treated with caution until confirmed. 
 
The differential effect on T cell proliferation of inhibiting TF on immature compared 
to mature DC could be explained by differences in the form of TF between the DCs.  
It is possible that immature DCs express encrypted TF which is more likely to signal 
through PAR-2 (246), whereas the more mature DCs possess TF to generate 
downstream coagulation proteins, which in turn form clot or signal through PARs in a 
paracrine fashion.  This model is consistent with the work of Niessen and colleagues 
who have shown that PAR-1 signalling on activated DCs drives lethality in a mouse 
model of endotoxaemia and that this occurred following generation of thrombin from 
TF on DCs (234). The former aspect is addressed in this chapter whilst the latter is, to 
some extent, addressed in the next chapter when the effect of thrombin is examined.  
 
At times, addition of a PAR-2 agonist following incubation of immature DCs with 
anti-TF Ab led to reversal of the effect on T cell proliferation, suggesting a role for 
PAR-2 in downstream signalling of TF.  This occurred when DCs were maintained in 
a maximally immature state as reflected by low T cell proliferation.  In contrast this 
did not occur when T cell proliferation was high, suggesting stimulation by more 
mature DCs.  
 
TF signalling has previously been described through PAR-2 but also through its 
cytoplasmic tail including a study in which transgenic mice with a deletion of the tail 
had an altered T cell response (256).  This would be another possible mechanism to 
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address especially when the DCs are more mature. The results described above 
suggest an alternative mechanism for TF activity in this setting. 
  
Anti-TF Ab was used in vivo in an antigen specific model to assess if, like the in vitro 
studies, blocking TF would enhance the T cell response.  Antigen without adjuvant 
was given to ensure there was submaximal T cell proliferation and cytokine 
production.  
 
As expected there was no proliferation of the antigen specific T cells without 
sensitisation with antigen whether LPS adjuvant was given or not. Giving LPS did not 
cause cell death or any other apparent adverse effects on the antigen specific T cells. 
Sensitisation with antigen alone, compared to antigen with LPS adjuvant, produced 
significantly less antigen specific T cell proliferation and significantly fewer IFN-γ 
producing antigen specific T cells. This is in accordance with previously published 
data (375).  The differences in proliferation and cytokine production when adjuvant 
was given would be anticipated and are due to the inflammatory effect of the 
adjuvant. 
 
When anti-TF Ab was given prior to sensitisation with antigen there was no 
significant increase in the degree of antigen specific T cell proliferation and no 
alteration of the cytokine profile towards Th1 differentiation. However there was an 
increase in the number of IFN-γ producing T cells although not to the extent of giving 
antigen with an adjuvant.  The results suggest that blocking TF in this model is pro-
inflammatory and enhances the immune response. The broad variation between mice 
may have been due to the fact that the anti-TF Ab had a significant effect on some 
mice but did not affect others at all. 
 
Other published literature has shown that another difference between sensitisation 
with ovalbumin, and with ovalbumin plus adjuvant, is the persistence of memory T 
cells and development of immunological priming in the latter, but not in the former 
(375).  This was demonstrated by the increased number of antigen specific T cells 
present at a later time point following sensitisation in the ovalbumin plus adjuvant 
group. Moreover when these T cells were rechallenged either in vivo or in vitro there 
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were high levels of IFN-γ with little IL-2 production. However in the ovalbumin alone 
group there was both very little IFN-γ and IL-2 production.  Results from this project 
suggest that by blocking TF prior to sensitisation with ovalbumin, the T cell response 
is enhanced as if adjuvant was also given.  Therefore it would be worthwhile 
strengthening this finding by assessing whether the same occurred when the T cells 
were rechallenged. 
 
The effect of blocking TF in this model was not limited to one particular cell type and 
so TF is likely to be inhibited at a number of sites within the mouse which may have 
different and even opposing effects.  For example, anti-TF Ab administration may 
block TF signalling on immature DCs leading to a pro-inflammatory effect as seen in 
vitro; whereas at other sites, administration of the Ab may prevent initiation of 
coagulation, which may affect inflammation either directly or indirectly, by inhibiting 
generation of downstream coagulation proteins and preventing signalling through 
PAR.  TF signalling through its cytoplasmic tail has been shown to affect migration of 
macrophages (254, 256) and inhibition of this may have a role in this model.   
 
Further in vivo experiments were performed, which specifically blocked TF on the 
DC.  When TF was inhibited on untreated DCs there was no effect on T cell 
sensitisation which concurs with the in vitro data using untreated DCs.  However 
there did appear to be an increase in the frequency of IL-4 and IL-10 secreting T cells, 
suggesting that blocking TF enhanced but did not alter the overall Th2 skewed 
cytokine pattern.  This last result requires confirmation.   
 
It would also be interesting to perform the complementary in vitro experiment by 
analysing the cytokine profile of the T cells stimulated by TF blocked untreated DCs 
to assess if the same occurred with enhancement of the cytokine T cell response, but 
without skewing of the profile.  In an inflammatory arthritis murine model using 
transgenic mice possessing TF with its cytoplasmic tail deleted, Yang and colleagues 
showed enhanced IL-4 production from T cells (256).  Therefore the mechanism of 
action of TF on untreated DCs, as suggested by Yang, may be through its cytoplasmic 
tail and is again worth further investigation.  
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In the same set of experiments no effect on T cell proliferation was seen when TF was 
inhibited on dexamethasone treated DCs.  However it is not possible to come to any 
firm conclusions related to blocking TF on dexamethasone treated DCs in this setting.  
The DCs did not behave as truly tolerogenic DCs but instead appeared to sensitise the 
T cells.  This particular protocol was able to induce tolerance as seen in the previous 
optimisation experiments, and so the reason for the problem was most likely related to 
lack of efficacy of the dexamethasone.   
 
In summary, this chapter has conclusively shown that a subset of mouse bone marrow 
derived DCs express TF.  The antigenic expression of TF was similar on DCs of 
different levels of maturity however the pro-coagulant activity of the TF increased 
with increasing maturity of the DCs.  It was possible that the discrepancy between the 
antigenic expression and functional activity may have been related to the differential 
expression of encrypted TF depending on the level of DC maturity.  Possible 
mechanisms regulating this expression were investigated and, at least on mouse DCs, 
it did not appear to be through PDI or TFPI.   
 
The function of TF on DCs was also examined and, like the differential pro-coagulant 
activity of the TF, there appeared to be differential function of the TF on more 
immature compared to LPS-matured DCs.  Blocking TF on immature DCs appeared 
to enhance their ability to stimulate allogeneic naive CD4+ T cells as assessed by T 
cell proliferation whilst this was not seen with more mature DCs.  In vivo data from 
an antigen specific model of T cell sensitisation also correlated with the in vitro 
results, suggesting that blocking TF has a pro-inflammatory effect. 
 
Further enhancement of the predominant T cell cytokine pattern was seen in the 
antigen specific system when TF was blocked on immature DCs in vitro. This was 
also seen in vivo when TF was blocked on untreated DCs, however further work is 
required before drawing any definitive conclusions. 
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Chapter 6: Thrombin 
Initiation of the coagulation cascade leads to the generation of several activated 
coagulation proteins, the main one of which is thrombin.  The role of thrombin in clot 
formation is well described and results from conversion of fibrinogen into fibrin.  
Cellular effects of thrombin and some of the other activated coagulation proteins are 
now recognised to occur through a family of receptors called PARs.  PARs have been 
shown to be involved in a number of inflammatory conditions and in general their 
activation on a number of cell types has been shown to be pro-inflammatory.  
 
Experiments in the previous chapter focused on TF, which is the initiator of the 
coagulation cascade, and its role in the adaptive immune response.  These results, 
together with other literature, demonstrate that DCs and other cells of the immune 
system, through the expression of TF, have the ability to generate downstream 
coagulation proteins.   
 
The presence of exogenous molecules from microbial components during infection 
and inflammation activates the immune system and coagulation is initiated in the 
same setting. There is now mounting evidence for the role of endogenous molecules 
derived from self to also alert the immune system to danger.   These endogenous 
molecules comprise of released components from necrotic cells but also innate factors 
such as coagulation proteins. 
  
Experiments described in this chapter address the hypothesis that coagulation proteins 
including thrombin affect the T cell response through interactions with PAR on DCs 
and/or T cells.  The specific experimental aims are: 
- To determine whether DCs and T cells express PARs 
- To characterise the effect of thrombin on the T cell response  
- To determine through which cell type any effects of thrombin occur  
- To examine the mechanism through which thrombin exerts its effects on the T 
cell response  
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Testing of anti-PAR antibodies 
A panel of Abs against PAR exist and have been used in several applications.  The 
Abs are generated against human PAR, which does raise the issue of the lack of cross 
reactivity with other species even though there is a high degree of interspecies 
homology (for example 83% between mouse and human PAR-2 (376, 377)).  Using 
flow cytometry, studies have shown PAR expression on a number of cell types in both 
humans and mice (298-301, 303-305) and so this method was employed for the next 
set of experiments. 
 
Where possible PAR Abs were tested on cells known to express PAR as a positive 
control to ensure the Ab worked.  Mouse microvascular ECs are known to express 
PAR-1 and PAR-4 and figure 6.1 shows positive staining of these cells using anti-
human PAR-1 and PAR-4 Abs in flow cytometry.  DAP.3 cells, which are a mouse 
fibroblast cell line, are known to express PAR-2 and figure 6.1 shows positive 
staining of these cells using an anti-human PAR-2 Ab in flow cytometry.   
 
Figure 6.1 Assessment of anti-PAR Abs on murine cells by flow cytometry
Cultured mouse vascular endothelial cells (EC) were analysed for PAR-1 and PAR-
4 expression as indicated and cultured DAP.3 cells (DAP.3) were analysed for PAR-
2 expression by flow cytometry. Shaded profiles show isotype control and open
profiles show specific binding. Numbers shown are percentage positive cells.
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PAR expression on T cells 
T cells were purified by negative depletion from spleen and lymph nodes of BALB/c 
mice as described in chapter four.  As shown in figure 6.2, no PAR expression was 
found on CD4+ T cells using flow cytometry.  There are no previous reports in the 
literature of PAR expression on mouse T cells.  Studies have shown expression of 
PAR-1, -2 and -3 on human naive CD3+ T cells (301, 304), which contrast with this 
finding. 
 
 
M180%
PAR-4
\
PAR-2
CD4
PAR-1
Figure 6.2 PAR expression on CD4+ T cells
BALB/c CD4+ T cells were purified from lymph nodes and spleen by negative selection
and analysed by flow cytometry for purity (CD4) shown as a percentage above and
expression of PAR-1, PAR-2 and PAR-4 as indicated. Shaded profiles show isotype
control and open profiles show specific binding.
 
PAR expression on dendritic cells 
As the DCs were derived from bone marrow progenitor cells, PAR expression on the 
latter was analysed as well as on DCs to examine any changes in expression during 
development.  The bone marrow cells were attained by flushing the femurs and tibiae 
of C57BL/6 mice and an aliquot was taken for analysis by flow cytometry prior to 
culture for DCs in medium supplemented with 10% FCS and GM-CSF.  
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Low levels of PAR-1, -3 and -4 were found on mouse bone marrow progenitor cells 
using flow cytometry as shown in figure 6.3.  At least two distinct populations were 
visualised in terms of forward and side scatter properties with differences in PAR 
expression between them suggesting some heterogeneity. 
Figure 6.3 PAR expression on bone marrow progenitor cells
C57BL/6 bone marrow progenitor cells were analysed by flow cytometry. Two distinct populations
were gated (R1, R2) on the plot showing forward and side scatter (A). PAR expression as indicated
(B) was analysed for each population. Shaded profiles show isotype control and open profiles show
specific binding. Numbers represent median fluorescence index for isotype control (white) and
specific binding (black).
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The population labelled R2 in figure 6.3, which was larger in size and more granular 
as assessed by greater forward and side scatter properties respectively, had low level 
expression of PAR-1, -3 and -4.  Whilst only a proportion of the second population, 
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which were relatively smaller and less granular, labelled R1 in figure 6.3 appeared to 
express PAR-1, -3 and -4 at low levels; both populations had no PAR-2 expression. 
 
Culture of bone marrow progenitor cells for seven days in GM-CSF supplemented 
medium resulted in DCs with high purity, as already described in chapter five, and a 
phenotype typical of DCs.  These cells were analysed by flow cytometry for PAR 
expression, which was found to be variable between experiments.  Overall there was 
low level expression of PAR seen on DCs as shown on untreated DCs in figure 6.4A. 
 
RT-PCR was used to assess for expression of PAR at the mRNA level.  
Dexamethasone treated, untreated and LPS matured DCs were harvested and RNA 
was extracted and treated with DNAase to ensure there was no DNA contamination of 
samples.  RT-PCR was performed on the RNA using primers for mouse PAR-1 to -4 
and β actin as shown in figure 6.4B.  Expression of all the PARs was found at the 
mRNA level in DCs and each PAR was found at equivalent levels between DCs of 
increasing maturity.   
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Figure 6.4 PAR expression on DCs
C57BL/6 DCs were analysed by flow cytometry for expression of PAR as shown (A).
Shaded profiles show isotype control and open profiles show specific binding. RNA
was extracted from C57BL/6 DCs, which were dexamethasone treated (D), untreated
(U) or LPS matured (L). RT-PCR was performed for PAR-1 to -4 as shown (B). No
reverse transcriptase was added as a negative control (N). Beta actin (β actin) shown
as control.
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Effect of thrombin in MLRs 
In order to determine the effect of coagulation factors on T cell proliferation 
allogeneic MLRs were set up as previously described.  The prediction was that 
thrombin would enhance T cell proliferation and so a ratio of one DC to 20 T cells 
was used from previous titration experiments discussed in chapter four. Using these 
numbers would ensure that either enhancement or reduction of the T cell response 
would be detected.  Varying concentrations of thrombin from one to 1500nM final 
concentration were added to the wells at the beginning of the MLR.  Physiological 
concentrations of thrombin vary considerably and under normal conditions levels are 
negligible.  Upon activation of the coagulation cascade small amounts of thrombin are 
generated initially of 5 to 10 nM, which then increase exponentially during the 
propagation phase up to 1000nM (194).   Other studies using thrombin have used 
similar concentrations (296, 297, 302-304, 378).  Therefore, the range of thrombin 
concentration used in these experiments encompassed physiologically encountered 
levels.   
 
Thrombin enhanced T cell proliferation when added to a co-culture of untreated DCs 
and allogeneic CD4+ T cells.  This effect was dose dependent up to a concentration 
250nM thrombin, when the increase in T cell proliferation was consistent and 
statistically significant using the t-test, as compared to that without thrombin, in three 
separate experiments.  There did appear to be enhancement of T cell proliferation at 
higher doses of thrombin but this was not consistently statistically significant in 
separate experiments although the trend was always more than when no thrombin was 
added to the co-culture.  Representative data from one experiment is shown in figure 
6.5A.  For further experiments involving thrombin, a concentration of 250nM was 
used.  There was no effect on T cell proliferation when thrombin was added to either 
immature DCs or mature DCs with CD4+ T cells as shown in figure 6.5B and 6.C 
respectively.  
 
In this system the effect of thrombin may have been on either T cells or DCs but since 
PAR expression was only found on DCs it was logical to assume that thrombin was 
acting on the DCs and not the T cells.  To confirm this, the effect of thrombin on 
individual cell types was next assessed.  
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Figure 6.5 Effect of thrombin on T cell proliferation in co-culture with allogeneic DCs
2x105 BALB/c T cells were co-cultured with 1x104 C57BL/6 DCs, which were untreated (A
untx DC), dexamethasone (B dex DC) or LPS matured (D LPS DC). Increasing doses of
thrombin, as indicated above, were added into the culture and T cell proliferation was measured
by 3H incorporation five days later. DCs alone (DC) and T cells alone (T) are shown as controls.
Mean +/- SE shown of triplicate wells. Comparison of 250nM to no thrombin for untreated
DCs *p<0.05. Representative data of three independent experiments.
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Effect of thrombin on T cells 
A non-antigen presenting cell system using cross linking CD3/28 Ab for T cell 
stimulation was used to address the question of whether thrombin was affecting the T 
cells directly.  T cells were cultured in 96 well plates, which had been coated with 
varying concentrations of CD3/28 Abs.  Proliferation was measured by 3H 
incorporation three days later and compared with T cells cultured with CD3/28 Ab 
coated beads as shown in figure 6.6.  
 
Figure 6.6 Titration of CD3/28 Ab mediated stimulation of T cell proliferation
0 to 5µg/ml of anti-CD3 Ab (α-CD3) and anti-CD28 Ab (α-CD28), as indicated above, in PBS
were added to wells and incubated at 37°C overnight. The following day the wells were washed
with PBS prior to the addition of T cells. 2x105 BALB/c T cells were added to these wells
coated with Ab or clean wells with anti-CD3/28 coated beads (bead) in the ratio indicated
above. T cell proliferation was measured by 3H incorporation three days later. Mean +/- SE
shown of triplicate wells.
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Proliferation was seen even with no anti-CD28 Ab as long as anti-CD3 Ab was 
present, which suggests that co-stimulation from contaminating cells in the T cell 
population was sufficient to mount a T cell response.   When between 1 and 5 µg/ml 
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of anti-CD3 Ab with 0 to 5 µg/ml of anti-CD28 Ab was used to coat the plate, there 
was little variation in T cell proliferation.  There are two possible explanations for 
this. Firstly, that addition of the lowest concentration of Ab was sufficient to 
maximally coat the well such that an increased concentration of Ab would not lead to 
more Ab within the well.  Secondly, that although there was more Ab coating the well 
with each increase in concentration of Ab incubated in the well, the T cell 
proliferation remained unchanged as the limitation was the number of T cells that 
were able to encounter Ab within the dimensions of the well.  
 
Figure 6.7 Titration of CD3/28 Ab coated bead mediated stimulation of T cell
proliferation
2x105 purified BALB/c CD4+ T cells were cultured with anti-CD3/28 coated beads (bead)
in ratio as indicated above. T cell proliferation was measured three days later by 3H
incorporation. T cell alone (T) is shown as a control. Mean+/-SE shown of triplicate
wells.
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Proliferation was greater with the addition of Ab coated beads into the MLR, which 
may be due to the fact that there was a higher concentration of Ab in the T cell culture 
or that more T cells were able to encounter Ab with this method.  Titration of the 
number of beads added to the MLR was performed and, as shown in figure 6.7, there 
was a dose response with increasing proliferation as more beads were added.  The 
latter method was employed for assessment of the effect of thrombin.  When varying 
concentrations of thrombin were added to the MLR there was no significant change in 
T cell proliferation compared to without thrombin at a variety of bead numbers. This 
was seen in all three experiments and figure 6.8 shows representative plots for Ab 
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coated beads added to 2x105 T cells at a bead to T cell ratio of 1:6 and 1:16.  There 
was a suggestion of reduction in the T cell proliferation at a thrombin concentration of 
1000nM, which may have been due to increased T cell death at this high 
concentration.  This was not statistically significant and not investigated further. 
 
Figure 6.8 Effect of thrombin on T cell proliferation with CD3/28 Ab mediated
stimulation
2x105 purified BALB/c CD4+ T cells were cultured with a specified ratio of anti-
CD3/28 Ab coated beads (bead) as indicated above with the addition of 0 to
500nM thrombin. T cells alone were shown as controls. Mean +/- SE are shown
of triplicate wells.
cp
m
 x
10
3
0 125 250 500 1000
0
10
20
30
40
T cells alone
bead & T cells
[thrombin] nM
1 bead: 16 T cells
0 125 250 500
0
100
200
[thrombin] nM
cp
m
 x
10
3
1 bead : 6 T cells
 
 
Results: Chapter 6 
144 
 
To complement these experiments T cells were then stained with CFSE prior to 
culture in an identical system.  T cell proliferation was measured by assessing CFSE 
dilution using flow cytometry.  In this way information was assimilated relating to the 
pattern of T cell proliferation as well overall magnitude.  This was done with the 
addition of 250nM thrombin at a variety of Ab coated bead numbers.  Figure 6.9 
shows representative profiles using Ab coated beads with 2x105 T cells at a bead to T 
cell ratio of 1:2, 1:16 and 1:32.  The percentage of T cells in each generation was 
calculated and plotted as shown in the figure and no difference was seen whether 
thrombin had been added to the system or not.   
 
Proliferative index was also calculated and compared in a graph shown in figure 6.10.  
There does not appear to be a significant difference in proliferative index when 
250nM thrombin was added to the culture compared to no thrombin. Although this 
experiment was only done once results appear to concur with the previous set of 
experiments in that thrombin does not appear to affect T cell proliferation through a 
direct action on T cells.   
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Figure 6.9 Effect of thrombin on T cell proliferation using CFSE with CD3/28 Ab mediated 
stimulation 
2x105 CFSE stained BALB/c CD4+ T cells were cultured with a specified ratio of anti-CD3/28 
Ab coated beads (bead) with or without 250nM thrombin as indicated above.  Cells were 
harvested three days later and analysed by flow cytometry to assess T cell proliferation by CFSE 
dilution as shown in the profiles above.  Each divison cycle was gated and numbered as shown.  
%  total cells in each division cycle was calculated for T cells cultured with (0nM thrombin) or 
without (250nM thrombin) thrombin and compared as shown in the graphs. 
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Figure 6.10 Effect of thrombin on proliferative index of CD3/28 
stimulated T cells
2x105 CFSE stained BALB/c CD4+ T cells were cultured with a specified
ratio of anti-CD3/28 Ab coated beads (bead) with or without 250nM 
thrombin as indicated above.  Cells were harvested three days later and 
analysed by flow cytometry to assess T cell proliferation by CFSE dilution.  
The number of T cells in each division cycle was enumerated and the 
number of parent T cells was calculated.  The proliferative index was then 
determined and plotted as shown. 
 
Effect of thrombin on dendritic cells 
T cell proliferation 
To determine whether thrombin exerted an effect on DCs, it was added to DC culture 
16 hours prior to harvest.  The DCs were then washed prior to being added to a co-
culture with allogeneic CD4+ T cells.  T cell proliferation was measured by 3H 
incorporation.  The same ratio of 1:20 DC to T cells was used as in the previous 
experiments with 2x105 T cells per well to ensure detection of either enhancement or 
reduction of the T cell response.  Overall there was significant enhancement of T cell 
proliferation with 250nM thrombin incubated DCs compared to control DCs. Figure 
6.11 shows a graph representative of one experiment.  Controls used were untreated 
DCs, which had been incubated with medium alone, and DCs incubated with inactive 
thrombin, which has the same structure as thrombin but with the active site blocked 
by FPRCK.  T cell proliferation is similar with both of these controls suggesting that 
the action of thrombin is through its known active site.  
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Figure 6.11 Effect of thrombin incubated DCs on CD4+ T cell proliferation in an
allogeneic co-culture
C57BL/6 DCs which were dexamethaosne treated (dex), untreated (untx), treated with
250nM inactive thrombin (ithr) or thrombin (thr) or LPS matured (LPS) were co-
cultured with purified BALB/c CD4+ T cells (DC+T). Five days later T cell
proliferation was measured by 3H incorporation. T cells alone (T) and DCs alone (DC)
are shown as controls. Comparison of thrombin incubated with untreated DCs *p<0.02.
Mean shown +/- SE of triplicate wells.
 
A further dose of thrombin was also included in the proliferation assay from the 
beginning of the culture to assess if there was further enhancement of T cell 
proliferation.  Representative data seen in figure 6.12 show that there does not appear 
to be further enhancement when an additional dose of thrombin is added to the co-
culture compared with only DCs being incubated in thrombin.  This is in keeping with 
the effect of thrombin being solely through DCs with no additional effect through the 
T cells even following T cell activation by DCs. 
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Figure 6.12 Effect on CD4+ T cell proliferation of thrombin incubated DCs
with or without the addition of further thrombin to the allogeneic co-culture
C57BL/6 DCs (DC), which were untreated (0nM thr), incubated with 250nM
(250nM thr) or 500nM (500nM thr) thrombin were co-cultured with purified
BALB/c CD4+ T cells (DC+T). A further equivalent dose of thrombin was added
into some co-cultures (DC+T+thrombin). Five days later T cell proliferation was
measured by 3H incorporation. T cells alone (T) and DCs alone (DC) are shown as
controls. Mean +/- SE are shown of triplicate wells. Data representative of two
independent experiments.
 
T cell cytokines  
Supernatant from the allogeneic co-culture of DCs and CD4+ T cells was collected 
and analysed by ELISA for Th1 cytokine IFN-γ and Th2 cytokine IL-4 as shown in 
figure 6.13.  As predicted from the high expression of co-stimulatory molecules and 
IL-12, there was a high amount of IFN-γ produced from T cells co-cultured with LPS 
mature DCs.  There was detectable but 60 fold less IFN-γ production from T cells 
cultured with untreated DCs compared with LPS treated DCs, and barely detectable 
levels from T cells cultured with dexamethasone treated DCs.  The level of IFN-γ was 
unchanged when T cells were cultured with thrombin incubated DCs compared with 
untreated DCs.  
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Figure 6.13 Effect of thrombin incubated DCS on T cell cytokines in an allogeneic co-
culture
2x105 purified BALB/c CD4+ T cells were cultured with 1x104 C57BL/6 DCs,
dexamethasone treated (dex), untreated (untx), LPS matured (LPS) or thrombin incubated
(thr). Supernatant was collected two (d2) or four (d4) days later and subjected to ELISA
quantification of IFN-γ or IL-4 cytokine production. Mean shown +/- SE of triplicate wells.
Representative of two experiments.
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IL-4 levels were analysed on days two and four of culture.  Initially, on day two 
negligible levels were detected from T cells cultured with dexamethasone treated DCs 
and LPS matured DCs however this was at the very lower limit of what was 
detectable in the assay. Later, on day four low levels of IL-4 were detected in cultures 
from T cells with LPS treated DCs.  No IL-4 was found in any of the other conditions 
by ELISA. 
 
Another way to assess cytokine secretion by T cells is through intracellular staining.  
The information attained is different from the ELISA method, which measures total 
quantity of cytokine whereas intracellular staining identifies the number of cells 
producing specific cytokines.  To complement the ELISA results, T cells, following 
culture with treated DCs, underwent intracellular staining for IFN-γ, IL-4 and IL-10. 
IL-10 is produced by Tregs (182, 379, 380) and so high levels may indicate induction 
of a regulatory phenotype.  Following culture and prior to staining the cells were 
stimulated with ionomycin and PMA, to counter any heterogeneity in cytokine 
kinetics within the cell population.  Brefeldin was added for the last two hours of the 
incubation, which has been shown to increase the intensity of specific cytokine 
staining by acting on the Golgi of cells and preventing protein secretion (369). 
 
1x106 purified BALB/c CD4+T cells were co-cultured with 1x105 C57BL/6 DCs in 1 
ml of medium. Four days later the cells were split and on day seven of culture they 
were stimulated as described above then stained and analysed by flow cytometry. 
 
This experiment was done twice with representative data from one of the experiments 
shown in figure 6.14.  Th2 skewing of the cytokine profile with a low percentage of 
IFN-γ secreting T cells and a higher percentage of IL-4, IL-10 and both IL-4 and IL-
10 secreting T cells was seen when stimulated with DCs in all conditions. When 
stimulated with thrombin incubated DCs the predominant Th2 pattern seen in the two 
experiments did not change, however there was an increase in the proportion of IL-4 
secreting T cells compared to stimulation with untreated DCs.  In the experiment 
shown in figure 6.14 there was also an increase in the proportion of IL-10 and both Il-
4 and IL-10 secreting T cells not seen in the second experiment. 
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Figure 6.14 Effect of thrombin incubated DCs on T cell cytokine profile in an
allogeneic co-culture
C57BL/6 DCs which were untreated (untx) or incubated with 250nM thrombin
(thrombin) were co-cultured with purified BALB/c CD4+ T cells. Four days later the
cells were split and on day seven of culture the cells were stimulated with PMA and
ionomycin with brefeldin added for the last two hours prior to intracellular staining for
IFN-γ, IL-4 and IL-10 as shown. Cells were analysed by flow cytometry and profiles
shown. Staining with isotype (isotype) is shown as a control for setting the quadrant
boundaries. Numbers represent percentage positive cells within the quadrant.
isotype untx thrombin
 
 
Thrombin does not appear to change the cytokine polarisation of the T cell response.  
However there is a suggestion that it further enhances Th2 polarisation by increasing 
the number of IL-4 secreting T cells.  It is not evident from these experiments whether 
overall conditions with thrombin favour Th2 polarisation or enhance the existing 
differentiation pattern. 
T cell tolerance 
To determine the effect of thrombin incubated DCs on T cell tolerance, in vitro two 
step anergy assays were performed.  Antigen specific hyporesponsiveness would be 
anticipated with initial exposure of the T cells to immature DCs whereas an 
exaggerated secondary response would be seen to mature DCs.  The secondary 
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response was assessed following exposure of T cells to thrombin incubated DCs 
compared with untreated DCs.   
 
Initial experiments were performed to establish optimal conditions using C57BL/6 
DCs and BALB/c T cells.  1x106 T cells were co-cultured with 1x105 DCs in 1 ml 
medium per well and the T cells were harvested four days later.  This provided a 
sufficient yield of cells, which were centrifuged at a low speed to remove dead cells.  
An aliquot of the cells was taken and analysed by flow cytometry to assess the 
proportion of T cells and DCs present.  Representative profiles are seen in figure 6.15 
and show that there is a shift of the whole population with increased mean 
fluorescence intensity when stained with anti-CD3 Ab as opposed to no shift with the 
anti-CD11c Ab.  This confirms that the majority of the cells are T cells with little if 
any contamination by DCs.  If DCs were present it would be important to remove 
them as their presence could potentially affect results in the second MLR. 
 
Figure 6.15 Analysis of cells following primary allogeneic co-culture of DCs and T cells
Following the first culture of BALB/c purified CD4+ T cells and C57BL/6 DCs for the two
step rechallenge assay, an aliquot of cells was taken and analysed by flow cytometry for
expression of CD3 and CD11c. Shaded profiles show isotype control and open profiles show
specific binding. Profiles are representative of three independent experiments.
CD3 CD11c
 
 
Following the first MLR the T cells were rested for a further forty eight hours before 
challenging them again in a second MLR.  Stimulation in the second MLR was with 
C57BL/6 DCs, which entailed a rechallenge, or with C3H DCs, which was a 
challenge with a third party control.  2x105 T cells were co-cultured with 1x104 
mature DCs and T cell proliferation was measured by 3H incorporation at three, five 
and seven days of culture. 
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Results are shown in figure 6.16.  In this system both the rechallenge and the third 
party challenge had secondary kinetics which were maximal early on day three of the 
culture.  There was significant T cell proliferation when the T cells were plated 
without antigen presenting cells, which would account for these findings.  A potential 
confounding factor was contamination with antigen presenting cells from the first 
MLR.  However this was excluded by the lack of CD11c staining as shown in figure 
6.15.    
 
A number of changes were made to the method in order to optimise the experimental 
conditions and ensure the controls behaved as expected.  These changes included the 
extension of the rest period for the T cells harvested from the primary culture, the use 
of untreated rather than matured DCs and a change in the ratio of T cells: DCs used in 
the second MLR. 
 
As shown in figure 6.17 these changes resulted in the controls behaving as expected. 
There was minimal proliferation of T cells plated alone, a secondary response when T 
cells were rechallenged with C57BL/6 DCs and a primary response when third party 
DCs were used.  
 
These conditions were used to assess the secondary response of T cells stimulated 
with thrombin incubated DCs in the first MLR.  Figure 6.17 shows that the secondary 
response of such T cells did not change in quality.  However it was enhanced 
compared to T cells stimulated with untreated DCs in the first MLR, although to a 
lesser degree than T cells stimulated with LPS matured DCs.  This was statistically 
significant in two independent experiments.  
 
These results indicate that the secondary response of naive T cells is enhanced when 
stimulated with thrombin incubated DCs compared to untreated DCs but not as much 
as with LPS matured DCs.  The results are in keeping with the effect of thrombin 
incubated DCs on T cell proliferation in a primary MLR.  These suggest that the 
presence of thrombin enhances the stimulatory capacity of DCs in a quantitative 
manner but leaves the nature of the response unchanged.   
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Next, the question of whether thrombin incubated DCs affected the response of 
memory T cells was addressed.  The same system was used to assess whether 
rechallenge with thrombin incubated DCs, compared with untreated DCs, in the 
second MLR altered the secondary response.  BALB/c T cells were co-cultured with 
dexamethasone treated, untreated or LPS matured C57BL/6 DCs.  The cells were 
harvested four days later and rested for four days following which they were 
rechallenged with thrombin incubated or untreated C57BL/6 DCs, or with third party 
controls consisting of thrombin incubated or untreated CBA DCs.  
 
As shown in figure 6.18 the secondary response of T cells stimulated with mature 
DCs in the first MLR was overall greater than that of T cells stimulated with untreated 
or immature DCs. Importantly there was no significant difference whether the T cells 
were rechallenged with untreated or thrombin incubated DCs in the second MLR.  
This differs from challenge with CBA DCs, which act as a third party control for a 
primary response, in which there was enhanced proliferation of all sets of T cells 
when stimulated with thrombin incubated DCs compared to untreated DCs.  This 
concurs with previous data where thrombin incubated C57BL/6 DCs enhanced T cell 
proliferation in a primary MLR as shown in figure 6.11 and demonstrates that the 
effect of thrombin is not limited to a certain strain combination or haplotype 
mismatch. 
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Dendritic cell phenotype 
LPS is one of the many exogenous danger signals acting through TLR4 (64), which 
leads to maturation of DCs.  This allows for a change in function from antigen 
processing to presentation and stimulation of an immune response.  It is now clear 
that there are endogenous as well as exogenous danger signals (109, 381, 382) and it 
is therefore possible that thrombin’s action on DCs may be an endogenous danger 
signal. This would explain the enhanced DC mediated T cell response seen in the 
previous set of experiments. 
 
Maturation of DCs involves upregulation of MHC and co-stimulatory molecules, 
which as previously shown directly influence the degree of T cell proliferation.  
Therefore thrombin may be influencing the T cell response through the DCs by acting 
as a danger signal and upregulating such molecules.  To test this hypothesis, thrombin 
incubated DCs were analysed by flow cytometry and compared to control DCs.   
 
Initially MHCI, MHCII, CD80 and CD86 were assessed.  LPS matured and 
dexamethasone treated immature DCs were used as controls because they had 
relatively high and low levels of expression of these molecules respectively.  The 
levels on untreated DCs were between these positive and negative controls.  When 
thrombin or its control of inactive thrombin was added to the DC culture there was no 
change in the level of expression of these molecules, as shown in representative 
profiles in figure 6.19.   
 
Assessment was expanded to involve other molecules which may affect the T cell 
response including more recently described co-inhibitory molecules PDL1 and PDL2 
(150, 151, 383) as well as other co-stimulatory molecules CD40L and ICOSL (155, 
156, 384) and ICAM (171), which is involved in cell adhesion.  No significant 
difference was seen in terms of percentage expression or MFI between thrombin 
incubated DCs and its two controls, which were inactive thrombin incubated DCs and 
untreated DCs.  Representative profiles from one experiment are shown in figure 6.19. 
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Figure 6.19 Effect of thrombin on DC phenotype
C57BL/6 DCs which were dexamethasone treated (dex), untreated (untx), incubated with 250nM
inactive thrombin (ithr) or thrombin (thr) or LPS matured (LPS) were analysed by flow cytometry for
surface molecules as indicated above. Shaded profiles show isotype control and open profiles show
specific binding. Numbers represent percentage positive cells and (numbers) represent MFI. MFI for
all isotype controls is eight. Representative data of three independent experiments.
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Dendritic cell cytokines 
The T cell response is also affected by the pattern and amount of cytokine produced 
by DCs.  Therefore thrombin may be affecting DC cytokine production and hence 
influencing the T cell response.  To address this, supernatants from thrombin 
incubated DCs were harvested and analysed for cytokine levels by ELISA.  Pro-
inflammatory cytokines IL-12 and IL-6 produced by DCs were analysed with 
representative data shown in figure 6.20. 
 
Figure 6.20 Effect of thrombin on DC cytokine profile
2x106 C57BL/6 DCs were dexamethasone treated (dex), untreated (untx), LPS
matured (LPS) or thrombin incubated (thr). Conditioned medium was collected 18
hours later and subjected to ELISA quantification of IL-12 and IL-6 cytokine
production. Mean shown +/- SE of triplicate wells. Representative of two
independent experiments.
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IL-12 is known to induce a Th1 effector response and IL-6 is pro-inflammatory and 
known to be involved in inducing a Th17 pattern of response.  The factors that induce 
a Th2 response are not so clearly understood, but are in part thought to be a default 
pathway when there is a lack of IL-12.  Other factors such as IL-10 production are 
also involved. 
 
Significant IL-12 production was only seen from LPS matured DCs and none from 
untreated or dexamethasone treated DCs.  Treatment of DCs with thrombin did not 
alter the lack of IL-12 production.   
 
IL-6 was produced by DCs although the highest amount was from LPS matured DCs 
followed by untreated DCs, with minimal quantities from dexamethasone treated 
DCs.  Thrombin treatment did not alter the amount of IL-6 compared to control. 
 
In summary thrombin incubation of DCs did not affect production of IL-6 and IL-12.  
Future work should include expansion of the cytokines that are measured for a more 
comprehensive analysis to include TNFα, MCP-1, IL1β, IL10 particularly as thrombin 
has been shown to enhance release of some of these cytokines from other cell types 
including monocytes and NK cells (295-297).   
Effect of PAR agonists on dendritic cells 
T cell proliferation  
This chapter has so far demonstrated that PAR expression, although variable does 
occur on mouse DCs but not T cells and that thrombin appears to affect the T cell 
response through its action on DCs.  It is therefore likely that thrombin’s action on 
DCs is through PAR receptors and this hypothesis was next investigated.  
 
The mechanism of PAR activation involving a tethered ligand has been used to 
develop an amino acid sequence that activates individual PARs (277, 278).  Selective 
agonists for PAR-1, -2 and -4 are available and were used in the next set of 
experiments.  Existing PAR-3 agonists appear to activate PAR-1 and -2 but not PAR-
3 specifically and so were not used.  Bone marrow derived DCs were incubated with 
individual PAR agonists and compared to control DCs in their ability to stimulate 
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allogeneic CD4+ T cells.  The doses of PAR agonists used were similar to previous 
published data (278, 304, 385, 386) including work from other members of this 
laboratory (387, 388).   
 
During this set of experiments there were issues with the untreated DCs having 
equivalent phenotype to LPS matured DCs.  Their ability to stimulate allogeneic T 
cells was the same as LPS matured DCs plus expression of MHCII, CD80 and 86 was 
similarly high.  In view of this it was clear that the problem was related to the 
untreated DCs rather than the fact that the LPS was not effective and had lost potency. 
To complicate matters this effect was not a consistent phenomenon and occurred 
intermittently making it difficult to ascertain what was the cause of the problem.  
 
Initially DCs were incubated with increasing doses of PAR-1 agonist and then 
cultured with allogeneic CD4+ T cells as shown in figure 6.21.  There was no 
significant change in T cell proliferation when stimulated with PAR-1 agonist 
incubated DCs at all the concentrations used compared with untreated DCs. 
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Figure 6.21 Effect of PAR-1 agonist incubated DCs on T cell proliferation in
an allogeneic co-culture
Purified BALB/c CD4+ T cells were cultured with bone marrow derived
C57BL/6 DCs (DC+T), which were dexamethasone treated (dex), untreated
(untx), LPS matured (LPS) or incubated with 5µM (5µM PAR1), 10µM (10µM
PAR1) or 20µM (20µM PAR1) PAR-1 agonist. Five days later T cell
proliferation was measured by 3H incorporation. T cells alone (T) and DCs alone
(DC) are shown as controls. Mean +/- SE shown of triplicate wells.
Representative of two independent experiments.
 
 
Some studies have shown an effect with concentrations of PAR-1 agonist in the 
region of 100µM and so this higher concentration was employed for further 
experiments along with similar concentrations of PAR-2 and -4 agonists used in other 
studies.  As seen in figure 6.22A proliferation of T cells stimulated with untreated 
DCs was the same as with LPS matured DCs.  Proliferation with PAR agonist 
incubated DCs was the same as with untreated DCs, however the untreated DCs were 
already maximally stimulated, which limits interpretation of this result.  However it is 
reasonable to conclude that the PAR agonist incubated DCs did not reduce T cell 
proliferation; although it is not possible to observe whether an enhancement of T cell 
proliferation occurred as would have been predicted. 
Results: Chapter 6 
164 
 
Controls behaved as expected in two other experiments as there was less T cell 
proliferation following stimulation with untreated DCs compared with LPS matured 
DCs.  In both these experiments T cell proliferation with PAR-1 or PAR-4 incubated 
DCs was similar to that with untreated DCs.  In one of these experiments, this was 
also the case for T cell proliferation following stimulation with PAR-2 incubated 
DCs.  However in the other experiment T cell proliferation was enhanced when 
stimulated with PAR-2 incubated DCs compared with untreated DCs, which is shown 
in figure 6.22B.  This suggests that PAR-2 activation on DCs may enhance their 
stimulatory capacity although not a consistent finding.  The differences may be 
dependent on the level of PAR-2 expression, which was found to be variable between 
different sets of DCs.  It may be that only when PAR-2 expression is above a certain 
level on the DCs that incubation with PAR-2 agonist then enhances their stimulatory 
capacity.  Further work correlating PAR-2 expression on the DC with their functional 
ability would be required to confirm this.   
 
If the effect seen with PAR-2 activation was real, then this would not be through the 
action of thrombin, as PAR-2 is not a thrombin receptor, but likely to be through the 
action of other serine proteases. Possibilities include the coagulation protein TF/VIIa 
complex, other proteins such as trypsin and even unidentified ligands.  
 
Overall these results suggest that PAR-2 activation can play a role in enhancing the 
stimulatory capacity of DCs, which may be dependent on the level of PAR-2 
expression. 
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Figure 6.22 Effect of PAR agonist incubated DCs on T cell proliferation in an
allogeneic co-culture
C57BL/6 DCs, which were dexamethasone treated (dex), untreated (untx), LPS
matured (LPS) or incubated with 100µM PAR-1 (PAR1), 50µM PAR-2 (PAR2) or
120µM PAR-4 (PAR4) agonist were co-cultured with purified BALB/c CD4+ T cells
(DC+T). Five days later T cell proliferation was measured by 3H incorporation. T cell
alone (T) and DCs alone (DC) are shown as controls. Mean +/- SE shown of triplicate
wells. Compared to untreated *p<0.05. One of three independent experiments (A) and
one of two independent experiments (B).
 
Dendritic cell and T cell cytokines 
In conjunction with T cell proliferation the cytokine profile of the T cells stimulated 
with PAR agonist incubated DCs was assessed by intracellular staining and analysis 
by flow cytometry as described previously. 
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Results with the PAR agonist incubated DCs were inconsistent even when the 
difference in behaviour of the controls was taken into account although the reason for 
this is not clear.  Figure 6.23 shows an example of profiles when T cells stimulated 
with untreated DCs had equivalent response in terms of proliferation to stimulation 
with LPS matured DCs.  Overall there was a Th2 polarisation with more IL-4 than 
IFN-γ secreting T cells when stimulated with untreated DCs.  This pattern did not 
change when T cells were stimulated with any of PAR-1, -2 or -4 agonist incubated 
DCs.  There was also little change in the proportion of cytokine secreting T cells 
when stimulated with PAR-1 agonist incubated DCs but a reduction in the proportion 
of IFN-γ, IL-4, IL-10 and both IL-4 and IL-10 secreting T cells when stimulated with 
PAR-2 or -4 agonist incubated DCs compared to control.  The reduction was greatest 
when the T cells were stimulated with PAR-4 agonist incubated DCs.   
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Figure 6.23 Effect of PAR agonist incubated DCs on T cell cytokine profile in an
allogeneic co-culture
C57BL/6 DCs which were untreated (untx) or incubated with 100µM PAR-1 agonist (PAR-1),
PAR-2 agonist (PAR-2) or PAR-4 agonist (PAR-4) were co-cultured with BALB/c CD4+ T
cells. Four days later cells were split and on day seven of culture they were stimulated with
PMA and ionomycin.. Brefeldin was added for the last two hours prior to intracellular
staining with IFN-γ, IL-4 and IL-10. Cells were analysed by flow cytometry and profiles
shown above. Staining with isotype (isotype) is shown as a control for setting the quadrant
boundaries. Numbers represent percentage positive cells within the quadrant.
isotype untx
PAR-1 PAR-2 PAR-4
isotype untx
PAR-1 PAR-2 PAR-4
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Figure 6.24 shows a different example of profiles when controls in the T cell 
proliferation assay behaved as would be expected in that T cell proliferation with 
untreated DCs was less than with LPS matured DCs.  The Th2 polarisation occurred 
in the control condition with no change of this pattern of polarisation when the T cells 
were stimulated with any of the PAR agonist incubated DCs.  However this time the 
proportion of cytokine secreting T cells was similar when stimulated with PAR-2 
agonist incubated DCs and decreased when stimulated with PAR-1 or -4 agonist 
incubated DCs compared to control.  This differs from the first experiment and no 
pattern emerges on repeating these experiments.  Overall the cytokine profile does not 
appear to be altered significantly by PAR agonist incubated DCs compared to 
controls.  However the inter-experimental variability in the cytokine profiles leaves 
these results difficult to interpret.  
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Figure 6.24 Effect of PAR agonist incubated DCs on T cell cytokine profile in an
allogeneic co-culture (2)
C57BL/6 DCs which were untreated (untx) or incubated with 100µM PAR-1 agonist (PAR-
1), PAR-2 agonist (PAR-2) or PAR-4 agonist (PAR-4) were co-cultured with BALB/c CD4+
T cells. Four days later cells were split and on day seven of culture they were stimulated
with PMA and ionomycin. Brefeldin was added for the last two hours prior to intracellular
staining with IFN-γ, IL-4 and IL-10. Cells were analysed by flow cytometry and profiles
shown. Staining with isotype (isotype) is shown as a control for setting the quadrant
boundaries. Numbers represent percentage positive cells within the quadrant.
isotype untx
PAR-1 PAR-2 PAR-4
isotype untx
PAR-1 PAR-2 PAR-4
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Effect of thrombin with LPS on dendritic cells 
Coagulation and inflammation often occur simultaneously such as in sepsis, when 
upregulation of TF leads to activation of the coagulation cascade and the release of 
inflammatory cytokines.  This occurs in part due to the action of LPS and other 
exogenous danger signals.  Other work has shown thrombin enhances the effect of 
LPS on monocytes leading to increased cytokine release (296, 297).  The following 
experiments test the hypothesis that thrombin may act synergistically with LPS on 
DCs leading to an exaggerated immune response.  DCs were incubated with a 
submaximal concentration of 10ng/ml, as opposed to 1µg/ml LPS, and 250nM 
thrombin for 16 hours.  The DCs were then co-cultured with allogeneic CD4+ T cells 
and T cell proliferation was assessed five days later by 3H incorporation.   
 
Figure 6.25 shows a representative plot of one of three experiments.  T cell 
proliferation was significantly less when stimulated with DCs incubated with the 
lower concentration of 10ng/ml LPS compared to 1µg/ml LPS.  The addition of 
250nM thrombin to the DCs with 10ng/ml LPS led to a trend towards enhanced T cell 
proliferation compared to stimulation with just 10ng/ml LPS matured DCs, although 
proliferation was not as much as with high dose LPS incubated DCs.  
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Figure 6.25 Effect of thrombin and LPS incubated DCs on T cell proliferation in
an allogeneic co-culture
C57BL/6 DCs which were treated with 1µg/ml LPS (LPS 1µg/ml), 10ng/ml LPS (LPS
10ng/ml) or 250nM thrombin and 10ng/ml LPS (LPS+thr) were co-cultured with
purified BALB/c CD4+ T cells. T cell proliferation was measured by 3H incorporation
five days later. T cells alone (T) and DCs alone (DC) are shown as controls. Mean +/-
SE shown of triplicate wells. Comparison of DCs treated with 10ng/ml LPS compared
with 1µg/ml LPS * p < 0.05. Data representative of three experiments.
 
 
The T cells from the co-culture were also analysed by flow cytometry for IFN-γ, IL-4 
and IL-10 as previously described, following stimulation with PMA and ionomycin 
and treatment with brefeldin.  Representative profiles are shown in figure 6.26.  There 
is skewing towards a Th2 cytokine pattern with more IL-4 than IFN-γ secreting T 
cells.  This occurs in all conditions. 
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Furthermore there is enhancement of the number of IL-4 and IL-10 secreting T cells 
when stimulated with 10ng/ml LPS and 250nM thrombin incubated DCs compared to 
stimulation with 10ng/ml LPS incubated DCs.  This is the same pattern as seen with 
the cytokine profiles of T cells stimulated with thrombin incubated DCs compared to 
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untreated DCs, seen in figure 6.18, suggesting again that thrombin incubation of the 
DCs does not alter the cytokine profile of the stimulated T cells but does enhance the 
cytokine T cell response with increased numbers of IL-4 secreting T cells. 
 
LPS acts through TLRs on DCs leading to upregulation of surface MHC and co-
stimulatory molecules.  The possibility that thrombin enhances this effect leading to 
an enhanced T cell response was addressed by analysing these surface molecules on 
DCs by flow cytometry.  Figure 6.27 shows representative profiles.   
 
There is maximal upregulation of MHCII, CD80 and CD86 when DCs are incubated 
with high concentrations (1µg/ml) of LPS compared with immature DCs as expected.  
The MFI of MHCII and CD86 but not CD80 was slightly lower when DCs were 
incubated with the lower concentration of 10ng/ml LPS which suggests submaximal 
upregulation of the former molecules.  When comparing this with the addition of 
250nM thrombin with 10ng/ml LPS to DCs there is little difference in the level of 
expression of the three molecules and nothing that would account for the enhanced T 
cell response seen with the latter.   
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Discussion 
Anti-human PAR-1, -2 and -4 Abs were confirmed to work on mouse cells in flow 
cytometry.  Using these Abs, no PAR expression was found on mouse CD4+ T cells.  
This has not previously been reported but studies have shown expression of PAR-1, -2 
and -3 on human naive CD3+ T cells (304) although another study only found PAR-1 
and not -2 on human naive CD3 T cells but both PAR-1 and -2 on human leukaemic T 
cell lines (301).  Only the latter study specifically assessed CD4+ T cells and found a 
mean proportion of 10% expressing PAR-1 using flow cytometry.  This discrepancy 
may be due to interspecies differences, as has been noted on other cell types, however 
it should be noted that a different Ab was used in this latter study, which may also 
account for these differences.   
 
The absence of PAR expression was reflected by the lack of effect of thrombin on 
CD4+ T cells when cultured in a non-antigen presenting cell system by stimulation 
with CD3/28 Ab.  This has not been previously reported in a mouse system.  It differs 
from human studies where thrombin was found to enhance T cell proliferation and 
cytokine production of IL-6 and IL-2 in response to mitogenic stimulation (298, 304).  
However both CD8+ and CD4+ T cells, as well as PBMCs in some of the studies, 
were present in the culture and so the changes could have been due to thrombin’s 
effect on any combination of these populations and not necessarily the CD4+ T cells.   
 
Differential PAR expression was found on both mouse bone marrow progenitor cells 
and bone marrow derived DCs.  Using flow cytometry, PAR-1, -3 and -4 were found 
on the former and variable expression of all the PARs were found on the latter.  The 
level of expression was low, as assessed by the increase in MFI from the isotype 
control, but was similar to other studies which have reported PAR expression by flow 
cytometry on DCs (305, 306).  
 
Another study reported PAR expression on mouse bone marrow progenitors and bone 
marrow derived DCs although the pattern of expression was slightly different on the 
progenitor cells, which appeared to express all the PARs (307).  This study used RT-
PCR, rather than flow cytometry, and so detected changes at the mRNA level rather 
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than at the protein level, which may account for the difference.  The same study found 
all the PARs expressed on mouse bone marrow derived in keeping with our results.  
 
Studies on human DCs have also found PAR expression with one study suggesting 
differential expression between subtypes and PAR-1 found on circulating blood, but 
not monocyte derived DCs (306).  We only assessed mouse bone marrow DCs but 
another study found similar PAR expression on both mouse splenic and bone marrow 
derived DCs (307).  Blood DCs would be difficult to isolate from mice but protocols 
exist for culture of mouse plasmacytoid DCs, which are found in the blood, from bone 
marrow progenitor cells (30, 38) and it would be worthwhile investigating PAR 
expression on these cells. 
 
Addition of thrombin to an allogeneic co-culture of mouse untreated DCs and T cells, 
was found to enhance T cell proliferation.  This effect was not seen when LPS 
matured or dexamethasone treated DCs were used, which may be because the former 
were already at their maximal stimulatory capacity and thrombin may not be able to 
overcome the effect of dexamethasone on DCs. 
 
The effect of thrombin on T cell proliferation appeared to be purely through an effect 
on DCs as no change in proliferation was seen when thrombin was added to T cells 
with CD3/28 Ab mitogenic stimulation in a non-antigen presenting cell system.  
Moreover untreated DCs pre-incubated with thrombin had enhanced stimulatory 
capacity on allogeneic T cells.  This did not occur when DCs were pre-incubated with 
active site blocked thrombin, which confirms the effect is specific to thrombin and 
requires the proteolytic activity such as that which occurs with PAR activation.  This 
is the first known report of this effect in a mouse system.  Since this project started 
others have reported similar results in a human system with enhanced T cell 
proliferation with thrombin incubated blood DCs (306).  These results fit with the 
finding of PAR expression on DCs but not T cells therefore suggesting that thrombin 
would be able to exert an effect through PAR on DCs but not T cells.  
 
Analysis of supernatants from the DC and T cell co-cultures did not reveal any 
differences in levels of IFN-γ and IL-4 when DCs were pre-incubated with thrombin 
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compared to control.  However flow cytometric analysis of cytokine production from 
the T cells in the co-culture at a later time point did show changes with a consistent 
increase in the number of IL-4 secreting T cells and at times increased numbers of IL-
10 and decreased numbers of IFN-γ secreting T cells compared to stimulation with 
untreated DCs.  The overall pattern of cytokine polarisation from the T cells was 
unchanged and remained as a Th2 response; however thrombin appeared to enhance 
the numbers of T cells secreting Th2 type cytokines.  Further work needs to be done 
to clarify whether thrombin’s effect is simply enhancing the existing polarisation 
pattern or if it is specifically promoting a Th2 response.  This could be done by using 
conditions which normally promote a Th1 response and assessing whether the 
incubation of DCs with thrombin changes the polarisation to a Th2 or enhances the 
Th1 response.   
 
A human study found that thrombin incubated plasmacytoid DCs led to enhanced T 
cell production of IFN-γ with reduced IL-4 (306) suggesting that in this setting 
thrombin incubation of  DCs led to Th1 skewing of the stimulated T cells.  This is in 
contrast to these results and the difference may be related to the distinct subtypes of 
DCs under scrutiny. 
 
There are a number of possible reasons for the discrepancy between the findings for 
the cytokine levels measured by ELISA in the co-culture supernatant and the number 
of cytokine secreting T cells assessed by flow cytometry.  Assessments were done at 
different time points with the ELISA being done earlier when there may not have 
been detectable differences in T cell cytokines.  The actual amount of IL-4 secreted 
may have been low, even if there were differences between numbers of T cells 
secreting IL-4, and so the ELISA assay may not have been sensitive enough to detect 
this.  The IL-4 levels that were detected by ELISA were at the very lower limit of the 
assay, and the assay was therefore not used within its optimal range.  The sensitivity 
of the assays may have been improved by using a higher number of DCs in the co-
culture.  Titration of the ratio of DC: T cells for ELISA measurement of cytokines 
was not specifically performed as the same ratio was used as for the T cell 
proliferation assays in order to correlate findings.  
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The secondary response of naive T cells when initially stimulated with thrombin 
incubated DCs was enhanced but not to the extent of initial stimulation with LPS 
DCs.  The quality of the response was unchanged in that it remained a secondary 
response with secondary kinetics, but the overall magnitude of the response increased. 
This corroborates with the effect of thrombin on DCs in a primary response where T 
cell proliferation is enhanced.  The data would fit with the idea of thrombin being 
generated in inflammatory conditions, possibly by DCs themselves, in order to act on 
cells including other DCs to enhance the immune response. 
 
Further work should include examining the secondary response of T cells following 
initial stimulation with thrombin incubated dexamethasone treated DCs to assess if 
thrombin would alter the nature of this response and potentially break the tolerogenic 
capacity of the dexamethasone treated DCs.    
 
The response of stimulated T cells was not altered when rechallenged with thrombin 
incubated DCs.  However when the T cells were rechallenged with thrombin 
incubated third party DCs, there was significant enhancement of T cell proliferation.  
The latter supports the previous finding that thrombin incubated DCs enhance a 
primary allogeneic T cell response.  Overall it highlights the difference in the effect of 
thrombin through DCs on naive T cells, when there is enhanced T cell proliferation, 
compared to T cells that have already been activated, when there is no effect.  This is 
the first time a differential effect of thrombin on a primary compared to a memory 
immune response has been reported.   
 
Thrombin’s effect of enhancing the stimulatory capacity of DCs was next examined.  
Upon DC maturation, there is upregulation of MHCII and co-stimulatory molecules, 
which allows for antigen presentation and interaction of the DCs with naive T cells, 
leading to a T cell effector response. The degree of expression of MHCII and co-
stimulatory molecules directly correlated with the degree of T cell proliferation as 
confirmed in the titration assays for allogeneic DC and T cell co-culture shown in the 
previous chapter (figure 5.2).  LPS is probably the most well known DC maturation 
signal acting through TLRs.  However, unlike LPS, thrombin did not appear to alter 
the expression of any of the surface molecules examined, which included MHCII, 
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many of the B7 family of co-stimulatory molecules, ICAM and CD40.  Therefore it is 
most likely that thrombin’s effect is not mediated through upregulation of surface 
molecules on DCs.  It is still possible, however, that thrombin has a very specific 
action and changes surface expression of a molecule that was not tested.   
 
The family of co-stimulatory/inhibitory molecules is ever expanding and a number of 
more recently described members of the B7 family were not assessed.  Of particular 
note is OX40L, a member of the TNF family, which is known to promote a Th2 
effector response (167, 389) and so would be worthwhile exploring further in view of 
the possible role of thrombin in Th2 polarisation of the T cell response.  A study 
assessing human DCs has shown contrasting results with upregulation of MHCII and 
CD86 following thrombin incubation of DCs (306).  However these were 
plasmacytoid and myeloid DCs isolated from blood and so are not directly 
comparable. 
 
The T cell response is also shaped by the pattern and the amount of cytokines 
produced by DCs.  However, of the two cytokines measured in the DC supernatant no 
differences were seen in levels of IL-12 or IL-6 between thrombin incubated and 
untreated DCs.  The lack of IL-12 production would fit with promotion of a Th2 
response and work should be extended to assess Th2 promoting cytokines such as IL-
10.  A previous study found co-culture of human monocytes and allogeneic T cells 
with thrombin led to reduced IL-12 which was dependent on the production of IL-10 
(299) and so it may be that thrombin incubation of DCs does the same.  Naldini and 
colleagues also found that thrombin incubation of human monocytes enhanced IL-10 
production (297), which further strengthens this possibility. 
  
Thrombin may affect DC expression of chemokine receptors or molecules and in this 
way influence DC migration and chemoattraction of other cells including T cells.  
This may be another avenue worth exploring as a possible mechanism of action 
through which thrombin exerts its effect on DCs. 
 
These results also show that the addition of thrombin to a submaximal dose of LPS 
further promotes the ability of DCs to stimulate allogeneic T cell proliferation and 
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enhance T cell cytokine production.  Ligands acting through other PRRs, such a CLRs 
have been reported to modulate pathways initiated by TLRs (122) and so it is 
postulated that thrombin may have a similar role.  However the fact that there was no 
change in MHCII, CD80 and CD86 with the addition of thrombin to LPS compared to 
LPS alone makes this unlikely.  Therefore this effect is probably through the same 
mechanism as when thrombin alone is incubated with DCs rather than a synergistic 
effect through TLRs.   
 
The main way that thrombin exerts its cellular effects is through members of a family 
of receptors called PAR, specifically PAR-1, 3 and -4.  This and other work (300, 
305-307) has shown that DCs are able to express PAR and therefore have the ability 
to respond to thrombin.  When DCs were incubated with available individual PAR 
agonists there was no change in the ability of the DCs to stimulate allogeneic T cell 
proliferation.  There were issues related to the behaviour of the controls in some of the 
experiments but even when the controls performed as expected this was a consistent 
finding with PAR-1 and PAR-4 agonists. 
 
Possible reasons for this lack of response are firstly, that thrombin does not act 
through these receptors individually.  Redundancy and synergy in PAR signalling has 
been demonstrated (252) and so it may require simultaneous activation of multiple 
PARs by thrombin on DCs for an effect to be seen.  This may include activation of 
PAR-3, which was not tested due to the lack of availability of a selective PAR-3 
agonist.  Secondly, it may be that thrombin does not exert its effect on DCs through 
PAR although alternative receptors have not been identified.  Thirdly, the appropriate 
dose of PAR agonist may not have been used although this seems less likely as these 
doses have been used in other studies and found to stimulate PAR (278, 304, 385-
388).  Further work should involve the use of multiple PAR agonists simultaneously 
to assess their effect on DCs.   
 
The PAR-2 agonist was at times found to enhance the stimulatory capacity of DCs.  
Other ligands such as trypsin (273), FXa (220) but not thrombin are known to activate 
PAR-2 and so may affect DC function in this way.  PAR-2 has already been shown to 
influence DC development and maturation in the mouse (307). 
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In summary results in this chapter have shown that thrombin appears to enhance 
allogeneic T cell proliferation in primary and secondary responses and promote a Th2 
cytokine response through an effect on DCs.  In contrast thrombin stimulated DCs had 
no effect on the secondary response of memory T cells.  Thrombin’s effect on DCs 
remains unclear with no change in surface expression of MHCII or multiple co-
stimulatory molecules tested.  There was also no change in cytokine release from DCs 
with no IL-12 and minimal IL-6 production, which is compatible with promoting a 
Th2 response.  Other factors which should be assessed include OX40L expression and 
IL-10 production, both factors known to promote a Th2 response, plus chemokine and 
chemokine receptor expression on DCs.  DCs, but not T cells, were found to express 
PARs and so have the ability to respond to thrombin through these receptors.  
However, the incubation of DCs with individual PAR agonists did not mimic the 
effect of thrombin, suggesting either a different mechanism of action or the need for 
simultaneous multiple PAR activation.  
  
This is the first description of thrombin’s effect on mouse DCs and the first report of 
thrombin’s effect through DCs on secondary and memory T cell response.  Overall 
the former is similar to effects seen on human DCs with an enhancement of T cell 
proliferation.  There are discrepancies related to the pattern of T cell cytokine profile 
and effect on DC phenotype.  The reasons for this are not clear but may be related to 
the different DC subtypes examined.  
 
The data is in keeping with a recent publication by Ruf and colleagues, which 
described a pivotal role of PAR-1 signalling on DCs in the inflammatory response of 
endotoxaemia (234).  The study suggested that thrombin generated by the DCs then 
acts in an autocrine fashion on PAR-1 leading to migration of the DCs and 
dissemination of the immune response.   
 
These data suggest a role for coagulation proteases, released at the site of injury and 
inflammation, in shaping the adaptive immune response through DCs but not directly 
through T cells.  It indicates that thrombin may enhance the existing immune response 
without altering its quality. 
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Chapter 7:  Anti-thrombin  
Animal models of transplantation have used AT as an immunomodulatory agent 
without immunosuppressants and found increased and indefinite survival of allografts 
(344, 345).  The mechanism of action of AT in this context is not completely 
understood but one possibility is the inhibition of coagulation factors preventing their 
cellular effects through PAR, which was explored in chapter six.   
 
Another possibility for AT’s immunomodulatory effect is by a direct action on cells.  
Evidence exists for binding of AT directly to members of the HSPG family present on 
the cell surface.  Stimulation of these receptors have been shown to lead to effects on 
cell function and migration, which in part is through intrinsic cell signalling (352, 
354).  HSPGs are known to be expressed on DCs and have been found to be important 
receptors in binding virus like particles resulting in production of cytokines and 
upregulation of co-stimulatory molecules (390).  It is therefore possible that AT exerts 
a direct effect on DCs through these receptors.  
 
This chapter describes the results of a series of experiments investigating the 
hypothesis that AT has an immunomodulatory effect on the T cell response and that 
this response is through a direct effect on DCs.   Specific objectives of experiments in 
the chapter are: 
- to examine the effect of AT on DCs  
- to determine whether AT influences the effect of LPS on DCs 
- to characterise any effects of AT through DCs on the T cell response 
- to examine the effect of AT on the T cell response in vivo  
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Effect of anti-thrombin on dendritic cells 
Previous in vitro studies have used doses of AT between 1 and 20µg/ml and found the 
optimal dose to be 10µg/ml (351) therefore this dose was used in experiments.  Since 
AT is predicted to act as an immunomodulatory agent it was added to the DC culture 
on day five, on the basis that AT may keep DCs in a relatively immature state.  DCs 
were also incubated with AT prior to treatment with 100ng/ml LPS to assess whether 
AT makes DCs resistant to this maturation signal. 
The DC phenotype was assessed by flow cytometry of surface MHCII and co-
stimulatory molecules CD80 and 86.  Figure 7.1 shows representative profiles and as 
would be expected there was upregulation of all three surface molecules when DCs 
were treated with LPS compared to being untreated.  Comparing untreated with AT 
incubated DCs there was no significant difference between the levels of expression of 
these molecules in terms of the MFI.  This was a consistent finding throughout the 
experiments.  There was a slightly higher percentage of CD86 expression with AT 
incubation in this experiment but in other experiments CD86 expression was similar 
with slightly higher expression of CD80 compared to untreated DCs.  Overall these 
differences were small and not consistent. 
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There was a slight reduction in terms of MFI in all three molecules when the DCs 
were incubated with AT prior to LPS treatment.  However this was not down to the 
level of untreated DCs, which would be expected if AT rendered the DCs completely 
resistant to maturation signals of LPS.   
Effect of anti-thrombin through dendritic cells on the T cell response 
T cell proliferation 
To assess if these small shifts in the surface expression of molecules with AT 
treatment led to any change in the immune response, DCs were co-cultured with 
allogeneic T cells and T cell proliferation and cytokine profiles were measured by 3H 
incorporation and flow cytometry respectively.  
 
Figure 7.2 shows T cell proliferation when 1x104 treated DCs were co-cultured with 
1x105 purified BALB/c CD4+ T cells.  There was maximal proliferation when T cells 
were stimulated with LPS treated DCs and this was 10 fold greater than with 
untreated DCs.  This was not significantly altered when the DCs were pre-treated with 
AT prior to the addition of LPS.  With respect to T cell proliferation, there was no 
difference between stimulation with AT treated DCs and untreated DCs.  As expected, 
there was less proliferation with dexamethasone treated DCs.  
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Figure 7.2 Effect of AT treated DCs on T cell proliferation in an allogeneic co-culture
C57BL/6 DCs, which were dexamethsaone treated (dex), untreated (untx), LPS matured
(LPS), treated with AT (AT) from day five of culture or AT prior to LPS maturation (AT
then LPS) were co-cultured with purified BALB/c CD4+ T cells (DC+T). Five days later
T cell proliferation was measured by 3H incorporation. T cells alone (T) and DCs alone
(DC) are shown as controls. Mean shown +/- SE of triplicate wells.
 
T cell cytokine profiles 
Figure 7.3 shows the intracellular cytokine profiles of T cells co-cultured with 
allogeneic DCs followed by stimulation with ionomycin and PMA on day seven of 
culture, prior to staining.  The predominant cytokine secreted is IL-4 suggesting Th2 
polarisation.  This remains unchanged in all conditions.  There are fewer cytokine 
secreting T cells when stimulated with untreated DCs as compared to LPS matured 
DCs and little difference in the number of cytokine secreting T cells when comparing 
untreated DCs and AT treated DCs as stimulators.  The striking difference is the 
increase in the numbers of IL-4, IL-10 and both IL-4 and IL-10 secreting T cells when 
they are stimulated with DCs pre-treated with AT prior to LPS maturation compared 
to LPS alone.  The profiles shown are from one of four experiments and the changes 
described were seen in the other three experiments but to a lesser extent. 
 
Using the paired t test the changes were not statistically significant however there 
does appear to be a consistent trend towards enhancement of Th2 polarisation.  The 
greatly increased number of IL-10 secreting T cells suggests the development of a 
tolerogenic phenotype, possibly with the generation of IL-10 secreting Tregs. 
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Figure 7.3 Effect of AT treated DCs on T cell cytokine profile in an allogeneic co-culture
C57BL/6 DCs, which were untreated (untx), treated with AT on day five of culture (AT), LPS
matured (LPS) or treated with AT prior to LPS maturation (AT then LPS) were co-cultured with
purified BALB/c CD4+ T cells. Four days later the cells were split and on day seven of culture the
cells were stimulated with PMA and ionomycin. Brefeldin was added for the last two hours prior to
intracellular staining for IFN-γ (IFN gamma), IL-4 and IL-10. Cells were analysed by flow
cytometry and profiles shown. Staining with isotype (isotype) is shown as a control for setting the
quadrant boundaries. Numbers represent percentage positive cells within the quadrant.
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T cell tolerance 
To investigate whether AT treatment of DCs induced a tolerogenic phenotype, the 
following two experiments were performed. Firstly in a two step anergy assay, T cells 
from a primary co-culture were harvested and rechallenged with DCs.  The prediction, 
if this leads to tolerance, would be an anergic response in the second co-culture with 
relatively less proliferation, and primary rather than secondary kinetics. Secondly in a 
functional suppressor assay, T cells harvested from a primary co-culture were titrated 
into a second co-culture of naive syngeneic T cells and allogeneic DCs.  An aliquot of 
the harvested T cells was also stained for the Treg marker foxp3. 
 
These were preliminary experiments done at the end of the project and were only 
performed once.   
 
Figure 7.4 shows results of the two step anergy assay.  The conditions used were the 
same as described in chapter 6.  T cells stimulated with DCs, which were treated with 
AT prior to LPS, behaved in a similar fashion as T cells stimulated with LPS matured 
DCs suggesting no evidence of anergy induction. 
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Figure 7.5 shows results of the suppressor assay.  T cells were harvested from the first 
co-culture where C57BL/6 DCs, which were LPS matured or treated with AT prior to 
LPS maturation, were used as stimulators.  These T cells were irradiated to inhibit 
proliferation then added back in to a primary MLR in increasing numbers to assess 
whether they were able to suppress the primary immune response.  The MLR 
contained 1x104 C57BL/6 DCs co-cultured with 2x105 naive BALB/c CD4+ T cells.  
Figure 7.5A shows that a degree of suppression occurred in a manner dependent on 
the number of effector T cells added to the primary MLR.  This was equivalent 
whether the T cells were initially stimulated with LPS matured DCs or DCs pre-
treated with AT prior to LPS maturation.   
 
An aliquot of the T cells harvested from the first MLR was stained for foxp3 
expression to assess for the presence of a Treg phenotype.  There was a population of 
foxp3 expressing cells as shown in figure 7.5B but this population did not increase in 
the experiments where the T cells were stimulated with AT then LPS compared with 
LPS maturation alone.    
 
This supports the finding of the functional suppressor assay, which demonstrates that 
no Treg phenotype was induced when T cells were stimulated with DCs treated with 
AT then LPS matured. 
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Figure 7.5 Effect of AT treated then LPS matured DCs on the induction of Tregs
1x105 C57BL/6 DCs, which were LPS matured (LPS) or treated with AT prior to LPS
maturation (AT then LPS) were co-cultured with 1x106 purified BALB/c CD4+ T cells. Five
days later the T cells were harvested and rested for 96 hours following which the T cells were
irradiated and titrated to naive T cells at a specified ratio as indicated into a primary co-
culture of 1x104 C57BL/6 DCs and 2x105 purified naïve CD4+ BALB/c T cells (A). Five
days later T cell proliferation was measured by 3H incorporation. Mean shown +/- SE.
An aliquot of the T cells was taken prior to adding it back into the primary co-culture and
analysed for foxp3 expression using flow cytometry as shown (B). Shaded profiles show
isotype control and open profiles show specific binding. Numbers represent percentage
positive cells.
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Effect of anti-thrombin on the T cell response in vivo  
The next set of experiments used AT in vivo to assess whether it has an 
immunomodulatory effect on T cell sensitisation in an antigen specific model.  
DO11.10 and BALB/c mice were used.  Briefly, as previously outlined, cells from the 
lymph nodes and spleen of DO11.10 mice were CFSE labelled and injected 
intravenously into BALB/c mice.  Twenty four hours later the mice were sensitised by 
giving an intraperitoneal injection of ovalbumin with LPS adjuvant, which leads to 
antigen specific T cell activation and proliferation of the CFSE labelled DO11.10 
CD4+ T cells that had been adoptively transferred into the BALB/c mice.   
 
Prior to sensitisation the mice were given either AT or an equivalent volume of 
normal saline as a control to assess whether AT affected antigen specific sensitisation 
or T cell activation.  A group of mice were also given LPS alone to act as a naive 
control group that had not been sensitised, and in which no proliferation of the CFSE 
labelled DO11.10 should occur.  Seventy two hours later cells from the lymph nodes 
were harvested and stained.  CD4+ T cells were gated and analysed for T cell 
proliferation by assessing CFSE dilution of the antigen specific DO11.10 T cells by 
flow cytometry.  The cells were also stained and analysed for production of IFN-γ, IL-
4 and IL-10.  The prediction was that if AT affected sensitisation there would be a 
difference in T cell proliferation and possibly the number or pattern of the cytokine 
producing T cells. 
 
Three mice were used in each group and the experiment was done twice with 
representative data from the first experiment shown in figures 7.6 to 7.8.   Figure 7.6 
shows representative profiles of the gated CD4+ T cells from one of three mice in 
each group.  As expected there was no proliferation of the CFSE stained DO11.10 T 
cells with very little cytokine secretion from mice which had been given LPS alone.  
There was clear proliferation of the T cells when the mice were sensitised with 
ovalbumin and LPS as seen by the dilution of the CFSE, whether the mice were given 
AT or control, and these T cells appeared to produce mainly IFN-γ and a little IL-10 
but no IL-4. This suggested Th1 differentiation in accordance with previously 
published literature in this model (375).  
 
Results: Chapter 7 
193 
 
 
LP
S 
al
on
e
AT s
al
in
e
Fi
gu
re
7.
6
Ef
fe
ct
of
A
T
on
th
e
T
ce
ll
re
sp
on
se
in
an
in
vi
vo
an
tig
en
sp
ec
ifi
c
sy
st
em
of
T
ce
ll
se
ns
iti
sa
tio
n
10
x1
06
C
FS
E
st
ai
ne
d
ce
lls
fr
om
ly
m
ph
no
de
s
an
d
sp
le
en
of
na
ïv
e
D
O
11
.1
0
m
ic
e
w
er
e
in
je
ct
ed
in
tra
ve
no
us
ly
vi
a
th
e
ta
il
ve
in
in
to
na
ïv
e
B
A
LB
/c
m
ic
e.
24
ho
ur
sl
at
er
m
ic
e
w
er
e
gi
ve
n
an
in
tra
pe
rit
on
ea
li
nj
ec
tio
n
of
3m
g
A
T
(A
T)
or
eq
ui
va
le
nt
vo
lu
m
e
of
no
rm
al
sa
lin
e
(s
al
in
e)
fo
llo
w
ed
by
an
in
tra
pe
rit
on
ea
li
nj
ec
tio
n
of
5m
g
ov
al
bu
m
in
w
ith
25
µg
LP
S
or
on
ly
25
µg
LP
S
as
a
na
iv
e
m
ou
se
co
nt
ro
l.
72
ho
ur
sl
at
er
th
e
m
ic
e
w
er
e
ki
lle
d
an
d
ce
lls
fr
om
th
e
ly
m
ph
no
de
so
fi
nd
iv
id
ua
l
m
ic
e
w
er
e
st
ai
ne
d
an
d
an
al
ys
ed
fo
rp
ro
lif
er
at
io
n
an
d
IF
N
-γ
,I
L-
4
an
d
IL
-1
0
se
cr
et
io
n.
R
ep
re
se
nt
at
iv
e
pr
of
ile
s
fr
om
on
e
of
th
e
th
re
e
m
ic
e
fr
om
ea
ch
gr
ou
p
ar
e
sh
ow
n.
 
Results: Chapter 7 
194 
 
In order to compare mice given AT with mice given control, the CFSE+ T cells were 
gated and enumerated as were the CFSE+ T cells which produced IFN-γ and IL-10.  
The gating and percentage positive cells are shown in figure 7.6.  Fold increase was 
calculated by the ratio of the number of CFSE+ T cells to the mean number of CFSE+ 
T cells from the mice given LPS alone as a surrogate for the starting number of 
CFSE+ T cells.  Fold increase was calculated for the number of CFSE+ T cells as well 
as IFN-γ and IL-10 producing CFSE+ T cells, which are shown for the mice given AT 
compared to control in figure 7.7.  There was a significantly smaller increase in the 
number of CFSE+ T cells in the mice given AT compared to control suggesting less 
antigen specific T cell proliferation in the mice given AT.  There was also a trend to 
less of an increase in the number of IFN-γ producing CFSE+ T cells in the mice given 
AT compared to control although no real difference in the number of IL-10 producing 
CFSE+ T cells between the two groups. 
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Figure 7.7 Analysis of the fold increase in CSFE+ T cells when AT is administered in an in
vivo system of T cell sensitisation
10x106 CSFE stained cells from lymph nodes and spleen of naïve DO11.10 mice were injected
intravenously via the tail vein of naïve BALB/c mice. 24 hours later mice were given 3mg
antithrombin (AT) or an equivalent volume of normal saline (saline) intraperitoneally followed by
intraperitoneal injection of 5mg ovalbumin with 25µg LPS or 25µg LPS alone intraperiteonally
(LPS alone) as a naïve control. 72 hours later the mice were killed and cells from the lymph
nodes of individual mice were stained and analysed for proliferation and IFN-γ, IL-4 and IL-10
secretion. The number of CSFE+ (A), and IFN-γ (B) and IL-10 (C) producing CSFE+ CD4+ T
cells were enumerated from each mouse. Fold increase was calculated as the ratio of this number
for each mouse to the equivalent mean number of CD4+ T cells for the mice given LPS alone.
Mean and standard error were calculated for each group and plotted as shown. * p<0.02
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A comparison of proliferative index for the two groups also demonstrated a reduction 
in the amount of antigen specific T cell proliferation in the mice given AT as shown 
in figure 7.8A.  Histogram profiles of CD4+ CFSE+ gated T cells for each of the mice 
in the two groups with gating of each division cycle are shown.  The proliferative 
index was calculated from the ratio of the sum of the total number of T cells to the 
sum of the calculated number of parent T cells in each division cycle and is plotted in 
figure 7.8B.   
 
Representative profiles from the second experiment of the gated CD4+ T cells are 
shown in figure 7.9.  As previously seen, there was no proliferation of T cells from 
mice given LPS alone.  There was clear proliferation of T cells from mice sensitised 
with ovalbumin and LPS but unfortunately the peaks of the proliferating CFSE+ 
DO11.10 T cells merge into the peak of CFSE- BALB/c T cells without a distinction.  
This means that it was not possible to accurately count just the proliferating CFSE+ 
DO11.10 T cells, which makes all subsequent data difficult to interpret and therefore 
no further analysis has been done on this set of experiments. 
Results: Chapter 7 
197 
 
 
 
A
T
sa
lin
e
A
051015
proliferative index
sa
lin
e
A
T
B
A
T
sa
lin
e
A
A
T
sa
lin
e
A
051015
sa
lin
e
A
T
B
051015 051015
sa
lin
e
A
Tsa
lin
e
A
T
B
Fi
gu
re
 7
.8
 A
na
ly
sis
 o
f t
he
 p
ro
lif
er
at
iv
e 
in
de
x 
of
 C
SF
E
+ 
T 
ce
lls
 w
he
n 
A
T 
is 
ad
m
in
ist
er
ed
 in
 a
n 
in
 v
iv
o 
sy
st
em
 o
f T
 c
el
l s
en
sit
isa
tio
n
10
x1
06
C
SF
E 
st
ai
ne
d 
ce
lls
 fr
om
 ly
m
ph
 n
od
es
 a
nd
 s
pl
ee
n 
of
 n
aï
ve
 D
O
11
.1
0 
m
ic
e 
w
er
e 
in
je
ct
ed
 in
tra
ve
no
us
ly
 v
ia
 th
e 
ta
il 
ve
in
 in
to
 n
aï
ve
 B
A
LB
/c
 m
ic
e.
  2
4 
ho
ur
s 
la
te
r m
ic
e 
w
er
e 
gi
ve
n 
an
 in
tra
pe
rit
on
ea
l i
nj
ec
tio
n 
of
 3
m
g 
A
T 
(A
T)
 o
r e
qu
iv
al
en
t v
ol
um
e 
of
 n
or
m
al
 s
al
in
e 
(s
al
in
e)
 fo
llo
w
ed
 b
y 
an
 in
tra
pe
rit
on
ea
l i
nj
ec
tio
n 
of
 5
m
g 
ov
al
bu
m
in
 w
ith
 2
5µ
g 
LP
S 
or
 o
nl
y 
25
µg
 L
PS
 a
s a
 n
ai
ve
 m
ou
se
 c
on
tro
l. 
 7
2 
ho
ur
s l
at
er
 th
e 
m
ic
e 
w
er
e 
ki
lle
d 
an
d 
ce
lls
 fr
om
 th
e 
ly
m
ph
 n
od
es
 o
f i
nd
iv
id
ua
l m
ic
e 
w
er
e 
st
ai
ne
d 
an
d 
an
al
ys
ed
 f
or
 p
ro
lif
er
at
io
n.
  
Th
e 
pr
of
ile
s 
fo
r 
al
l t
hr
ee
 m
ic
e 
w
ith
in
 e
ac
h 
gr
ou
p 
ar
e 
sh
ow
n 
to
ge
th
er
 o
n 
th
e 
in
iti
al
 p
ro
fil
e 
an
d 
se
pa
ra
te
ly
 o
n 
su
bs
eq
ue
nt
 
pr
of
ile
s 
w
ith
 e
ac
h 
di
vi
si
on
 c
yc
le
 g
at
ed
 a
s 
sh
ow
n 
(A
). 
 T
he
 n
um
be
r 
of
 T
 c
el
ls
 i
n 
ea
ch
 d
iv
is
io
n 
cy
cl
e 
w
as
 e
nu
m
er
at
ed
 a
nd
 t
he
 n
um
be
r 
of
 p
ar
en
t 
T 
ce
lls
 w
as
 
ca
lc
ul
at
ed
.  
Th
e 
pr
ol
ife
ra
tiv
e 
in
de
x 
w
as
 th
en
 c
al
cu
la
te
d 
an
d 
pl
ot
te
d 
as
 sh
ow
n 
(B
). 
 
 
Results: Chapter 7 
198 
 
 
 
 
C
FS
E
C
FS
E
LP
S 
al
on
e
AT s
al
in
e
Fi
gu
re
7.
9
Ef
fe
ct
of
A
T
on
th
e
T
ce
ll
re
sp
on
se
in
an
in
vi
vo
an
tig
en
sp
ec
ifi
c
sy
st
em
of
T
ce
ll
se
ns
iti
sa
tio
n
10
x1
06
C
SF
E
st
ai
ne
d
ce
lls
fr
om
ly
m
ph
no
de
sa
nd
sp
le
en
of
na
ïv
e
D
O
11
.1
0
m
ic
e
w
er
e
in
je
ct
ed
in
tra
ve
no
us
ly
vi
a
th
e
ta
il
ve
in
in
to
na
ïv
e
B
A
LB
/c
m
ic
e.
24
ho
ur
s
la
te
r
m
ic
e
w
er
e
gi
ve
n
an
in
tra
pe
rit
on
ea
li
nj
ec
tio
n
of
3m
g
A
T
(A
T)
or
eq
ui
va
le
nt
vo
lu
m
e
of
no
rm
al
sa
lin
e
(s
al
in
e)
fo
llo
w
ed
by
an
in
tra
pe
rit
on
ea
l
in
je
ct
io
n
of
5m
g
ov
al
bu
m
in
w
ith
25
µg
LP
S
or
on
ly
25
µg
LP
S
as
a
na
iv
e
m
ou
se
co
nt
ro
l.
72
ho
ur
s
la
te
r
th
e
m
ic
e
w
er
e
ki
lle
d
an
d
ce
lls
fr
om
th
e
ly
m
ph
no
de
s
of
in
di
vi
du
al
m
ic
e
w
er
e
st
ai
ne
d
an
d
an
al
ys
ed
fo
r
pr
ol
ife
ra
tio
n
an
d
IF
N
-γ
an
d
IL
-4
se
cr
et
io
n.
R
ep
re
se
nt
at
iv
e
pr
of
ile
s
fr
om
on
e
of
th
e
th
re
e
m
ic
e
fr
om
ea
ch
gr
ou
p
ar
e
sh
ow
n.
 
 
Results: Chapter 7 
199 
 
Discussion 
Experiments in the first part of this chapter addressed whether AT has a direct effect 
on DCs.  No significant change in surface phenotype of DCs was seen when they 
were incubated with AT as compared with no treatment.  There was slightly less 
upregulation of MHCII, CD80 and CD86 on DCs treated with AT prior to LPS 
maturation compared to LPS treatment alone possibly suggesting a small effect of 
AT.  However this was not functionally significant as there was no difference in T cell 
proliferation when both types of DCs were used as stimulators with allogeneic CD4+ 
T cells.   
 
It is possible that the lack of effect was due to the dose of AT used.  A dose of 
10µg/ml was chosen based on a previous in vitro study (351), in which AT inhibited 
NFκB activation. However other in vitro studies have used different doses (346, 348) 
of AT with much higher doses for in vivo experiments, when it was used as an 
immunomodulatory agent in transplantation studies (344, 345). 
  
T cell cytokine profiles were also assessed using flow cytometry.  IL-4 was the main 
cytokine produced in all the conditions indicating Th2 polarisation.  The number of 
cytokine secreting T cells was not affected by stimulation with DCs treated with AT.  
Zuo and colleagues investigated the effect of AT on rat spleen cells stimulated with 
con A.  In contrast, they found a reduction in cytokine levels of IL-2, IFN-γ and IL-4 
but no change in other cytokine levels following AT treatment (346).  These data 
however are not directly comparable due to the possible effect of AT on a number of 
different cell types in the splenic population, in addition to the polygenic nature of 
stimulation.  Results from this project further showed a consistent trend towards a 
significant increase in IL-4, IL-10 and both IL-4 and IL-10 secreting T cells when 
stimulated by DCs pre-treated with AT then LPS matured.   
 
Overall results suggest that AT alone does not have a detectable effect on DCs.  On 
the other hand, when DCs are treated with AT prior to LPS maturation an effect is 
seen on the cytokine profile of stimulated allogeneic T cells.  This may be due to 
synergy of TLR4 with another receptor through which AT binds and one such 
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possibility is HSPG.  Alternatively it may be that AT itself interacts with TLR4 
modifying subsequent interaction with LPS.   
 
Although there were no significant changes to the DC phenotype as assessed by 
MHCII, CD80 and CD86 expression, it may be that the effect of AT is mediated 
through other surface molecules or cytokines, which have not been assessed.  Other 
studies support this possibility.  Komura and colleagues showed that AT appeared to 
inhibit LPS induced TNF-α production by monocytes through inhibition of egr-1 
(348) and Oelschlager and colleagues found that AT inhibited NFκB activation 
leading to inhibition of TNF-α, IL-6 and TF production by monocytes and ECs (347).  
It was suggested in both these studies that these effects were mediated through the 
interaction of AT with cell surface GAGs.  It may be that similar effects occur on DC 
cytokine production with AT pre-treatment prior to LPS maturation.  Mansell and 
colleagues demonstrated that AT pre-treatment appeared to inhibit LPS mediated 
NFκB activation of TLR4 in human monocytic cell lines and in cells stably 
transfected with TLR4 (351).    The results described in this chapter likewise suggest 
an effect of AT on subsequent LPS mediated activity although the specific 
transcription pathways have not been elucidated. 
 
The increased numbers of IL-10 secreting T cells additionally suggest the possibility 
that a Treg phenotype was induced.  It would be interesting to assess the levels of 
TGF-β production, which is another immunosuppressive cytokine secreted by induced 
Tregs.  This would involve ELISA of co-culture supernatant as an anti-mouse TGF-β 
Ab is not available for flow cytometry.  However the two step anergy assay did not 
support the initial suggestion of T cell tolerance although only T cell proliferation was 
measured in this experiment and future studies should additionally incorporate an 
analysis of cytokine profiles. 
 
Furthermore results of the functional T cell suppressor assay did not support the 
prediction that pre-treatment of DCs with AT prior to LPS leads to induction of a 
Treg phenotype.  Suppression of naive T cells occurred when higher numbers of 
effector T cells were added to the primary co-culture.  However there was no 
difference between the addition of T cells, stimulated with DCs treated with AT then 
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LPS, compared with DCs matured with LPS alone.  The equivalent amount of foxp3 
staining between the groups supported these findings.  
 
These results differ from in vivo studies using AT in a mouse allogeneic heart 
transplantation model, in which AT not only led to indefinite survival of the allografts 
but also suggested the generation of Tregs through tolerance transfer to naive 
recipients.  In this setting there was also marked suppression of splenocyte 
proliferation (345).  The discrepancy may be explained by the much higher doses of 
AT administered in the transplantation model.  Alternatively, in this model AT may 
induce tolerance through mechanisms other than a direct action on DCs, which were 
not at play in vitro. 
 
The set of experiments just described has only been done once in view of time 
limitations and clearly should be repeated before definitive conclusions are drawn. 
 
Experiments in the second part of this chapter addressed whether AT has an 
immunomodulatory effect similar to that seen in animal transplantation models 
elsewhere, by using an in vivo antigen specific model of T cell activation.  The 
prediction was that AT would inhibit T cell activation and proliferation as well as 
cytokine production.   
 
In the first experiment, there was less of an increase in the number of proliferating 
DO11.10 T cells compared to control demonstrating that AT inhibited the amount of 
T cell activation.  There was also a decrease in the number of IFN-γ producing T cells 
compared to control although no corresponding increase in IL-10 or IL-4 suggesting 
that AT did not lead to a Th2 phenotype.  Aramaki and colleagues used AT as an 
immunomodulatory agent in a mouse transplantation study and inferred the induction 
of tolerance by adoptive transfer studies (345).  Results from this chapter showed that 
less T cell activation occurred when AT was administered.  However the lack of an 
increase in IL-10 and persistent IFN-γ production point away from Treg induction 
although other markers such as foxp3 expression and TGF-β production were not 
assessed.   
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As shown in these experiments, and supported by other studies, the administration of 
antigen without adjuvant in this system still leads to antigen specific T cell 
proliferation, although both the peak number of proliferating T cells and the amount 
of IFN-γ produced is less than when adjuvant is also given (375).  These results show 
that AT administration does not prevent sensitisation but certainly reduces the level of 
T cell activation down to the level where antigen is given without adjuvant.  Therefore 
it may be that AT is acting to prevent the action of adjuvant.   
 
To further investigate the possibility of tolerance induction by AT administration, as 
suggested by Aramaki and colleagues, rechallenge of the stimulated T cells should be 
assessed.  Work in this model has already shown that sensitisation with antigen plus 
adjuvant leads to persistent but low levels of antigen specific T cells with a vigorous 
T cell response and production of high IFN-γ levels when restimulated with antigen.  
This does not occur when sensitisation is with antigen alone.  In this setting no 
antigen specific T cells are detected later on, with little cytokine production from T 
cells following antigenic restimulation.  Future work should involve assessment of 
whether the admin of AT alters the response of the stimulated T cells to rechallenge 
and if so, how it is affected.  
 
These results show that AT inhibits T cell activation with antigen plus LPS in an in 
vivo antigen specific model of T cell sensitisation.  There are several possible 
mechanisms through which this may occur. Firstly, AT may affect antigen processing 
and presentation.  Secondly, AT may influence the inflammatory milieu by affecting 
other innate cells and altering various cytokine levels (347, 351), which may then 
impact on the activation of the DCs or differentiation of effector T cells.  Thirdly, AT 
may reduce or partially inhibit activation of DCs.  This third effect could be indirectly 
through inhibition of coagulation proteins, which then act on DCs or via a direct 
effect on DCs.   In vitro studies described in this chapter have examined the 
possibility of a direct effect and found no significant change on the expression of co-
stimulatory molecules, however further studies should also include measurement of 
DC cytokine production. The lack of effect in vitro may have been due to the lower 
concentration of AT used compared to the in vivo studies.  DCs have been shown to 
possess a receptor belonging to the HSPG family through which AT may act and 
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affect DC phenotype (390).  This is further evidence for the role of a direct effect of 
AT. 
 
The final set of experiments was less clear cut as the profile of the proliferating 
CFSE+ DO11.10 T cells merged into the peak of the CFSE- BALB/c T cells.  It was 
therefore not possible to distinguish the proliferating DO11.10 T cells from the 
unlabelled BALB/c T cells and enumerate only the DO11.10 T cells.  To avoid this 
problem in future experiments, additional staining with KJ1-26 monoclonal Ab, 
which only binds to the transgenic TCR heterodimer, should be performed.  This 
would allow for identification and gating of the adoptively transferred population 
from DO11.10 mice as KJ1-26+ cells are not produced at detectable levels in BALB/c 
mice.   
 
In summary findings from this in vivo antigen specific model of T cell sensitisation 
suggest that AT inhibits T cell activation but without a shift in polarisation of the 
cytokine profile.  In view of the experimental set-up, there is little insight into AT’s 
mechanism of action in this model.  AT was given via the intraperitoneal route and so 
potentially could inhibit the effect of coagulation proteins as well as act directly on 
cells.   
 
The in vitro work investigates whether AT has a direct effect on DCs.  AT alone does 
not appear to have an effect on DCs by any of the parameters measured in the DC or 
T cell response.  However treatment of DCs with AT prior to LPS maturation 
enhances the number of cytokine producing T cells compared to LPS matured DCs 
alone although does not affect T cell proliferation.  This effect was not through a 
change in levels of MHCII, CD80 or 86 expression.  Enhancement of the number of 
IL-10 secreting T cells suggested the induction of a Treg phenotype, which was 
explored further.  However foxp3 staining of the T cells together with the findings of 
the functional T cell suppressor assay and the two anergy assay did not support this.
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Chapter 8: Conclusions 
TF is the initiator of the coagulation cascade and in chapter five the expression of this 
receptor was established on a subset of mouse DCs but not found on either mouse 
bone marrow progenitor cells or T cells.  Antigenic expression was similar on DCs of 
increasing maturity however functional pro-coagulant activity increased with 
increasing maturity of DCs suggesting a differential expression of encrypted TF 
depending on the level of DC maturity.  TF is known to exist in an encrypted 
(inactive) form that has the ability to become pro-coagulant. Control of this regulation 
on DCs was investigated but remains unsolved, although it does not appear to be 
through PDI or TFPI.  
 
The significance of TF on DCs in relation to the immune response was further 
explored. In vitro results showed that inhibiting TF on immature but not mature DCs 
enhanced their stimulatory capacity and also possibly enhanced their cytokine 
production, although the nature of the response was unchanged.  The results suggest 
that inhibiting TF on immature DCs has the potential to break tolerance and future 
work should explore this possibility further.   Data also suggested that the effect of TF 
may have been through PAR-2 signalling.  In vivo results corroborated with these 
findings although one of the potential drawbacks of the experimental system used was 
that anti-TF Ab had the potential to inhibit all TF, not just that on DCs or indeed 
antigen presenting cells.  Therefore the in vivo data provided little mechanistic insight 
into the role of TF in the DC and T cell interaction.  Nevertheless, overall these results 
suggest a differential form and function of TF on immature compared with mature 
DCs.  On immature DCs TF appears to affect the immune response through 
signalling, whereas on mature DCs it appears to be pro-coagulant and so generate 
downstream coagulation proteins including thrombin.  
 
Chapter six addresses the role of thrombin, generated following initiation of the 
coagulation cascade by TF.  This chapter demonstrated that thrombin appeared to 
have an effect on the interaction of DCs and T cells purely through DCs.  DCs were 
shown to possess PARs, which are the receptors through which thrombin and other 
coagulation proteases exert many of their cellular effects.  Thrombin enhanced the 
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stimulatory capacity of the DCs but the quality of the immune response was not 
affected.  The mechanism through which this occurred was examined but remains 
unclear; the phenotype of DCs was unchanged as was production of certain DC 
cytokines.  Further aspects of DC cytokine and chemokine production should be 
assessed in future studies. 
 
Together the findings of chapter five and six suggest that TF exists on a subset of 
DCs.  The effect of TF on immature DCs appears to maintain them in this immature 
form by signalling through PAR-2 and possibly through its cytoplasmic tail, although 
the latter was not specifically addressed.  As the DC matures the form of TF appears 
to change, although the regulating mechanism remains unclear.  On mature DCs TF 
exists in a pro-coagulant form and so initiates coagulation and the generation of 
downstream coagulation proteins, which includes thrombin.  Apart from leading to 
clot formation, thrombin also exerts cellular effects, possibly in a paracrine fashion, 
on other less mature DCs and enhances their stimulatory capacity.  Thrombin also acts 
synergistically with LPS on DCs to enhance their stimulatory capacity.  This synergy 
may occur with other danger signals released during inflammation although was not 
specifically tested. 
 
The model is in keeping with recently published data from Ruf and colleagues.  They 
used a series of transgenic mice including PAR-1 KO mice in a model of sepsis and 
proposed that PAR-1 on DCs played a pivotal role in the dissemination of coagulation 
and inflammation. 
 
Chapter seven addressed the effect of the anti-coagulant AT on the immune response.   
AT has been used successfully as an immunomodulatory agent in animal models of 
transplantation.  In vivo experiments suggested that AT inhibited T cell activation 
although work still needs to be done to confirm these results and fully elucidate the 
mechanism of action.  This may be by inhibiting the pro-inflammatory effects of 
coagulation proteins such as thrombin, although another possibility is through the 
direct action of AT on DCs.  The latter mechanism was investigated and no apparent 
effect was demonstrated with AT alone, although AT prior to LPS treatment of DCs 
appeared to enhance cytokine production of T cells compared to LPS treatment alone. 
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Overall work from this project suggests that DCs possess the ability to initiate and 
generate coagulation proteins as well as respond to the actions of them in a number of 
ways.  The effect appears to be a general enhancement of the immune response but 
without a qualitative change.   
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